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The classical functions of the skeleton encompass locomotion, protection and 
mineral homeostasis. However, cell-specific gene deletions in the mouse and human 
genetic studies have recently identified bone as an endocrine organ possessing the 
capabilities to regulate both energy metabolism and reproduction. Preliminary data 
suggested that Phosphatase, Orphan 1 (PHOSPHO1) a bone specific phosphatase, 
indispensable for bone mineralisation, may crosstalk with osteotesticular protein 
tyrosine phosphatase (OST-PT, Esp), a signalling molecule that dephosphorylates 
the insulin receptor (InsR) on the osteoblast, negatively regulating the osteoblast 
insulin signalling cascade.  
 
The work of this thesis has expanded upon preliminary data confirming that Esp 
was up-regulated 60-fold in Phospho1-/- osteoblasts. Furthermore in silico analysis 
revealed Phospho1 ablation is significantly associated with insulin dependent 
diabetes mellitus. These data form the basis of this thesis examining the role of 
PHOSPHO1 in energy metabolism.  
 
Initial in vivo characterisation of Phospho1-/- mice revealed that the ablation of 
Phospho1 results in decreased blood glucose levels, improved insulin sensitivity and 
glucose tolerance in juvenile, adult and aged mice. Following high fat feeding, 
Phospho1 ablation conferred a remarkable degree of protection against diet-induced-
obesity and non-alcoholic fatty liver disease (NAFLD) despite the 60-fold increase in 
Esp expression.  
 
The metabolic protection observed in Phospho1-/- mice served to strengthen 
PHOSPHO1’s potential role in energy metabolism. However the mechanisms 
remained unclear. Mice overexpressing Esp specifically in osteoblasts are glucose 
intolerant and insulin resistant, due to the negative regulation of osteoblast-insulin-





release.  This thesis identified however that the serum levels of a GLU13-OCN were 
normal in Phospho1-/- mice suggesting that there was a GLU13-OCN-independent 
mechanism for PHOSPHO1 regulated energy metabolism.  Moreover, mass 
spectrometry analysis identified > 100 differentially expressed proteins in Phospho1-/- 
serum associated with the regulation of glycolysis and gluconeogenesis. These 
candidates displayed an enrichment for microRNA Mir34a and the transcription 
factor hepatocyte nuclear factor 1, both reported to regulate hepatic glucose 
homeostasis. These data therefore support the notion that further, yet undefined 
osteoblast derived factors contribute to whole body energy metabolism and 
highlight a new and unconventional role of Esp suggestive that it may act as a fine 
controller of insulin sensitivity in mice, offering protection from severe 
hypoglycaemia and dyslipidaemia.   
 
Finally, this thesis also explored the notion that decreased levels of choline may 
contribute to the insulin sensitivity observed in Phospho1-/- mice. Phosphocholine (P-
Cho) is a recognised substrate for PHOSPHO1 being hydrolysed into choline and 
inorganic phosphate (Pi). Phosphatase Orphan 1 deficient mice, hypothesised to 
have reduced choline levels were fed a 2% choline rich diet; mice displayed a 
normalisation in insulin sensitivity and fat mass. These data suggest that Phospho1-
deficiency improves the metabolic profile of mice in vivo and confers resistance to 
obesity and diabetes via the alteration of serum/tissue choline levels. 
 
The work described herein has characterised the metabolic phenotype of Phospho1-/- 
mice and began to unravel the mechanisms underlying the improved metabolic 
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Traditionally the skeleton has been viewed as an inert structural organ essential for 
locomotion, ion homeostasis and maintenance of the hematopoietic niche. However, 
in the last decade, bone has been identified as a true endocrine organ, possessing the 
capabilities to regulate both energy metabolism and reproduction. These recent 
advances expand our understanding and identify a new and unconventional role of 
bone beyond its classical functions. However, much is still to be learned. This thesis 
will investigate the role of Phosphatase, Orphan 1 (PHOSPHO1) in energy 
metabolism. The bone specific phosphatase, PHOSPHO1 has a well-established role 
in bone mineralisation and excitingly preliminary data suggested that PHOSPHO1 
may be involved in the regulation of global energy metabolism. Understanding the 
mechanisms in which bone specific proteins can influence whole body homeostasis 
is essential to identify potential therapeutic targets beyond the well accepted and 
reported candidates. It should be noted that sections of this introduction are based 
on the published review by Oldknow et al., highlighting the endocrine roles of bone 
(Oldknow et al., 2015). 
 
1.1 Skeleton form and function 
The vertebrate skeleton is one of the largest mammalian organs, providing the 
framework of the body, supporting the softer tissues and creating points of 
attachment for most skeletal muscles. In addition, the skeleton provides protection 
for vital organs and blood cells, assists in movement and acts as a storage system for 
minerals, namely calcium and phosphorus, in order to repair micro-damage and 
participate in fracture healing, thus maintaining a high bone quality adequate to 
fulfil its major functions. 
 
The structure of bone is adapted to its function. Bone is a composite material 
composed of living cells enmeshed in a mineralised collagenous matrix. These 
collagen fibres enable the bone to withstand torsion and tension, whereas the 
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Figure 1.1 Bone as a composite material 
Bone explant treated with hypochlorite (left) to digest collagen, leaving the mineral 
component intact and hydrochloric acid (right) to dissolve mineral, leaving the collagen 
component intact. With kind permission from Tim Arnett. 
 
Bone is organised into two distinct structures, cortical (compact) and trabecular 
(cancellous). Cortical bone accounts for 80% of the total skeletal mass, primarily 
located in the shaft of the long bones (diaphysis) surrounding the medullary cavity. 
Cortical bone is highly organised; osteons, the chief structural unit of cortical bone 
consists of concentric lamellae organised in Haversian systems, resulting in a highly 
dense, poorly porous (2-5%) material. Central to the Haversian system is the 
Haversian canal. This canal contains blood vessels, connective tissues, nerve fibres 
and lymphatic vessels that supply osteocytes and nerves, this system proves 
advantageous when bone is subjected to high tensile forces from contracting 
muscles (Sommerfeldt and Rubin, 2001)(Fig 1.2). Unlike cortical bone, trabecular 
bone does not contain a Haversian system. As an alternative, trabeculae, accounting 
for 20% of the bone mass, form the functional units of trabecular bone. Arranged in 
a highly organised three dimensional manner, trabeculae provide continuous units 
of bony tissue aligned in parallel with the lines of major compressive or tensile 
forces. Accordingly, trabecular bone is less dense and more elastic than cortical 
bone, possessing 10 times the surface area of cortical bone. Due to this arrangement, 
Chapter 1                                                                                                                                            Introduction  
4 
 
trabecular bone is more porous (30-90%) and has a higher bone turnover than 
cortical bone (Fig. 1.2).  
 
Figure 1.2 The bone structure and bone cells 
The bone consists of two structures, cortical and trabecular bone. (A) Cortical bone with a 
central Haversian canal. Osteocytes are visible, present in the concentric layers of bone 
matrix. (B) Low power scanning electron microscope image showing normal bone 
architecture in the third lumbar vertebra of a 30 year old woman. Strong, interconnected 
plates of trabecular bone are visible allowing the bone to withstand compressive forces. (C) 
Mineralisation of osteoblast cells in vitro. (D) Scanning electron microscope image of 
osteocytes organised in functional syncytia collectively referred to as the osteocytic lacunar–
canalicular system. (E) Scanning electron micrograph showing an osteoclast resorbing bone. 
Images provided from the Bone Research Society, by kind permission of (A,C,E) Tim Arnett 
(B) Alan Boyde (D) Kevin Mackenzie.  
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1.2 Embryonic bone formation 
Skeletal development involves the growth, expansion and remodelling of the bony 
structure. During development, bone is formed from three distinct cell lineages: the 
neural crest, paraxial mesoderm, and lateral plate mesoderm, which form the flat 
bones of the jaw and skull, vertebral column and appendicular skeleton 
respectively.  Two mechanisms of bone formation (ossification) exist: endochondral 
and intramembranous, which are dependent upon a complex assimilation of 
biochemical and morphological events. 
 
1.2.1 Intramembranous ossification 
Intramembranous ossification is responsible for the formation of the frontal and 
parietal bone of the skull, mandible, maxilla and the periosteum of long bones. 
Ossification commences with mesenchymal condensations that secrete the early 
extra cellular matrix (ECM) and collagen concomitantly with mesenchymal cells that 
form a membrane of osteoprogenitor cells that differentiate into osteoblasts and 
osteocytes, secreting  bone matrix resulting in the formation of spicules that fuse 
into trabeculae constituting primary bone (Samuelson, 2007).   There is no 
intermediate cartilage template formed during the process of intramembranous 
ossification. 
  
1.2.2 Endochondral ossification 
Endochondral bone formation begins as a cartilaginous anlage and is observed 
during formation of long bones, such as those of the limbs.  Long bones of the 
skeleton develop from limb buds comprised of an aggregate of undifferentiated 
mesenchymal cells (precartilage condensations). Upon differentiation into 
chondrocytes, cells secrete ECM forming the cartilaginous template of the bone; 
simultaneously the perichondral sheath is formed from mesenchymal cells at the 
periphery of the template. Proliferating chondrocytes within the cartilaginous 
template hypertrophy, concomitant with this, perichondral cells around the mid 
diaphyseal region of the cartilage model differentiate into osteoblasts and lay down 
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the supportive bony collar which is infiltrated by blood vessels transporting cells / 
elements that will form the bone marrow and osteoclasts. Osteoclasts resorb the 
cartilage template forming the primary ossification centre. Osteoblasts secrete bone 
matrix forming lamellar bone. Finally, the secondary ossification centre forms in the 
epiphyseal region of the cartilage, and a highly specialised epiphyseal growth plate 
forms between the two ossification centres.  
 
The growth plate is essential postnataly, allowing the bone to grow in a longitudinal 
manner. The growth plate comprises chondrocytes arranged in columns that are 
parallel to the axis of the bone, and surrounded by their ECM (consisting of 
collagens, proteoglycans and numerous other non-collagenous proteins (NCP) 
(Gentili and Cancedda, 2009; Heinegard, 2009) (Fig. 1.3).  Specifically, endochondral 
bone growth is characterised by the precise temporal and spatial organisation of 
chondrocytes (section 1.4) within the epiphyseal growth plate. These chondrocytes 
sit in distinct cellular zones of maturation, separated by longitudinal and transverse 
septa. The cells of each region can be distinguished by differences in their rate of 
proliferation and morphology. Chondrocytes proceed through these stages of 
differentiation whilst maintaining their spatially fixed locations (Hunziker et al. 
1987).  Resting chondrocytes and undifferentiated progenitors are situated in the 
resting zone located at the top of the growth plate, nearest the epiphysis, these cells 
progress through to the proliferating zone where they become proliferative and 
adopt a flattened and oblate shape; arranging themselves spatially into longitudinal 
columns (Hunziker et al., 1987). Following the cessation of cell division, 
chondrocytes enter the hypertrophic zone, undergoing phenotypic changes. In brief, 
the cells become spherical and their volume increases approximately 10 times larger 
than that of the proliferative chondrocytes with increases in endoplasmic reticulum 
and Golgi apparatus, thus increasing matrix production. Associated with this 
hypertrophic phenotype is the increase in tissue non-specific alkaline phosphatase 
(TNAP) activity and expression of collagen type X, chondrocalcin, osteonectin (ON) 
and osteopontin (OPN) and decreased expression of collagen type II (early 
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chondrocyte marker), indicative of the final maturation phase (Buckwalter et al. 
1986; Hunziker et al. 1987; Farnum et al. 2002). Finally, mineralisation of the ECM 
surrounding the hypertrophic chondrocytes of the longitudinal septa occurs 
allowing vascular invasion. This invasion  facilitates the resorption of the transverse 
septa via osteoclast migration, allowing osteoblasts to replace this degraded 
cartilage with a bone matrix forming the primary spongiosa (Mackie et al. 2011). 
Upon sexual maturity, the primary and secondary ossification centres meet, fusion 
occurs and longitudinal bone growth ceases (Fig.1.3). Interestingly, in mice the 
growth plate never closes 
 
1.2.3 Appositional bone growth 
In addition to intramembranous and endochondral bone formation it is also 
important to address appositional bone growth.  Appositional bone growth is the 
formation of new bone on the outer surfaces of existing bone to increase its width; 
necessary to allow the bone to withstand increasing loading pressures by increasing 
the cross sectional moment of inertia. Osteoblasts situated on the periosteum 
deposit bone in successive  laminae, whilst osteoclasts resorb bone on the endosteal 
surface, resulting in a net increase in bone mass and marrow cavity diameter. Upon 
the termination of appositional growth, the periosteum is responsible for the 


















Figure 1.3 Endochondral ossification 
Stages of endochondral ossification. (A) Mesenchymal stem cells (B) condense and aggregate 
to form the cartilage anlagen. (C) Pre-chondrocytes differentiate into chondrocytes and 
secrete ECM. The formation of a supportive bony collar is initiated. (D) Chondrocytes in the 
centre become hypertrophic and mineralise their surrounding matrix. (E) Invasion of the 
anlagen by blood vessels allows the infiltration of osteoblasts and osteoclasts leading to the 
formation of the primary ossification centre. (F) The primary ossification centre expands 
towards the epiphysis. (G)  A secondary ossification centre and growth plate develops in the 
epiphysis. The epiphyseal growth plate is organised into distinct zones of the growth plate; 
the resting, proliferating, and hypertrophic zone, functioning until the point in which the 
two ossification centres fuse and growth ceases. Adapted from (Gilbert, 2006).  
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1.3 The process of bone remodelling and modelling 
Bone remodelling is a biphasic process occurring throughout life in a constant and 
balanced manner, responsible for bone maintenance during adulthood, 
demonstrating a true homeostatic function. Bone remodelling is fully dependent 
upon the actions of two antagonistic cell populations: the osteoblasts and 
osteoclasts. The primary function of mesenchyme-derived osteoblasts is to deposit 
bone matrix that subsequently becomes mineralised (section 1.5). Conversely, the 
haematopoietic-tissue-derived osteoclasts are a unique cell type possessing the 
capability to destroy the host tissue by reabsorbing mineralised bone matrix (Rodan 
and Martin, 2000; Teitelbaum, 2000; Harada and Rodan, 2003; Teitelbaum and Ross, 
2003; Karsenty, 2006). The misregulation of bone remodelling inevitably results in 
bone loss and disease, the most common, by far, is osteoporosis. These concepts will 
be discussed in greater detail hereafter. 
 
Bone modelling differs from bone remodelling as bone resorption and formation 
occur on separate surfaces resulting in changes in the bone micro-structure (Frost, 
1990) The process of bone modelling, unlike remodelling occurs from birth to 
adulthood and is responsible for adapting structure to loading by changing bone 
size and shape and removes damage thus maintaining bone strength (Seeman, 
2009). 
 
1.3.1 Osteoblasts  
Constituting approximately 5% of all bone cells, osteoblasts are specialised ‘bone 
building’ cells, originating from pluripotent mesenchymal stem cells (MSC’s) (Fig. 
1.2 C). In addition to osteoblasts, MSC’s are capable of differentiating into 
chondrocytes, adipocytes, fibroblasts, myoblasts and stromal cells; however, 
commitment of MSCs to these lineages is dependent upon the coordinated 
expression and activation of a number of transcription factors and cytokines 
including runt-related transcription factor 2 (Runx2), Osterix (Osx), Wnt, 
Transforming growth factor beta (TGFβ), β-catenin and bone morphogenetic 
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proteins (BMPs) (Table 1.1) (Ducy et al., 2000b; Manolagas, 2000). Required at each 
stage of bone development, and throughout the remodelling process, osteoblasts are 
cuboidal in shape and contain abundant mitochondria, Golgi apparatus, ribosomes 
and endoplasmic reticulum, all characteristic of secretory cells (Dudley and Spiro, 
1961). Ideally situated on the bone surface, the osteoblasts primary function is to 
synthesise bone matrix, termed the osteoid, predominantly consisting of collagen 
(94%) in addition to proteoglycans and other NCPs.  Following matrix deposition 
and mineralisation, the osteoblast either remains on the surface of the bone as 
inactive lining cells, undergoes apoptosis, or becomes entombed by their secreted  
matrix and differentiate into osteocytes (section 1.3.3) (Dallas and Bonewald, 2010).  
 
1.3.2 Osteoclasts            
Osteoclasts act in a synchronised manner with osteoblasts, however, having 
opposite roles. Osteoclasts are responsible for the resorption of mineralised bone 
and together with the osteoblasts they regulate remodelling of bone tissue. Derived 
from the hematopoietic lineage, osteoclastogenesis is stimulated by factors such as 
macrophage colony-stimulating factor, and receptor for activation of receptor 
activator of nuclear factor kappa B ligand (RANKL) requiring contact with 
osteoblasts and stromal cells (Sommerfeldt and Rubin, 2001).  Osteoclasts are 
multinucleated, rich in lysosomes, migratory giant cells. They have numerous 
mitochondria and a well-developed Golgi apparatus. Osteoclasts reside on the bone 
surface, ideally located for their function, where upon maturation osteoclasts 
become polarised and form a ruffled border that allows the osteoclast to attach to 
the bone surface forming a microenvironment which is key to the resorptive event. 
This compartment, isolated from the general extracellular space becomes acidified 
by an electrogenic proton pump, the Cl- channel and secretion of acid proteases.  
The formation of the acid milieu (pH 4.5) mobilises the mineralised component of 
bone, exposing the organic matrix, mainly type 1 collagen that is degraded by the 
lysosomal enzyme cathepsin K. Furthermore, the secreted enzymes, tartrate-
resistant acid phosphatase (TRAP) and matrix metalloproteinase (MMP) are also 
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responsible for the breakdown of the ECM.   Diminished functions of osteoclast 
function in animals and human results in an excess of bone mass (osteopetrosis or 
pyknodysostosis). Conversely, increased activity or an imbalance between bone 
formation and resorption leads to bone loss and osteoporosis. Osteoclasts are 
known to be regulated in an endocrine manner e.g. through the secretion of 
calcitonin from the thyroid and parathyroid hormone (PTH) from the parathyroid 
gland (Samuelson, 2007; M. Lyons, 2013).  
 
1.3.3 Osteocytes 
Osteocytes are regarded as terminally differentiated osteoblasts and are the most 
abundant cell type, constituting over ninety percent of the cells in bone. It was 
previously thought that the osteoblast was the dynamic cell and upon maturation 
into an osteocyte, the cell became quiescent. However, it is now becoming clear that 
the osteocyte is also an important regulator of bone mass and a key endocrine 
regulator of phosphate metabolism (Dallas and Bonewald, 2010).  
 
Osteocytes reside in lacunae and are immobilised in mature bone, they possess 
extensive filopodia, cellular processes that extend to adjacent osteocytes within 
canaliculi, allowing the passage of nutrients and metabolites.  Gap junctions present 
between processes from different cells allow the osteocytes to form a functional 
network, communicating with osteoblasts and osteoclasts situated at the periosteum 
and endosteum. Ideally positioned within the bone matrix, osteocytes sense 
mechanical strain and translate that strain into biochemical signals of resorption or 
formation related to the intensity and distribution of the strain signals (Lanyon 
1993). Osteocytes are also central to the regulation of system phosphate homeostasis 
and coordinate bone mineralisation with fibroblast growth factor 23 (FGF23) 
production and renal phosphate handling (Bonewald and Wacker, 2013). 
Furthermore, studies have highlighted that osteocytes and not osteoblasts or 
osteoblast progenitors are the major source of the osteoclastogenic cytokine receptor 
activator of nuclear factor kappa B (NF-kB), RANKL and the decoy receptor, 
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osteoprotegerin (OPG) (Nakashima et al., 2011; Xiong et al., 2011; Wysolmerski, 
2012).  
Molecule Function In vivo and in vitro effects 
BMP2 Osteogenic factor 
Osteochondrogenic factor; might initiate bone formation and 
bone healing and can induce expression of other BMPs. 
BMP4 Osteogenic factor Osteochondrogenic factor in vivo and in vitro. 
BMP7 Osteogenic factor 












Mutations induce chondrodysplasia and craniosynostosis; 
can stimulate Sox9; might be a negative regulator of 




Stimulates growth plate formation, endochondrate 
ossification and bone formation by osteoblasts. 
Ihh Osteochondrogenic factor 
Pivotal role for growth plate and endochondral formation; 






Crucial for regulation of intracellular signalling induced by 









Inhibits the differentiation of MSCs and committed 
osteoblastic cells. 
Noggin 
BMP2, 4 and 7 specific 
inhibitor 
Suppresses osteoblastic differentiation. 
OPG 
Decoy receptor of 
RANKL, inhibition of 
RANKL 










Induces proliferation and osteogenic differentiation of 
MSCs; crucial for vascularisation. 
PTHrP Osteochondrogenic factor 
Pivotal role for growth plate and endochondral formation; 









Master regulator of early osteogenesis; Runx2-/- mice died, 




Can induce osteoblast differentiation at the early stage of 





Most potent angiogenic and vasculogenic factor; crucial at 
the onset of bone formation. 
Wnt(s) 
Mitogenic and osteogenic 
factors 
Depending on Wnt type, crucial for osteoprogenitor 
proliferation; can also inhibit final osteoblast maturation. 
Table 1.1 Molecules involved in bone formation 
(Modified from (Deschaseaux et al., 2009; Mohammad Hafiz et al., 2010).  
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1.4 Chondrocytes and cartilage 
Each cartilage subtype has a single cell type – the chondrocyte, which are referred to 
as chondroblasts during the initial production of ‘ground material’ and as they 
become less active they become chondrocytes, which are rounded in shape present 
in the central regions of hyaline and elastic cartilage and to a lesser extent in 
fibrocartilage. The role of chondrocytes in the process of endochondral bone growth 
is discussed in section 1.2.2. Cartilage is a specialised form of connective tissue that 
is neither innervated nor vascularised. Cartilage is subdivided into three types: 
hyaline or articular, elastic and fibrous or fibrocartilage. Hyaline cartilage is the 
most common type of cartilage occurring at most bone forming sites, joint surfaces 
of articulating bones and tracheal rings, functioning to disperse forces on joints 
caused by movement, form growth templates for pre- and post-natal long bone 
growth and is involved in fracture repair (Shum and Nuckolls, 2002).  The ability of 
hyaline cartilage to withstand large compressive and tensile forces is due to the 
arrangement of the collagen type II fibres that are arranged in accordance with the 
stress placed on the body. Within articular cartilage collagen type II fibres form 
irregular bundles between the chondrocytes and near the surface they are orientated 
parallel to the surface. Elastic cartilage is found in the ear, larynx and epiglottis. 
Having a well-developed network of elastic fibres, elastic cartilage gives support to 
external structures. Finally fibrocartilage, the least common of the three forms, often 
associated with dense connective tissue and hyaline cartilage, aids in transferring 
loads between tendons and bone. Present at intervertebral disks and certain 
ligamentous and tendinous attachments to bones, fibrocartilage, is very similar to 
hyaline however type I collagen fibres predominate which form discrete bundles 
enabling cartilage to withstand large forces thus remaining resilient to deformation 
(Samuelson, 2007). 
 
1.5 The mineralisation process 
Bone predominantly consists of ECM, with approximately 70% (by weight) of this 
being inorganic. Of the inorganic matrix, calcium and inorganic phosphate (Pi) are 
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abundant. Derived from both nutritional sources and enzymatic activity, (e.g. Pi 
generation via TNAP and calcium via Vitamin D metabolites and PTH) calcium and 
phosphate form hydroxyapatite (HA) crystals (Ca10(PO4)6(OH)2), Hydroxyapatite 
crystals also contain other elements such as magnesium, sodium, potassium, copper, 
zinc and manganese.  These HA crystals are arranged in an organised manner, 
deposited alongside and in close juxtaposition to type I collagen fibres in bone and 
within their gap regions and surrounded by aggrecan composites producing a hard 
but lightweight composite material (Millan, 2013). The proteoglycans within the 
amorphous aggrecan composites are instrumental in initiating and inhibiting bone 
mineralisation allowing water to contact HA crystals and ion exchange to occur. 
Glycoproteins such as osteocalcin (OCN) and OPN bind to HA crystals (section 1.5).  
 
The mineralisation process occurs by a series of complex physio-chemical and 
biochemical processes that together facilitate the deposition of a solid phase HA 
(Houston et al., 2004).  Most simply, mineralisation is a two-step process (Fig 1.4): 
 
1. De novo induction of mineral formation within the protective enclave of 
the matrix vesicles (MV) lumen (Anderson, 1995). 
2. Propagation of induced mineral into the extravesicular matrix (Anderson 
et al., 2005).  
 
It is important to mention that although the formation of HA in cartilage is widely 
accepted to involve membrane-limited MV, an alternative mechanism  is suggested 
to occur in bone termed collagen-mediated calcification, whereby  collagen fibrils 
induce the deposition of apatite crystallites through a process of heterogeneous 
nucleation (Bonucci, 2012). Both mechanisms do however require the concentration 




Chapter 1                                                                                                                                            Introduction  
15 
 
1.5.1 The role of matrix vesicles 
Matrix vesicles bud from distinct areas of the membrane on the surface of all 
mineralising cells. Within cartilage, MV’s bud off from the hypertrophic 
chondrocyte plasma membrane whereas bone MV’s are restricted to the freshly 
formed osteoid that is located at the basal plasma membrane of mineralising 
osteoblasts (Morris et al., 1992). Within the MV lumen, calcium  and Pi accumulate 
until sufficient amounts are present for precipitation to occur resulting in the 
formation of HA. Calcium accumulation is achieved by Ca2+ channels and the MV 
affinity for calcium binding lipids and proteins, whereas Pi accumulation remains 
highly controversial.  
 









Figure 1.4 Mineral formation and alignment with collagen fibrils 
(A) Accumulation of Calcium and Pi within the matrix vesicle instigating the formation of 
HA crystals within the protective enclave of the MV lumen (B) HA crystals grow in size and 
the pierce the MV membrane resulting in growth in the extravesicular matrix (C) Analysis of 
mineral in mice (D) Mineral is aligned with collagen fibrils of the ECM (Anderson, 1995; 
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1.5.2 The regulatory factors of matrix mineralisation 
Traditionally, TNAP was solely recognised as the generator of high levels of P i via 
its ATPase activity, however it was later observed that MV’s from patients with 
hypophosphatasia (characterised by mutations in the TNAP gene - Akp2) contain 
apatite crystals, which is also observed in TNAP null (Akp2-/-) mice. This observation 
therefore suggested that other phosphatases must work with TNAP to generate P i 
and regulate matrix mineralisation. Following the identification of PHOSPHO1, this 




PHOSPHO1 is a bone specific phosphatase, identified over a decade ago at The 
Roslin Institute, University of Edinburgh (Houston et al., 1999). Thereafter, work 
concentrated in characterising its role in bone mineralisation. More specifically, 
PHOSPHO1 is a member of the large family of the haloacid dehalogenase (HAD) 
superfamily of Mg2+ dependent hydrolases and its expression is upregulated in 
mineralising cells (Houston et al., 1999; Roberts et al., 2008). PHOSPHO1 shows high 
phosphohydrolase activity towards phosphoethanolamine  (PEA) and 
phosphocholine (P-Cho) and is active inside chondrocyte and osteoblast derived 
MV’s where it has been speculated to scavenge Pi from MV membrane 
phospholipids to favour intravesicular HA deposition (Stewart et al., 2003; Roberts 
et al., 2004; Stewart et al., 2006; Roberts et al., 2007).   
 
Chemical inhibition of PHOSPHO1 by lansoprazole resulted in impaired skeletal 
mineralisation during limb development of the chick and markedly reducing 
mineralisation of the long bones of the leg and wings (MacRae et al., 2010). 
Furthermore, genetic ablation of the Phospho1 gene in mice resulted in significant 
skeletal pathology, spontaneous fractures, bowed long bones, osteomalacia, and 
scoliosis in early life (Fig. 1.5) (Huesa et al., 2011; Yadav et al., 2011). Curiously 
Phospho1-/- mice had reduced levels of TNAP and elevated pyrophosphate (PPi) 
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concentration (suppresses HA crystal formation and propagation and acts as a 
potent calcification inhibitor in biological fluids), however transgenic 
overexpression of TNAP did not correct the Phospho1-/- phenotype, despite 
correcting plasma PPi levels (Yadav MC, 2011).  The superimposing 
haploinsufficiency of TNAP (Akp2+/–) with Phospho1-/- caused a progressive 
worsening of the skeletal defects, whereas simultaneous ablation of Phospho1 and 
Akp2 results in the complete absence of skeletal mineralisation in the developing 
embryo and perinatal lethality. These data suggest that PHOSPHO1 and TNAP 
have complementary, non-redundant functional roles during skeletal mineralisation 
in the mouse (Yadav MC, 2011). 
 
Using these models, a comprehensive paradigm of skeletal mineralisation was 
suggested, whereby PHOSPHO1 is responsible for intravesicular production of Pi 
and TNAP mediates extravesicular Pi transport into the MV, via phosphate 
























Figure 1.5. Phospho1-/- mouse bone phenotype 
(A) Micro Computed tomography (µCT) image of a Phospho1−/− E16.5 shows reduced skeletal 
mineralisation compared with WT embryos (B) Radiographic images of WT and Phospho1−/− 
mice on postnatal days 10 and 25. Phospho1−/− mice show skeletal abnormalities including 
deformed long bones (C) Normalised backscattered electron intensity maps of tibial cross 
sections from non-mineralised (0, black) to high mineralisation (255, white). Bone matrix was 
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1.5.2.2 NPP1 & ANK 
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) is the founding 
member of the NPP family. These glycoproteins have pleiotropic roles in 
hydrolysing phosphodiester or pyrophosphate bonds in various substrates, 
including nucleoside triphosphates, lysophospholipids and choline phosphate esters 
(Bollen et al., 2000; Stefan et al., 2005; Zimmermann et al., 2012). Specifically, NPP1 
forms disulphide-bonded homodimers and is highly expressed in the plasma 
membrane and mineral-depositing MV of osteoblasts (Johnson et al., 1999; 
Vaingankar et al., 2004; Terkeltaub, 2006). Mice lacking NPP1 (Enpp1−/−) have severe 
mineralisation defects in long bones and calvariae, pathological soft tissue and 
medial arterial mineralisation associated with abnormally low pyrophosphate (PPi)  
levels (Anderson 2005; Mackenzie et al., 2012a; Mackenzie et al., 2012b; Oldknow et 
al., 2015). Therefore NPP1 has been identified as a critical regulator of tissue 
mineralisation, hydrolysing nucleotides such as adenosine triphosphate into 
extracellular PPi (Terkeltaub, 2001). Ankylosis protein (ANK), whose expression is 
upregulated in osteoblasts and chondrocytes, mediates the channelling of the 
intracellularly produced PPi to traverse to the ECM (Hakim et al. 1984; Terkeltaub et 
al. 1994; Ho et al. 2000; Nurnberg et al. 2001). Mice lacking the ANK protein are 
characterised by pathological calcification of articular cartilage and the synovial 
fluid surrounding these regions (Fig. 1.6) (Hakim et al., 1984). 
 
1.5.2.3 Purinergic signalling 
Purines can act as extra signalling molecules, and it is now accepted that 
extracellular nucleotides, signalling via P2 receptors, participate in a wide number 
of biological processes in both neuronal and non-neuronal tissues. P2 receptors 
existing in P2X ligand-gated ion channels and P2Y G-protein-coupled receptors 
respond to nucleotides including adenosine triphosphate (ATP), adenosine 
diphosphate (ADP), uridine triphosphate (UTP) and uridine diphosphate (UDP) 
(Burnstock and Kennedy, 1985; Abbracchio and Burnstock, 1994; Burnstock, 2007). 
Initial studies concerning purinergic signalling demonstrated that extracellular 
Chapter 1                                                                                                                                                                     Introduction  
21 
 
nucleotides could induce increases in intracellular calcium in bone cells and inhibit 
bone formation whilst promoting bone resorption (Kumagai et al., 1989; Kumagai et 
al., 1991; Reimer and Dixon, 1992; Yu and Ferrier, 1993; Morrison et al., 1998; 
Hoebertz et al., 2002). New evidence suggests that ATP released from osteoblasts, 
stromal cells and osteocytes can act locally to inhibit bone mineralisation and 
stimulate osteoclast formation and activity (reviewed in (Orriss et al., 2010). 
Specifically uridine-5'-triphosphate (UTP), the P2Y2 receptor agonist strongly 
inhibits bone nodule formation, partly due to the decreased activity of TNAP 
(Hoebertz et al., 2002; Orriss et al., 2007). Moreover, osteoblasts have been shown to 
express P2X receptors, and P2X1 and P2X7 receptors within this class negatively 
regulate bone mineralisation (Orriss et al., 2012). It has also been suggested that ATP 
released from osteocytes entombed in bone might help to prevent matrix 
mineralisation at the periphery of the osteocyte and prevent cell death (Orriss et al., 
2010). 
 
Figure 1.6 Model of initiation of skeletal mineralisation including the 
function of PHOSPHO1, TNAP, NPP1, and phosphate transporters.  
The first step of MV-mediated mineralisation involves the convergence of two independent 
biochemical pathways 1) intravesicular Pi generation by the enzymatic action of PHOSPHO1 
hydrolysing P-Cho generated from sphingomyelin phosphodiesterase 3 (SMPD3). 2) Influx 
of Pi via the Pit1 transporters, generated in the perivesicular space by the activities of TNAP 
and NPP1. OPN acts as a mineral inhibitor (Modified from (Zhou et al., 2012; Millan, 2013).  
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1.5.2.4 Polyphosphate  
Polyphosphates, predominantly located within nuclei, mitochondria and the plasma 
membrane, are long polymers of three to several hundred orthophosphates bound 
by energy-rich phosphoanhydride bonds (Kulaev, 1975; Kornberg, 1995; 1999). They 
have been  implicated in phosphate storage (Harold, 1966), cation sequestration 
(Dunn et al., 1994), counter-ion actions for basic amino acids (Cramer and Davis, 
1984), regulation of intracellular adenylate nucleotides (Lorenz et al., 1995) and 
modulation of cellular responses to stress (Lorenz et al., 1997). Polyphosphates are 
found at high levels in osteoblast-like cells, and calcium/phosphate rich 
polyphosphate granules have been identified at sites of bone resorption and in 
calcified cartilage suggestive of an involvement of polyphosphates in matrix 
mineralisation (Casey et al., 1972; Leyhausen et al., 1998; Schroder et al., 2000). Early 
studies showed that subcutaneous injection of polyphosphates inhibited ectopic 
calcification by direct binding to HA crystal thus halting crystal growth with equal 
or better potency than PPi (Fleish and Neuman, 1961; Fleisch et al., 1965; Francis, 
1969). Most recently, in an osteoblast cell culture model polyphosphates (PolyP5 
and PolyP65, polyphosphates of 5 and 65 phosphate residues in length) have been 
shown to be potent mineralisation inhibitors via direct binding to HA mineral 
crystals and by inhibition of TNAP activity (Hoac et al., 2013). 
 
1.5.2.5 SIBLING family of proteins  
The small integrin binding ligand N-linked glycoprotein (SIBLING) family of 
proteins have been identified to be key in the regulation of HA crystal initiation and 
propagation.  Comprising a structurally and phylogenetically homogeneous group 
of matricellular factors this family consists of OPN, bone sialoprotein (BSP), dentin 
sialophosphoprotein (DSPP), dentin matrix acidic phosphoprotein 1  (DMP1) and 
matrix extracellular phosphoglycoprotein (MEPE) (Malaval et al., 2008). Briefly, 
OPN is secreted by both osteoblasts and osteoclasts and has been shown to inhibit 
the in vitro formation of HA (Hunter et al., 1994). Supporting the role for OPN in 
mineralisation, mice lacking the OPN gene (Spp1-/-) mice display a normal skeletal 
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phenotype, however have increased crystal size and crystallinity (Boskey et al., 
2002). Bone sialoprotein (BSP (encoded by the Ibsp gene)) is highly expressed by 
osteoblasts, hypertrophic chondrocytes and osteoclasts, acting as a local nucleator 
for HA production (Hunter et al., 1994; Raynal et al., 1996).  Bone sialoprotein 
knockout mice (Ibsp-/-) exhibit impaired bone growth and mineralisation, 
concomitant with dramatically reduced bone formation (Ganss et al., 1999; Malaval 
et al., 2008). First described in 1977, DSPP has since been shown to play a primary 
role in the formation and growth of HA crystals in an extracellular matrix of hard 
tissue such as bone and teeth (MacDougall et al., 1997). The importance of DSPP in 
bio-mineralisation has been illustrated by human and mouse genetic studies, which 
showed the association of Dspp gene mutations or ablations with mineralisation 
defects in the dentin (Xiao et al., 2001; Zhang et al., 2001) and bone (Verdelis et al., 
2008). Current data suggests that BMP2, RUNX2, nuclear factor Y and DMP1 may 
be involved in the regulation of DSPP, however the exact molecular pathways 
governing the expression of DSPP are still poorly understood. Expression of DMP1 
is primarily restricted to osteocyte however osteoblasts and hypertrophic 
chondrocytes also express DMP1 (Toyosawa et al., 2001; Feng et al., 2002). In vitro, 
DMP1 overexpression promotes ECM mineralisation, in vivo Dmp1-/- mice display 
significantly lower mineral content than control mice (Ling et al., 2005). 
Furthermore, Dmp1-/- mice exhibit a dramatic increase in fibroblast growth factor 23 
(Fgf23) expression in the osteocytes. Fibroblast growth factor 23 regulates kidney Pi 
homeostasis suggesting that DMP1 can indirectly control P i levels via FGF23. These 
findings are consistent with the hypophosphatemia observed in the Dmp1-/- mice 
(Feng et al., 2006). Similarly to DMP1, MEPE is primarily expressed by osteocytes 
however it is also expressed by osteoblasts (Nampei et al., 2004). In vitro, during 
osteoblast matrix mineralisation Mepe mRNA expression is increased (Petersen et al., 
2000; Argiro et al., 2001). In vivo, Mepe-/- mice had increased bone mass and were 
resistant to age associated trabecular bone loss. Furthermore, isolated osteoblasts 
produced significantly more mineralised nodules in ex vivo cell cultures than wild 
type (WT) osteoblasts, these mice also display a decrease in TNAP activity in the 
Chapter 1                                                                                                                                                                     Introduction  
24 
 
growth plate and  the primary spongiosa (Gowen et al., 2003; David et al., 2009a). 
The functional component of MEPE (acidic serine aspartate-rich MEPE-associated 
motif (ASARM) peptide), in vitro and in vivo has been shown to inhibit the uptake of 
Pi. (Liu et al., 2007; Martin et al., 2008; Shirley et al., 2010). These data suggest that 
MEPE is involved in both bone mineralisation and Pi homoeostasis, however the 
pathways still remain somewhat elusive (Staines et al., 2012).  
  
1.5.2.6 Secreted protein acidic and rich in cysteine (SPARC) 
Secreted protein acidic and rich in cysteine (SPARC) alternatively known as 
osteonection (ON) or BM-40, is a bone matrix non-collagenous calcium binding 
matricellular glycoprotein that is involved with, but not restricted to, tissue 
remodelling, repair, cell turnover and bone mineralisation and is secreted by many 
different types of cells, such as osteoblasts, fibroblasts, endothelial cells, and 
platelets (Termine et al., 1981; Brekken and Sage, 2000; Alford and Hankenson, 
2006). Its precise function in bone remains unclear, in vitro ON has the ability to 
inhibit HA crystal growth (Romberg et al, 1986).  Osteonectin-deficient (Sparc-/-) mice 
exhibit decreased bone formation, remodelling and osteopenia, due to a negative 
bone balance resulting from decreased osteoblast and osteoclast surface area and 
number. Furthermore, ON has been shown to be important for osteoblast formation, 
maturation, and survival (Delany et al., 2000; Delany et al., 2003). 
 
1.5.2.7 SMPD3 
Recent in vitro results have indicated that sphingolipids are implicated in osteoblast 
and chondrocyte apoptosis and in the regulation of osteoclastogenesis (Takeda et al., 
1998; MacRae et al., 2006); reviewed by (Khavandgar and Murshed, 2015). In vivo, 
sphingolipid metabolism plays a critical role in skeletogenesis. Mouse models 
lacking the ceramide-generating neutral sphingomyelinase 2 enzyme 
(nSMase2/SMPD3 – gene-targeted Smpd3−/− and fro/fro mice (deletion mutation in 
Smpd3 gene fragilitas ossium (fro))) display gross skeletal abnormalities, including 
deformed long bones, short-limb dwarfism, hypomineralisation, delayed dentin 
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mineralisation and enamel formation (Aubin et al., 2005; Stoffel et al., 2005; 
Alebrahim et al., 2014). Conversely, the overexpression of Smpd3 in osteoblasts only 
(fro/fro;Col1a1–Smpd3 mice) corrects embryonic bone abnormalities, demonstrating a 
direct role of SMPD3 in skeletal mineralisation (Khavandgar et al., 2011; 
Khavandgar et al., 2013). However, the mechanisms underlying this role, while 
remaining unclear, are now becoming a little less hazy. It has now been proposed 
that SMPD3 hydrolyses sphingomyelin to P-Cho (Stoffel et al., 2005), which is 
subsequently hydrolysed into choline and phosphate by the bone-specific 
phosphatase, PHOSPHO1 (Fig. 1.6) (McKee et al., 2013). As described in section 
1.5.2, ablation of Phospho1 in mice results in a similar phenotype to that 
of fro/fro mice, with Phospho1−/−  mice having significant skeletal pathology (Huesa et 
al., 2011; Yadav et al., 2011; Rodriguez-Florez et al., 2015). These results suggest that 
PHOSPHO1 and SMPD3 are functional within the same metabolic pathway 
required for skeletal mineralisation in the mouse (Khavandgar, Oldknow, Murshed 
& Farquharson, unpublished observations). Interestingly, both Phospho1 and Smpd3 
deficient models exhibit decreased body size, indicating that, in addition to the de 
novo pathway, the sphingomyelinase pathway may have the potential to regulate 
energy metabolism (Chapter 6) (Stoffel et al., 2005; Oldknow et al., 2013). 
 
1.5.2.8 Vitamin K dependent proteins  
Osteocalcin (OCN) or bone Gla-protein was isolated from bone over three decades 
ago by two independent groups (Hauschka et al., 1975; Price et al., 1976; Hauschka et 
al., 1989b) and is the most abundant osteoblast-specific non-collagenous protein 
accounting for 10-20% of non-collagenous protein content (Hauschka et al., 1989b). 
Named due to the presence of three vitamin K-dependent γ carboxyglutamic acid 
residues, OCN is a small protein (46 and 49 amino acids long in mice and humans 
respectively) initially synthesised in the osteoblast as a pre–pro molecule. Vitamin 
K-dependent post-translational modifications occur, causing three glutamic acid 
residues (GLU13, GLU17 and GLU20) to be γ carboxylated into carboxyglutamic 
acid (GLA) residues by a γ carboxylase. Final intracellular cleavages produce the 
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mature OCN, which is subsequently secreted (Hauschka et al., 1989a). The presence 
of the three γ carboxyglutamic acid residues is critical for the structure and function 
of OCN in the fully carboxylated state allowing the binding of OCN to HA with a 
high affinity, regulating the maturation of bone mineral (Hauschka et al., 1989b). In 
the fully carboxylated form, OCN is largely unstructured when calcium is not 
present, however in the presence of calcium the OCN protein becomes folded, 
allowing calcium sequestering thus inhibiting mineral formation and matrix 
mineralisation (Chenu et al., 1994) . However, OCN also exists in the general 
circulation in fully carboxylated, partially carboxylated and completely 
uncarboxylated forms (Plantalech et al., 1991; Cairns and Price, 1994; Vergnaud et al., 
1997; Schilling et al., 2005). On the basis of results from human and rodent studies, 
serum OCN concentrations have been correlated with bone formation and 
osteoblast number, thus being used as a serum marker of bone formation (Brown et 
al., 1984). To investigate the role of OCN in bone health, OCN-deficient mice (Bglap3-
/-) were generated and these mice were found to have a normal bone phenotype at 
birth but increased bone density and thickness at 6 months of age.  This was due to 
the increased deposition of bone matrix without the impairment of bone resorption, 
thus OCN was concluded to be a negative regulator of bone formation (Ducy et al., 
1996; Wolf, 1996). Analogous to OCN, Matrix Gla protein (MGP) contains 5 vitamin 
K dependent GLA residues (Price and Williamson, 1985) and appreciably 
accumulates in the matrix of bone, cartilage, and dentin, functioning to promote the 
binding of HA through the affinity to calcium ions (Hale et al., 1988). Despite this, 
OCN and MGP have non redundant and other unrelated functions. Mice that lack 
MGP are severely compromised and fatality is observed within two months of age 
as a result of arterial calcification which leads to blood-vessel rupture (Luo et al., 
1997). Mice also exhibit inappropriate calcification of the growth plate, which 
eventually leads to short stature, osteopenia and fractures (Luo et al., 1997), thus 
MGP was concluded to inhibit calcification of arteries and cartilage.  Interestingly 
expression of OCN at sites of ectopic mineralisation in MGP-deficient mice was not 
able to reverse the abnormal phenotype which is in contrast with the re-expression 
Chapter 1                                                                                                                                                                     Introduction  
27 
 
of MGP at those same sites (Murshed et al., 2004). Furthermore, overexpression of 
MGP in hypertrophic chondrocytes reduces their mineralisation potential (Newman 
et al., 2001). However, the mode of action at the molecular level still remains 
somewhat elusive.  Keutel syndrome, an autosomal recessive disease, is triggered 
by MGP loss of function mutations, and the disease is characterised by excessive 
cartilage (Cancela et al., 1990; Munroe et al., 1999; Cancela et al., 2014).   
 
1.6 Bone as an endocrine organ 
Energy is required in all cells and organs, allowing biological processes to proceed; 
bone shows no exception to this rule. More specifically, bone is an energy-expensive 
organ due to the constant modelling and remodelling it undergoes. It is therefore 
logical to postulate that bone may have a means of regulating the flow/supply of 
energy storage to fulfil its metabolic needs. The initial realisation that leptin, an 
adipocyte-derived hormone inhibits both appetite (Flier and Elmquist, 1997; 
Friedman and Halaas, 1998) and bone mass accrual though a hypothalamic relay 
over a decade ago (Ducy et al., 2000a), provided the basis for this potential link 
between bone remodelling and energy metabolism. Thereafter, a rapid expansion of 
evidence supporting this crosstalk has occurred, further elucidating the complex 
roles of leptin (Fig. 1.7) and identifying further adipocyte (adiponectin) and gut-
derived hormones (glucagon-like peptides 1 and 2 and serotonin) that regulate bone 
mass, remodelling and energy homoeostasis. The revelation that bone itself 
regulates energy metabolism in a reciprocal manner via secreted OCN, which 
favours insulin secretion and insulin sensitivity and increased energy expenditure 
was uncovered several years ago (Lee et al., 2007; Ferron et al., 2010a; Rached et al., 
2010). Recently an explosion of avant-garde research has explored this concept, 
uncovering new and atypical roles of bone beyond its traditional functions. The 
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I. How bone mass is controlled by the brain. 
II. The role of insulin in the osteoblast. 






Figure 1.7. Bone related Functions of Leptin 
↑ indicates up regulation or increase, ↓ indicates down-regulation or decrease,  Indicates 
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1.6.1 The role of insulin in the osteoblast 
Osteoblasts have very few specific genes, the most specific being Bglap3 which codes 
for OCN (section 1.5.2.8). To investigate the role OCN in bone health, Bglap3-/- mice 
were generated, but surprisingly no major skeletal deformities were observed in 
these mice (Ducy et al., 1996).  In 2007, further phenotypic evaluation of these mice 
resulted in an unanticipated finding. OCN-deficient mice were hyperglycemic, 
hypoinsulinemic and had a reduced insulin secretion and sensitivity compared to 
the litter mate WT mice.  Additionally, islet size, number, β cell mass, pancreas 
insulin content, and insulin immunoreactivity were all markedly decreased in 
Bglap3-/- mice. Moreover, Bglap3-/- mice had increased fat mass and adipocyte 
number, being insulin resistant in the liver, muscle, and white adipose (Table 
1.2)(Lee et al., 2007).  In this same study the group took advantage of the small 
number of genes encoding secreted or signalling molecules that are expressed 
exclusively by the osteoblast in the hope to uncover further osteoblast-enriched 
genes affecting energy metabolism. One gene that was found to be of most interest 
was embryonic stem cell phosphatase (Esp), which is expressed by only two cell 
types, the osteoblast and the sertoli cells of the testis. Embryonic stem cell 
phosphatase encodes osteotesticular protein tyrosine phosphatase (OST-PTP) 
(Mauro et al., 1994).  In vitro, Esp coordinates the progression of the pre-osteoblast to 
a mature, mineralising cell, and in vivo may be a critical regulator of the 
commitment of mesenchymal cells to the ossification of new bones during 
skeletogenesis (Mauro et al., 1994; Chengalvala et al., 2001; Yunker et al., 2004). 
However, it is well established, protein tyrosine phosphatases (PTPs) are key 
regulators of insulin receptor signalling (InsR) in many cell types 
dephosphorylating and inactivating the InsR within minutes of stimulation, 
maintaining glucose homeostasis (Mauro et al., 1994; Hunter, 1995; Schlessinger, 
2000; Tonks, 2006; Lee et al., 2007). As a result, two mutant mice were created, a 
whole body knock out of Esp (Lee et al., 1996) and an osteoblast specific knock down 
of the phosphatase domain of OST-PTP (Dacquin et al., 2004). Both mutants 
exhibited severe hypoglycemia and hyperinsulinemia leading to postnatal lethality 
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in the first two weeks of life. Further analysis demonstrated the pancreas of Esp-/- 
had greater islet content, number of islets, islet size and β cell mass, resulting in 
increased insulin secretion. In addition, mutants were significantly more tolerant to 
glucose upon challenge, displaying an insulin sensitive phenotype (demonstrated 
by insulin tolerance testing), thus mice were protected from induced obesity and 
diabetes (Lee et al., 2007; Ferron et al., 2008). In parallel, mice overexpressing full-
length Esp cDNA selectively in osteoblasts exhibited hyperglycemia, 
hypoinsulinemia, glucose intolerance, insulin resistance, decreased β cell 
proliferation, lower β cell mass, and impaired insulin secretion (Lee et al., 2007).  
Subsequently, it was noted Esp-/- mice were a mirror image of Bglap3-/- mice, whilst 
the OST-PTP overexpressing mice were a phenocopy of Bglap3-/- mice.  Further 
genetic studies revealed that the metabolic phenotype of Esp-/- mice was fully 
corrected by removing one allele of Bglap3, implying that Esp-/- mice are a model for 
a gain of function of OCN, providing solid evidence that OST-PTP and OCN reside 
in the same regulatory pathway (Lee et al., 2007).  Biochemical analysis revealed Esp-
/- mice have significantly higher serum GLU13-OCN levels than WT controls, 
however, total Ocn gene expression and OCN serum levels was normal in Esp-/-, 
suggestive that OST-PTP is involved in the decarboxylation of OCN and subsequent 
release of GLU13-OCN into the systemic circulation (Table 1.2) (Lee et al., 2007; 
Ferron et al., 2010b).  
 
Notwithstanding, it still remained unclear how carboxylation status could regulate 
whole body energy metabolism. Clues came from several key studies concerning 
forkhead box protein O1 (FoxO1) and activating transcription factor 4 (ATF4). The 
transcription factor FoxO1 is targeted by insulin and regulates glucose homeostasis 
in tissues involved in energy metabolism including adipocytes and hepatocytes, yet 
its function in osteoblasts had not been explored until recently (Rached et al., 2010). 
A FoxO1 osteoblast conditional knockout mouse was generated, mice displayed 
decreased fasting blood glucose levels, increased insulin sensitivity and a 30% 
increase in serum OCN levels, coupled with a 75% reduction in Esp expression, 
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suggestive of an association between Esp and carboxylation status of OCN (Lee et 
al., 2007). In the same study, it was demonstrated that mice lacking one allele of 
FoxO1 and one allele of Esp in osteoblasts showed improved insulin sensitivity. 
Similarly, the metabolic phenotype was corrected in heterozygous mice lacking one 
allele of FoxO1 in osteoblast by the removal of one allele of Bglap. Utilising these 
models to investigate the mechanisms underlying the phenotype, it was established 
that FoxO1 regulates the bioactivity of OCN via OST-PTP via direct binding to its 
promoter, reducing serum OCN (Rached et al., 2010; Kousteni, 2011; 2012).  
Activating transcription factor 4 belongs to the subfamily of cAMP-response 
element-binding protein / ATF basic leucine zipper proteins broadly expressed 
throughout the body, however predominantly accumulates in osteoblast where it 
regulates virtually all functions of the osteoblast related to the control of bone mass 
including bone formation and matrix mineralisation (Yang and Karsenty, 2004; 
Elefteriou et al., 2005; Yoshizawa et al., 2009). Mice deficient in Atf4 primarily show 
phenotypic abnormalities in the skeleton, however the global or osteoblast specific 
ablation of Atf4 results in favourable metabolic changes, including improved 
glucose tolerance and insulin sensitivity associated with decreased Esp expression. 
Contrary, the overexpression of ATF4 in osteoblasts mirrored this phenotype, 
resulting in glucose intolerance associated with increased Esp expression. This effect 
was due to the direct regulation of Esp expression in osteoblasts by ATF4 which was 
established by a ChIP array confirming that ATF4 binds to the CRE element in 
the Esp promoter (Yoshizawa et al., 2009). Finally, it has been shown that FoxO1 co-
localises with ATF4 in the osteoblast nucleus, promoting the transcriptional activity 
of AFT4 thus up-regulating the expression of Esp in osteoblasts, resulting in OCN 
inactivation (Kode et al., 2012). 
 
But how does OST-PTP affect insulin signalling in osteoblasts?  In the search for the 
OST-PTP substrate in osteoblasts, utilising multiple genetic and biochemical 
modalities the InsR was identified as a potential substrate. As a result, two studies 
conducted simultaneously by Professors Gerard Karsenty’s and Thomas Clemens’ 
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laboratories were initiated to explore the role of insulin signalling in osteoblasts.  
They generated InsR-deficient mice which presented with hyperglycemia, increased 
peripheral adiposity, reduced insulin secretion, severe glucose intolerance and 
decreased levels of circulating GLU13-OCN (Table 1.2). These mice also displayed a 
skeletal phenotype with a reduction in bone acquisition due to reduced bone 
formation; however the marker of bone resorption (CTx) was also decreased.  Upon 
infusion of exogenous GLU13-OCN, the metabolic phenotype was fully corrected, 
suggestive that insulin signalling in osteoblasts has the potential to regulate whole 
body glucose homeostasis via carboxylation status of OCN (Ferron et al., 2010a; 
Fulzele et al., 2010). It was also suggested that insulin signalling in osteoblasts might 
favour bone resorption, due the observation of decreased CTx in osteoblast-
specific InsRosb-/- mice which mirrored the increase in CTx observed in the Esp-/- 
mice. Utilising the InsRosb-/- and Esp-/-, Ferron et al. established using a co-culture 
system, whereby WT osteoclast precursor cells cultured with osteoblasts isolated 
from InsRosb-/- mice decreased resorption pit formation whilst a 50% increase was 
seen utilising the Esp-/- primary osteoblasts. Moreover, Opg a negative regulator of 
osteoclast function, encoding the decoy receptor for RANKL was increased in InsR-/- 
and decreased 50% in Esp-/- osteoblasts. Further unravelling of this complex 
pathway found that insulin signalling in osteoblasts inhibited FoxO1 expression, 
favouring bone resorption via suppression of Opg, as well as supressing twist basic 
helix-loop-helix transcription factor  (Twist2) expression (Runx inhibitor) (Ferron et 
al., 2010a; Fulzele et al., 2010; Rached et al., 2010).  It appeared that osteoclasts were 
important in the connection between bone and energy metabolism, therefore Ferron 
and colleagues investigated genes associated with OPG dependent events in the 
osteoclast. It was found that T cell, immune regulator 1, ATPase, H+ transporting, 
lysosomal V0 protein A3 (Tcirg1) expression was decreased in osteoclast / InsRosb-/-  
osteoblast co-culture models.  Present in acidification of the bone prior to bone 
resorption Tcirg1 is present in osteoclasts (Teitelbaum, 2000; Teitelbaum and Ross, 
2003; Bronckers et al., 2012). These data suggested that insulin signalling in 
osteoblasts induces osteoclast acidification and consequently bone resorption.  This 
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is via altered via both OPG and the OPG/RANKL ratio resulting in acidic pH which 
is known to decarboxylate proteins (Engelke et al., 1991). Utilising biochemical and 
mass spectroscopy analysis it was established that an acidic environment generated 
by osteoclasts situated in osteoclast resorption lacuna can decarboxylate OCN 
present in the ECM.   
  
In addition to the classical osteoblast specific PTP’s, which has a specificity for 
phosphotyrosine (Alonso et al., 2004; Barr et al., 2009), 37 other mammalian classical 
PTP’s exist. Of these, the only other identified PTP able to bind to the osteoblast 
InsR and respond to isoproterenol treatment similar to OST-PTP (Hinoi et al., 2008) 
is T-cell PTP (TC-PTP). This finding further strengthens the notion that bone is 
involved in the regulation of glucose metabolism, increasing our understanding of 
the complex regulation of OCN mediated glucose homeostasis (Zee et al., 2012). 
 
1.6.2 Male fertility and the discovery of the osteocalcin receptor 
The discovery of the OCN receptor (Gprc6a) occurred simultaneously with the 
elucidation of the role of OCN in fertility. Briefly, male and female patients with 
gonadal failure possess low bone mass and menopause favours bone loss (Riggs et 
al., 1982; Wishart et al., 1995; Riggs et al., 1998). These clinical observations led to 
studies investigating the possible relationship between bone and fertility.  
Fortuitously it was noted that Bglap3-/- mice were poor breeders, resulting from 
decreased testes weight with a 50% reduction in sperm count. This was associated 
with impaired Leydig cell maturation and decreased circulating testosterone (Oury 
et al., 2013).  Mirroring this phenotype, Esp-/- mice had increased male reproductive 
organ weights with a 30% increase in sperm count and increased circulating 
testosterone (Oury et al., 2011).  This data suggested a link between OCN and 
testosterone production which was relevant to males only as no change in 
circulating oestrogen or the aromatase enzyme required to convert testosterone to 
oestrogen (Cyp19A1) was observed in the Esp or Bglap3-deficient mice.  In an effort 
to elucidate the signalling mechanism underlying this pathway, several factors were 
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taken into consideration, namely, the target cells affected by OCN (β cells of the 
pancreas and Leydig cells of the testis) and the sexually dimorphic aspects of OCN. 
These clues led to the identification of GPRC6A, a G protein–coupled receptor 
(GPCR) linked to adenylate cyclase. Present in is present in the Leydig cells, 
GPRC6A inactivation in mice leads to a metabolic phenotype very similar to the 
Bglap3-/-  mice characterised by glucose intolerance, decreased in β-cell area and β-
cell mass. In addition, these mice demonstrate defective bone mineralisation (Pi et 
al., 2008; Pi et al., 2010). Moreover, the compound heterozygous mice lacking 
Bglap3−/+ Gprc6a−/+ had a reproductive phenotype identical in all aspects to the one 
seen in Bglap3-/- and Gprc6a-deficient mice models (Oury et al., 2011). These data 
identified GPRC6A as an OCN receptor, demonstrating the importance of CREB in 
the regulation of OCN mediated testosterone biosynthesis.  Additionally, utilising 
the Gprc6a-/- mouse model it was shown that intraperitoneal injection of OCN failed 
to markedly stimulate ERK activity, thus having only minor effects on circulating 
serum insulin levels, which was in contrast to WT mice whose insulin levels were 
increased when challenged with OCN (Yoshikawa et al., 2011). The G protein–
coupled receptor (Gprc6a) has been shown to be integral in the promotion of β cell 
proliferation during development and adulthood via OCN thus highlighting Gprc6a 
as an important receptor for skeletal mediated energy regulation via the pancreas 
(Pi et al., 2011) (Wei et al., 2014b). Most recently, Oury et al. demonstrated that OCN 
acts via the pancreas-bone-testis axis where OCN stimulated testosterone synthesis 
is positively regulated by insulin signalling in osteoblasts and is independent of 
luteinizing hormone (Oury et al., 2013).  
 
To highlight the importance of the role of bone in energy metabolism, Wei et al. 
evaluated the consequences of the overexpression or loss of the InsR in osteoblasts 
of high fat diet (HFD) fed mice. These studies revealed that insulin resistance in 
bone affects whole-body glucose homeostasis in mice fed a HFD by decreasing OCN 
activity; moreover they demonstrated that Smad Ubiquitination Regulatory Factor 1 
(SMURF1)-mediated InsR ubiquitination contributes to the development of insulin 
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resistance in osteoblasts. This data underpins the notion that bone is a highly 
important site for the regulation of global energy homeostasis (summarised Fig. 1.8) 
(Wei et al., 2014a). 
 
 
Figure 1.8 OCN a bone-derived multifunctional hormone 
A feed forward loop links insulin, bone resorption and OCN activity. Insulin signalling in 
osteoblasts decreases OPG. The decrease in the ratio of OPG (a RANKL decoy receptor) to 
RANKL increases bone resorption by osteoclasts. The acidic pH (4.5) in resorption lacunae 
decarboxylates OCN stored in the bone extracellular matrix. Undercarboxylated active OCN 
stimulates insulin secretion by the β-cells of the pancreatic islets and promotes insulin 
sensitivity in peripheral organs. Esp acts as an inhibitor, dephosphorylating the insulin 
receptor, supressing the levels of GLU13-OCN.   Undercarboxylated OCN stimulates insulin 
secretion and β cell proliferation in the pancreas, energy expenditure by muscle, and insulin 
sensitivity in adipose tissue, muscle and liver. In addition, it promotes male fertility by 
stimulating testosterone synthesis in leydig cells of the testis through the activation of its 
receptor, GPRC6A, in these cells ECM, extracellular matrix; InsR, insulin receptor.  (Adapted 








































































































































































































































































































































































































































































































































1.6.3 Clinical evidence: osteocalcin and metabolism/fertility 
The first association between OCN and glucose metabolism in 1998 highlighted that 
OCN serum levels were significantly lower in diabetic patients and higher in 
patients with improved glycaemic control (Rosato et al., 1998). Many human studies 
have since quantified both total circulating OCN and the hormonally active 
undercarboxylated OCN, yielding mixed results. A positive correlation between 
serum undercarboxylated OCN levels and enhanced β-cell function was observed in 
several studies (Hwang et al., 2009; Prats-Puig et al., 2010; Pollock et al., 2011), 
however, in contrast, other studies have found no association between lower 
circulating uncarboxylated OCN levels and higher HOMA-IR (Shea et al., 2009). 
These conflicting results are likely attributed to the lack of a commercially available 
undercarboxylated OCN assay (Ducy 2011). Similarly, it appears that the 
reproductive function of OCN translates to humans, with the identification of a 
positive association between OCN and testosterone serum levels in the general 
population, patients with bone disorders and patients with T2DM (Hannemann et 
al., 2013; Kanazawa et al., 2013). Furthermore, two subjects were identified from a 
cohort of patients displaying testicular failure that harboured a heterozygous 
missense variant in one of the transmembrane domains of GPRC6A, giving credence 
to a role of OCN function in humans (Oury et al., 2013; Karsenty and Oury 2014; 
Oldknow et al., 2015). 
 
1.6.4 GLUT and bone 
Cellular uptake of glucose is mediated by either of the two families of membrane-
associated carrier proteins, namely the sodium coupled glucose transporters 
(SGLTs) via active transport and glucose transporter (GLUT) facilitators via 
facilitated diffusion (Bell et al., 1990; Carruthers, 1990). The SGLT family comprises 
12 members including co-transporters for sugars, anions, vitamins and short-chain 
fatty acids (Wright and Turk, 2004). Currently, the presence of SGLT in bone has not 
been reported; however, SGLT2 receptor inhibitors, acting as glucose-lowering 
agents in the management of type two diabetes mellitus (T2DM), have been 




reported to have no significant effects on bone formation and resorption or BMD in 
humans (Ljunggren et al., 2012). In contrast, GLUT receptors have recently been 
reported to be expressed in bone. To date, the GLUT family consists of 14 members 
sub-classified into three groups, according to sequence similarities and characteristic 
elements (Joost and Thorens, 2001; Mueckler and Thorens, 2013). GLUT receptors 
exhibit striking tissue-specific expression, each possessing differential sensitivities 
to stimuli such as insulin, thus allowing for complex and specific regulation of 
glucose uptake according to cellular requirements (Gould and Holman, 1993). It was 
first suggested that insulin promotes increased glucose uptake via GLUT1 in the 
osteoblast, independently of Insulin like growth factor – 1 (IGF-1) signalling to 
increase the metabolic activity of the osteoblast (Fulzele et al., 2007).  Most 
recently, solute carrier family 4 (Slc2a4) has been found to be expressed at similar 
levels to those in skeletal muscle in osteoblasts, osteocytes and chondrocytes, with 
the genetic ablation of  Slc2a4 in osteoblasts/osteocytes resulting in increased 
peripheral adiposity associated with mild hyperinsulinemia. These mice also 
presented with insulin resistance. These metabolic changes were assumed to 
originate from osteoblasts/osteocytes as no altered gene expression was identified in 
the liver or adipose tissue, indicating that decreased Slc2a4-mediated glucose uptake 
in bone is sufficient to influence whole-body metabolism (Zhu et al., 2013). 
Emerging results from two independent laboratories have indicated that, in 
addition to GLUT4, GLUT1 is necessary for bone formation and whole-body glucose 
homoeostasis. Moreover, GLUT1 is modulated by high glucose levels (Wei et al., 
2014a; Wei et al., 2014b; Wei J, 2014). Collectively, these results provide a deeper 
understanding of the role of bone in the regulation of glucose metabolism (Fig. 1.9). 
 
Excitingly, recent evidence suggests that other osteoblast-derived hormones may 
contribute to the emerging function of the skeleton as a regulator of the energy 
metabolism. This was demonstrated by the partial ablation of osteoblasts in 
transgenic mice which resulted in profound affects in glucose metabolism, gonadal 
fat mass combined with increased energy expenditure. Administration of OCN 




partly corrected the metabolic phenotype, however it did not improve the increased 
energy expenditure or decrease gonadal fat. This suggests that osteoblasts have the 
ability to affect glucose metabolism through both OCN dependent and independent 
mechanisms (Yoshikawa et al., 2011). This observation forms the theme of this thesis.  
 
1.6.5 Fibroblast growth factor 23 
In addition to OCN, it is also important to highlight that osteocyte derived FGF23 
has a central role in the regulation of energy metabolism (David et al., 2009a; David 
et al., 2009) in addition to its well documented roles in phosphate homeostasis and 
the coordination of  bone mineralisation (section 1.3.3). Mouse models either 
overexpressing MEPE, ASARM peptides or infused with ASARM peptides display 
increased adiposity, are hyperglycaemic and have increased OCN, whereas FGF23-
null mice are hypoglycaemic (ASARM peptide modulates PHEX–DMP1-mediated 
FGF23 expression; Rowe et al., 1996; David et al., 2009a; David et al., 2009b; David et 
al., 2011). Intriguingly, patients subjected to a 4 hour euglycaemic–
hyperinsulinaemic clamp showed increased FGF23 that correlated positively with 
insulin infusion (Winther et al., 2011). These combined data are indicative of key 
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1.7 Aims and strategy 
Whilst the functional importance of PHOSPHO1 in the regulation of skeletal 
mineralisation and in the formation of mechanically competent bones has been 
clearly demonstrated, the role of PHOSPHO1 in the regulation of energy 
metabolism has yet to be established.  This potential role of PHOSPHO1 emerged 
from striking preliminary data obtained by Dr. Carmen Huesa, which suggested 
that: 
 
I. Phospho1-/- osteoblasts have a 20-fold increase in Esp expression compared to 
WT osteoblasts. 
II. PHOSPHO1 dephosphorylates the InsR at serine 1322. 
III. PHOSPHO1 interacts with GYF protein 1 (GIGYF1), GIGYF1 forms a 
complex with GRB10 to regulate both insulin and IGF-1 receptor signalling. 
 
Therefore, the aim of this thesis was to test the hypothesis that PHOSPHO1 
regulates energy metabolism and PHOSPHO1 deficiency protects from obesity and 
insulin resistance.  To address this I have completed the following aims: 
 
I. Establish if PHOSPHO1 controls energy metabolism through cross talk with 
the InsR.  
II. Determine if Phospho1 overexpression in osteoblasts down regulates Esp 
expression and thereby regulate hormonally active GLU13-OCN. 
III. Examine glucose metabolism and the energy status of Phospho1-/- mice. 
IV. Investigate the potential regulation of energy metabolism by bone though 
PHOSPHO1 deficiency. 
 
These aims have been achieved through the use of both in vitro and in vivo models. 
Prior to the phenotypic metabolic characterisation of Phospho1-/- mice it was first 
necessary to confirm/oppose preliminary data obtained by Dr. Carmen Huesa, 
suggestive that PHOSPHO1 controls energy metabolism through cross talk with the 
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InsR (Chapter 3). Furthermore, I ascertained that Esp which controls GLU 13-OCN 
secretion, was more highly expressed in Phospho1-/- osteoblasts (Chapter 3). This 
chapter highlighted that PHOSPHO1 was an interesting candidate for in vivo 
studies.  
 
Thereafter, Phospho1-/- mice were examined under both normal and diet challenged 
(60% HFD) conditions, assessing multiple parameters inclusive, but not limited to, 
insulin sensitivity, activity monitoring, oxygen consumption, liver spectroscopy and 
whole body adiposity (Chapter 4 and 5).  
 
The identification of candidates underlying the remarkable protection from obesity 
and insulin resistance observed in Phospho1 deficiency would serve to cement 
Phospho1’s role in the regulation of the metabolic profile of mice. This role was 
examined both in vitro and in vivo using various cell lines (FAZA, INS1E, C2C12, 
3T3-L1), primary calvarial osteoblasts and blood serum. Chapter 6 therefore 
provides a platform for future research.    
 
In conclusion, these studies have revealed that the genetic ablation of Phospho1 
improves the metabolic profile of mice in vivo and confers a remarkable protection 
against obesity and diabetes.  Specifically, Phospho1-/- mice are hypoglycaemic, show 
improved glucose and insulin tolerance and are protected from HFD induced 
obesity. These observations were not OCN dependent or related to increased 
physical activity and are consistent with the noted smaller fat deposits. 
Furthermore, preliminary in vitro studies indicated that conditioned medium (CM) 
from Phospho1-/- primary osteoblasts increased basal and insulin stimulated 
sensitivity in osteoblasts, adipocytes and β cells. These data are suggestive that the 
observed metabolic phenotype is primarily bone driven. Such data is essential to 
further unravel the links between energy metabolism, mineralisation and bone.
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2.1 Reagents and solutions   
All chemicals were purchased from Sigma-Aldrich (Dorset, UK) and tissue culture 
medium and buffers were purchased from Life Technologies (Paisley, UK) unless 
otherwise stated. All medium and buffer recipes are shown in Appendix I.  
 
2.2 Cell culture       
2.2.1 Cell culture reagents 
All tissue culture reagents were prepared in a sterile category 2 hood.  Cell media 
was supplemented with the broad spectrum antibiotic gentamicin (0.05mg/ml, Life 
Technologies). Heat inactivated foetal bovine serum (FBS, Life Technologies) was 
filter-sterilised through a 0.22μm filter prior to use. Prepared medium was 
subsequently stored at 4C prior to use.  
 
2.2.2 Isolating primary osteoblasts 
Under sterile conditions calvariae were dissected from 3-4 day old new-born WT 
and Phospho1-/- mice as previously described (Zhu et al., 2011). Extracted calvaria 
were washed in Hank's Balanced Salt Solution and subject to successive cellular 
digestions with constant agitation at 37C.  Briefly, the digests consisted of: 
I. 10 minute collagenase type II digestion (10mg/ml, Worthington, Lakewood, 
NJ) whereby the supernatant was discarded. 
II. 30 minute collagenase digestion which was retained together with a 
phosphate-buffered saline (PBS) wash of the calvaria (fraction 1). 
III. 10 minute ethylenediaminetetraacetic acid (EDTA, 4mM) digestion which 
was retained together with a HBSS wash (fraction 2). 
IV. A 30 minute collagenase digestion (fraction 3).  
Osteoblasts were isolated from the fractions by centrifuging (1800g, 5 minutes), 
resuspended in primary osteoblast medium (Appendix I) and finally pooled to 
obtain a single cell suspension. The extracted osteoblasts cells were expanded in 
flasks in a humidified atmosphere of 95% air/5% CO2 and maintained at 37 °C until 
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80–90% confluence and were then plated at 10 000 cells/cm2 in multi-well plates for 
individual experiments as described in section 2.2.3.2. 
 
2.2.3 Freezing/thawing of cells   
2.2.3.1 Cell lines      
Cryopreservation of cell lines was carried out to maintain stocks. Upon confluency 
cells were trypsinised and counted as described in section 2.2.4. The cell suspension 
was then centrifuged at 2000g for 5 minutes and resuspended in 50/50 maintenance 
media and freezing mix 1 (Appendix I) to obtain the  desired number of cells (3 x 106 
cells per cryovial) (Corning, Surrey, UK). The cryovials were then wrapped in 
cotton wool, placed inside a polystyrene box and stored at -80C for 4-7 days. For 
longer term storage, vials were transferred to -150C.  Upon requirement, stored 
cells were thawed quickly at 37C and added drop wise to 5ml of pre-warmed 
appropriate maintenance media (Appendix I). The cell suspension was mixed and 
centrifuged for 5 minutes at 2000g to remove the toxic dimethyl sulfoxide (DMSO), 
which acts as a cryoprotectant to prevent cell death during the freezing process. The 
cell pellet was resuspended in maintenance media and transferred to a T175 tissue 
culture flask. 
 
2.2.3.2 Primary Calvarial Osteoblasts 
Primary osteoblasts were trypsinised and counted as described in section 2.2.4 and 
resuspended in 1.5 ml freezing mix 2  (Appendix I) to obtain the  desired number of 
cells (3 x 106 cells per cryovial). The cryovials were placed in isopropanol at -20C 
for two hours, transferred to -80C overnight and for longer term storage, vials were 
transferred to -150C.  To thaw primary calvarial osteoblasts, cryovials were gently 
shaken in a 37C water bath. The total contents of the cryovial (1.5ml) was and 
added drop wise to 4.5ml of pre-warmed primary osteoblast medium  (Appendix I). 
The cell suspension was mixed and centrifuged for 5 minutes. The cell pellet was 
resuspended in primary osteoblast medium and transferred to a T175 tissue culture 
flask. 
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2.2.4 Maintenance and passaging of cells 
Upon sub-confluence (70-80%), adherent cells were passaged by trypsinisation. 
Initially the culture medium was removed and the monolayer was washed with 
PBS. Cells were detached from the plastic by incubation with trypsin/EDTA for 
approximately 5 minutes at 37C. The trypsin was neutralised by the addition of at 
least double the volume of appropriate cell medium containing the neutralising FBS. 
The cellular suspension was centrifuged at 2000g for 5 minutes in order to obtain a 
cellular pellet. The medium was removed and the cells were counted (if 
appropriate) using a Neubauer haemocytometer and then resuspended in a known 
volume of appropriate cell medium. 
 
2.2.5 Conditioned media  
Conditioned media was collected from WT and Phospho1-/- primary osteoblasts that 
were plated at a density of 10 000 cells/cm2 as described. Media was changed every 3 
days and on at day 0 (upon plate confluency), 3, 6 and 9 was removed from the cells, 
centrifuged to remove particulates and frozen at -80°C until required.  Collected 
conditioned media from Phospho1-/- primary osteoblasts was incubated for 1 hour 
with C2C12 (mouse myoblast cell line), FAZA (rat liver cell line), Ins1e 
(rat insulinoma cell line), MLOA5 (mouse postosteoblast / preosteocyte-like cell 
line), 3T3-L1 (mouse fibroblast cell line that were differentiated into to adipocytes), 
MC3T3 (mouse osteoblastic cell line) and WT primary osteoblast cultures. WT 
osteoblast conditioned medium was used as a control. Following incubation cells 
were subject to Insulin treatment as described in section 2.3.1. Protein and mRNA 
were then extracted (section 2.6.1 and 2.7.1).  
 
2.2.6 Viral transduction of primary osteoblasts        
For overexpression experiments, primary Phospho1-/- calvarial osteoblasts were 
cultured in T25 flasks and left to reach 75% confluency. Half of the media was 
removed from the flask and either 2.5µl of empty vector (EV), 5µl PHOSPHO1 
overexpression or 5µl flag tagged PHOSPHO1 (FP1) lentivirus was added to the 
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media along with and 4µg/ml of FuGENE transfection reagent (Promega, 
Southampton, UK). Virus packaging was conducted by Dr. Carmen Huesa. 
Following 6 hours the media was replaced. In order to select for successfully 
transfected osteoblasts, 5mg/ml of puromycin was added to the osteoblast cultures 
for 3 days. Media was then replaced, supplemented with 2.5mg/ml of puromycin to 
maintain selection pressure and ensure successful transfection during the growing 
phase. Cell growth was observed every day until confluency had been achieved. 
 
2.3 In vitro procedures for metabolic assessment of cells 
2.3.1 Insulin treatment of cells 
Following confluency the appropriate cells were washed three times in PBS and 
cultured for 24 hours in αMEM supplanted with 0.5% FBS.  Medium was then 
changed to αMEM supplemented with 0.1% BSA (Fraction V) and 10mM HEPES 
10mM (pH 7.4) for 3-6 hours. Cells were then stimulated with 10mM of insulin 
(Sigma) for 15 minutes, washed in ice-cold PBS and protein and mRNA was 
extraction described in sections 2.6.1 and 2.7.1.  
 
2.3.2 Immunocytochemistry 
Primary calvarial osteoblasts were plated on rat tail type I collagen coated plastic 
ware containing a sterile 22mmx22mm glass coverslip (Scientific Laboratory 
Supplies, Yorkshire, UK). Upon confluency, cells were stimulated with 100nM 
insulin (section 2.3.1), fixed with 4% paraformaldehyde (PFA) and subsequently 
washed in PBS 3 x 5 minutes. For permeabilisation, fixed cells were incubated with 
ice cold 100% methanol for 5 minutes at -20°C. Cells were then washed 3 x 5 
minutes in PBS and blocked for 1 hour in blocking buffer (1xPBS, 5% normal goat 
serum, 0.3% triton X-100). The blocking buffer was removed and cells were 
incubated overnight at 4°C with the primary antibody against the InsR (Cell 
signalling, Boston, USA) diluted in blocking buffer overnight at 4°C. Cells were 
washed in PBS 3 x 5 minutes and incubated with the fluorochrome-conjugated goat-
anti-rabbit secondary antibody (Life Technologies) diluted in blocking buffer for 90 
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minutes at room temperature in the dark (Appendix II). Finally, cells were washed 3 
x 5 minutes in PBS and the coverslips were mounted using ProLong Gold Antifade 
Mountant with 4',6-diamidino-2-phenylindole (DAPI - Life Technologies). Slides 
were analysed using a Nikon EC-1 confocal microscope.                 
 
2.3.3 2-deoxyglucose [3H] in vitro 
WT and Phospho1-/- primary osteoblasts were cultured in 6 well plates at a density of 
10 000 cells/cm2 as described in section 2.2.4. Upon confluency primary osteoblasts 
were washed with PBS and incubated in in serum alpha MEM for 4 hours. 
Osteoblasts were washed in PBS again, and 2ml of PBS was added to each well. 
Osteoblasts were then treated with either 100nM insulin, 1000nM insulin or 10µM 
Cytochalasin B (PBS acted as the control) for 15 minutes at 37oC.  Radioactive 2-
deoxyglucose [3H] (Glucose, 2DG-[3-3H], PerkinElmer, Buckinghamshire, UK) was 
then added to each well (0.1 mM (9250 Bq/ml (0.25µCi/ml)) for 15min at 37°C.  2-
deoxyglucose [3H] uptake was terminated by washing the osteoblasts 3 times with 
ice cold 0.9% saline. The osteoblasts were scraped in in 600µL PBS + 0.1% sodium 
dodecyl sulphate (SDS) and transferred to Eppendorf tubes where the cell extract 
was homogenised with a needle and syringe. Half the volume of the cell lysate 
(300µl) was transferred into a scintillation tube containing 4ml of scintillation liquid 
(Ecoscint Ultra, National Diagnostic’s, Hessle, UK) and mixed well. Radioactivity 
was counted using the Hidex 300 SL Automatic Liquid Scintillation Counter (Turku, 
Finland) and the counts per minute (cpm), disintegrations per minute (dpm) were 
recorded. The remaining cell lysate was stored at -20°C and used for protein assay 
(DC) (section 2.7.2.1). Counts in the experimental wells were normalised to protein 
level following the subtraction of counts from the cytochalasin B control wells 
(cytochalasin B blocks GLUT-mediated transport and therefore any radioactivity 
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2.3.4 Mitochondria stress test 
Calvarial osteoblasts were extracted as described in section 2.2.2 and plated on a 
Seahorse XF24 microplate at a density of  25,000 and 50,000 cells per well in 100 µL 
of primary osteoblast medium. The plate was left in the hood for one hour to allow 
the osteoblasts to adhere and 150 µL of primary osteoblast medium was 
subsequently added to each well and the plate was transferred to a 37C CO2 
incubator until 100% confluency was reached (approximately 1 day). Osteoblast 
were washed in 500µl XF assay media supplemented with 25 mM glucose and 10 
mM pyruvate and placed in a non-CO2 incubator at 37C for 1 hour prior to start of 
assay.  Calvarial osteoblasts were then exposed to oligomycin (1.2µM - a complex V 
inhibitor, that inhibits respiration by inhibiting ATP synthase), the uncoupling agent 
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP -(0.56µM)), antimycin 
A (that inhibits respiration by inhibiting oxidation of ubiquinol in the electron 
transport chain) and rotenone (0.96µM - complex I inhibitor involved in the 
inhibition of the mitochondrial respiratory chain). All reagents were prepared for 
the assay from 2.5 mM Seahorse stock solutions (Seahorse Bioscience, 
Massachusetts, United States). Following equilibration the Seahorse plate was 
placed in the Seahorse XF24 Analyser and the protocol in Appendix III was 
followed. OCR values are shown as pMoles/min compared over time at 3 different 
time points per condition. All Seahorse experiments were repeated at least twice. All 
the data shown in the assays are an average of at least 3 different wells per group.  
 
2.4 Histological analysis of cell cultures 
2.4.1 Oil-Red-O 
To observe and quantify fat droplets in cell culture, differentiated cells were washed 
in PBS and subsequently fixed with 10% Neutral buffered formalin (NBF) for 1 hour 
at room temperature. Following the removal of the fixative, cells were stained with 
freshly prepared Oil-Red-O working solution for 30 minutes (Appendix I), washed in 
PBS to remove excess stain and either visualised under a microscope or stored in PBS 
at 4°C until photography.  
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2.5 In vivo studies           
2.5.1 Animal welfare and generation  
All animal experiments were approved by The Roslin Institute’s Animal Users 
Committee and the animals were maintained in accordance with Home Office 
guidelines for the care and use of laboratory animals. Animals were maintained 
under conventional housing conditions with a 12 hour light/dark cycle. Phospho1 
null mice were generated as previously described (Yadav MC, 2011) and separate 
colonies of WT and Phospho1-/- were maintained.  This was preferable to using litter 
mates from Phospho1=/+ breeding parents as the identity of the genotype of new-born 
mice was required for calvarial osteoblast preparations.  Offspring carrying the 
mutant Phospho1 gene were identified by genotyping (section 2.5.2).  
 
2.5.2 DNA extraction and genotyping  
Genotyping of Phospho1-/- mice was performed in house. Ear snips were collected 
and DNA was extracted using prepared solution 1 and 2 (Appendix IV).  To each 
ear snip, 75µl solution 1 was added and incubated at 30 min at 95°C. To neutralise 
the reaction 75 µl solution 2 was added and extracted DNA was stored at -20°C 
until use. Extracted DNA was subject to direct PCR using primers and PCR 
conditions developed by Dr. Carmen Huesa (Appendix IV). To each DNA sample, 
5µl of restriction digest master mix (Appendix IV) was added, and samples were 
subsequently incubated at 65°C for 1 hour. Samples were run on a 1.5% agarose 
Tris-borate-EDTA (TBE) gel made containing 3% ethidium bromide following the 
addition of 5x loading buffer (Bioline Reagents Ltd, London, UK). Hyper ladder 1 
was used as a reference. Corresponding band patterns are show in Fig .2.1.  
 
2.5.3 Metabolic analysis of animal models  
Male juvenile (35 day old) adult (120 day old) and ageing (220 day old) WT and 
Phospho1-/- male mice were fed a control diet (CD - 6.2% fat; Harlan Laboratories, 
Indianapolis, IN, USA).  
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Adult mice diet challenged with: 
 
I. A HFD (58% fat; DBM Scotland, Broxburn, UK) Ad libitum from 35 day old to 
until analysis at 120 day old.  
II. 2% supplemented choline diet (Harlan Laboratories) from 85-days-old to 120 
day old.  
 
Food and water consumption was measured by housing mice individually for 5 
days, whereby 200g of food and 250ml of water was given on day 0. Remaining food 
was subsequently weighed each day for 5 consecutive days at the same time each 
day (10am), obvious food remnants in the cage were recovered and weighed. The 
volume of water drank was also recorded.  Average daily food and water intake 
was calculated over the 5-day time period. Observations on chewing of food pellets 
were also recorded. Due to the crumbly nature of the HFD it was not possible to 
weigh. Blood was extracted from mice via cardiac puncture. Collected blood was 
transferred to an EDTA coated tube and placed on ice for 30 minutes (Sarstedt, 
Nümbrecht Germany). Tubes were then centrifuged at 1000g which results in serum 
separation. Serum was carefully collected and stored at -80°C until use 
 
2.5.3.1 XY activity monitor 
Basal nocturnal activity was measured using an AM524 Single Layer X, Y IR activity 
monitor and associated Amonlite software (Linton Instrumentations, Norfolk, UK) 
These experiments were conducted at the Biological Resource Facility, Roslin, 
University of Edinburgh with help from Darren Smith. The AM524 uses an array of 
infrared beams to determine activity and mobility of a subject, which are arranged 
in an 8 x 16 pitched grid. The XY activity (fast, slow and total), active time, mobile 
time, distance travelled, mobile counts (fast and slow), static counts (fast and slow), 
static time, active time and front to back movement was automatically recorded. 
Prior to use with experimental mice, initial pilot studies were undertaken to ensure 
the results were reproducible, whereby the same mouse was placed in the activity 
for three consecutive overnight periods. These studies indicated no prior acquisition 
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period prior to experimental testing was necessary. Juvenile, adult (CD and HFD) 
and aged male mice were single housed placed inside the activity monitor on the 
evening of the experiment, nocturnal activity was subsequently recorded for 14.5 
hours to encompass the dark phase (18:00 – 08:30 hours the following day). During 
testing, mice were undisturbed, had free access to chow and water and the cage had 
the normal bedding retained in order to minimise external stimuli that may alter the 
normal activity.  
 
 
Figure 2.1 Genotyping of Phospho1-/- and WT mice using PCR and all Blue staining of 
polyacrylamide gel 
(A) PCR analysis shows that Phospho1-/- mice have a product of two distinct dark bands, 
heterozygous mice have one distinct dark band and two fainter and WT mice have only one 
distinct dark band (B) Simply Blue Safe Stain used to visualise recombinant PHOSPHO1 
protein run bands on  a polyacrylamide gel.  
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2.5.3.2 Metabolic activity measurement using indirect calorimetry 
The Oxymax Lab Animal Monitoring System: CLAMS (Columbus Instruments, OH 
USA), was used to measure heat production, volume (V) of CO2, VO2 and 
respiratory exchange rate (RER) via indirect calorimetry (Ridgman, 1988). These 
studies were completed at the McGill University, Montreal, Canada, in collaboration 
with Dr. Monuzur Murshed and Dr. Zohreh Khavandgar. Male 35 day old and 120 
day old HFD mice were placed in the Oxymax system and supplied with a known 
flow of air. The consumption of O2 and production of CO2 during the metabolic 
process was recorded and the following formulae to calculate the desired 
parameters: 
 
Oxygen consumption (VO2) = (InFlow x O2in) – (OutFlow x O2out). 
Volume of carbon dioxide (VCO2) = (OutFlow x CO2out) – (InFlow x CO2in). 
Respiratory exchange rate (RER) = (VCO2 / VO2). 
HEAT = ((3.815 + 1.232) x RER) x (VO2). 
 
Prior to analysis an initial acclimatisation was undertaken which involved placing 
the mice in the Oxymax system for 2 hours for three consecutive days. The 
experiments were conducted over a 24 hour period, from 12pm until 12pm to obtain 
both day and night measurements. Associated CLAMS data eXamination Tool 
(CLAX) was used to assist in the analysis of the produced data.  
 
2.5.3.3 Glucose and insulin tolerance tests 
Mice were fasted for 4 hours and administered either 2mg of D-glucose (Sigma, 
Poole, UK) per g of body weight (BW) by gavage or 0.5mU of insulin per g of BW by 
intraperitoneal injection (IP) (Fig. 2.2). At 0, 15, 30 and 60 minutes after 
administration, blood glucose was measured with an Accu-Chek Aviva glucose 
meter (Roche Diagnostics Ltd, Lewes, UK) and insulin was measured by ELISA 
(ChrystalChem, Chicago, IL, USA) to obtain glucose-stimulated insulin secretion 
(GSIS) measurements. Animals were allowed to recover for two weeks prior to cull 
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and tissue removal to ensure glucose or insulin challenge did not bias further 
experimentation (serum measurements, gene expression etc.). However it is 
important to note 2% choline diet were sacrificed immediately after metabolic 
testing as a two week recover may have diluted diet induced changes. 
  
2.5.3.4 In vivo 20 minute insulin treatment  
To examine the effects of insulin treatment on the expression of known targets of 
insulin action. Juvenile male mice were fasted for 4 hours and administered 1mU of 
insulin per g of BW. At 0 and 19 minutes following administration, blood glucose 
was measured (detailed in section 2.5.3.3) to ensure insulin had been delivered 
successfully. At 20 minutes following insulin administration, mice were sacrificed 
and tissues including tibiae, pancreas, liver, quadriceps femoris and brown, 
subcutaneous (SB), mesenteric (MF) and gonadal (GF) fat pads, were collected for 
protein and gene expression analysis.    
 
2.5.3.5 Beta 3-agonist-37344 administration 
As an alternative to acute cold exposure juvenile WT and Phospho1-/- male mice were 
weighed and fasted for 4 hours between 9am and 1pm. Beta 3-receptor agonist -
37344 (BRL-37344, Sigma) was administered IP 3 hours before euthanisa (1mg/kg 
BW) and adipose depots were collected for gene expression analysis (as described in 
2.6) (Doucette and Rosen, 2014).  
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Figure 2.2 Metabolic testing of Phospho1-/- and WT mice  
Representative photographs of oral gavage procedure (A), Glucose measurement using the 
glucose meter (B) and blood collection for serum analysis (C).  
 
2.6 RNA methods           
2.6.1 Isolation of RNA from cells and tissues 
Prior to RNA extraction cultured primary osteoblasts and cell lines were washed 
and scraped from individual wells in PBS and stored at -80°C until use.  Tissues 
were snap frozen and homogenised in QIAzol Lysis Reagent (RNeasy Lipid and 
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Tissue kit, Qiagen, Manchester, UK ) using a hand held homogeniser (Cole-Parmer 
Instruments Ltd, London UK). Bone samples were submerged in liquid nitrogen 
and homogenised using a mortar and pestle followed by a hand held homogeniser 
in QIAzol Lysis Reagent. RNA was extracted using the RNeasy lipid tissue kit 
following manufactures instructions. The RNeasy lipid contains a 
phenol/guanidine-based sample lysis step which facilitates the breakdown of fatty 
tissues.  An optional DNase treatment step was also included to completely remove 
any contaminating DNA (Qiagen). The concentration and quality (the ratio of 
wavelengths 260nm/280nm) of RNA was measured using a NanoDrop 
spectrophotometer (Labtech, Tampa, USA). Samples were diluted to the same 
concentration (that of the lowest sample) in nuclease-free water (NFW).  
 
2.6.2 Reverse transcription  
Complementary DNA (cDNA) was prepared from 10µl. of the diluted RNA using 
reverse transcription. Briefly, 2µl of random primers (1/60) was added to the diluted 
mRNA and heated for 10 minutes at 70°C in a Hybaid polymerase chain reaction 
(PCR) Express Thermal cycler (Thermo Scientific, Northumberland, UK).  Samples 
were cooled on ice. The Superscript II kit was used to obtain cDNA following 
manufactures guidelines. The samples were run on the following programme in the 
Hybaid PCR machine: 25°C for 10 minutes; 42ºC for 50 minutes; 70°C for 15 minutes 
and held at 4°C. The neat cDNA samples were stored at -20°C. The cDNA was 
diluted with NFW to 5ng/µl and stored at -20°C.  
 
2.6.3 Primer design 
Primers were designed to span an exon to avoid amplifying genomic DNA. Using 
Primer BLAST, primer sequences were entered to check that the melting 
temperature (Tm) of the primers was between 65°C and 75°C and within 5°C of each 
other and the GC content was between 40% and 60%.  In silico PCR was used to 
check primers before purchasing (http://genome-
euro.ucsc.edu/cgiin/hgPcr?hgsid=202376389_vk1kEGcrSPgtiTvcQk9GXSRJtLMn).   
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PCR oligonucleotides were purchased from MWG Eurofins (Ebersberg, Germany). 
Primer sequences are disclosed in Appendix V.  
 
2.6.4 Real time quantitative polymerase chain reaction and quantification of gene 
expression  
Real time qPCR reactions were conducted in a 96 well plate (Thermo Scientific) and 
cycled in a Stratagene Mx3000P PCR cycler (Agilent Technologies, Santa Clara, 
USA). For each qPCR reaction, 1µl of primer (200mM forward and reverse primer), 
10µl SYBR Green Master Mix (Primer Design, Southampton, UK), 4µl RNase/DNase 
free water was made up to a volume of 15µl and added to 5 µl of diluted cDNA 
(5ng/µl). The qPCR reaction was cycled using the following protocol: Initial hotstart 
enzyme activation (2 minutes 95°C) followed by 40 cycles of denaturation (15 
seconds at 95°C) and data collection (60 seconds at 60°C). A post PCR run melt 
curve was run to ensure the primers produced only one product. Each sample was 
tested in triplicate and compared to the appropriate housekeeping gene using 
MxPro software (Agilent, Cheshire, UK). The relative expression of the analysed 
genes was calculated using the ΔΔCT method(Laakso et al., 2001), whereby an 
arbitrary amplification threshold is set and relative expression levels of the samples 
are determined by comparison of the number of amplification cycles required to 
cross this threshold (CT).   
 
2.6.5 Optimisation of qPCR primers and PCR product sequencing 
Primers were tested for efficiency using serial dilutions of cDNA (known to express 
the gene of interest) to create a standard curve (Fig. 2.3). Primers were considered 
acceptable if the amplification efficiency was within the range of 90-110%, with an 
R2 value between 0.99 and 1.00 and an amplification curve with sigmoid curves at 
regular intervals along the dilution series.  Primer specificity was demonstrated by 
the generation of a single peak in the dissociation curve. Agarose gel electrophoresis 
was used to ensure the presence of one band following amplification. Bands were  
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cut from the gel and the DNA purified using a Qiaquick Gel Extraction Kit (Qiagen). 
To confirm primer specificity the purified DNA was sent for sequencing to 
Edinburgh Genomics (University of Edinburgh). NCBI Blast was used to match 
product sequence with sequence of interest.  
 
Figure 2.3 Validation of qPCR primer efficiency and specificity.  
Representative image of (A) standard curve and (B) dissociation curve. 
 
2.7 Protein methods          
2.7.1 Protein extraction from cells and tissues  
Cell monolayers were washed in ice-cold PBS to remove excess medium and 
scraped in an appropriate volume of radio-immunoprecipitation assay (RIPA) 
buffer (Appendix I) containing 0.15 x volume of complete mini protease inhibitor 
cocktail (Roche). Tissue samples were homogenised in the appropriate volume of 
RIPA buffer.  All samples were vortexed further and subjected to one freeze thaw 
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cycle to ensure cell disruption and protein release. Prior to quantification of protein 
concentration, samples were centrifuged and the supernatant removed and stored at 
-20°C to ensure no further protein release from the cell pellet/tissue material.  
 
2.7.2Quantification of protein concentration 
2.7.2.1 DC assay 
To quantify protein concentration in each sample, the Bio-Rad DC protein assay 
(Bio-Rad, Hertfordshire, UK) was used (similar to the well-documented Lowry 
assay) following manufactures instructions. Briefly, a protein standard (γ globulin) 
was used to generate a standard curve. Duplicates of 5μl of standard or sample was 
added to a well of a 96-well plate followed by 25μl alkaline copper tartrate (reagent 
A) and 200μl Folin’s reagent (reagent B). The plate was shaken and incubated at 
room temperature for 15 minutes prior to the measurement of absorbance (750nm) 
using a Multiskan Ascent microplate reader. The unknown sample protein 
concentrations were extracted using the generated standard curve.  
 
2.7.2.2 Bradford assay 
For samples containing high detergent levels, the Bradford protein assay was used 
to measure protein concentration (Bio-Rad). γ globulin protein standards were 
prepared ranging from 10 -90μg/ml and used to generate a standard curve to which 
unknown sample values were extrapolated as described in 2.7.2.1. Standard or 
diluted sample (160μl) were added in duplicate into a 96-well plate, followed by 
40μl Bradford dye reagent concentrate. The plate was shaken briefly and incubated 
at room temperature for 5 minutes prior to the measurement of absorbance (595nm) 
using a Multiskan Ascent microplate reader.  
 
2.7.3 Western blotting 
Following protein concentration quantification (section 2.7.2), protein samples were 
diluted to the same concentration (between 10-30µg) and the appropriate volume  of 
4x lithium dodecyl sulphate (LDS) sample buffer and reducing agent DTT was 
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added to each sample. Diluted protein samples were then denatured at 70°C for 10 
minutes.  The denatured protein samples and a pre-stained molecular weight 
marker to accurately determine protein size (All Blue, Bio-Rad) were chilled on ice 
for 5 minutes before being loaded onto pre-cast 3-8% Tris –Acetate or 10% Bis-Tris 
gels (Invitrogen, Paisley, UK - depending upon protein of interest molecular 
weight). Gels were run in a Novex Gel Tank (Invitrogen) containing 1x Tris Acetate 
or 1x MOPS running buffer, respectively. Anti-oxidant was added to the centre 
compartment of the tank to preserve reduced proteins (2.5µl/ml; Invitrogen). 
Proteins were separated by electrophoresis at 200V for 50mins.        If necessary, to 
visualise protein bands on polyacrylamide gels prior to transfer the gel was washed 
3 x 5 minutes in 100ml of ultrapure water, covered with 20ml of SafeStain (Life 
Technologies) and allowed to shake for 1 hour at room temperature. The gel was 
then washed with ultrapure water for at least 1 hour prior to visualisation either 
using a light box, or an Odyssey CLx scanner (LI-COR Biosciences, Lincoln, 
Nebraska) using the 700 channel (Fig. 2.1). Proteins were transferred onto a 
Hybound-ECL nitrocellulose membrane (GE Healthcare, Amersham), sandwiched 
between transfer buffer (Appendix I) soaked filter paper and sponges. This created a 
wet transfer within a transfer module (Invitrogen). Transfer was run on ice at 30V 
for 90mins. Following transfer, nitrocellulose was washed several times in a mixture 
of Tris-Buffered Saline and Tween 20 (TBST). Depending on western blot method 
(LICOR or ECL) the membrane was then blocked in Odyssey blocking buffer 
(LICOR) or 5% milk block, respectively. Primary antibodies were applied either 
overnight at 4°C with agitation or for 1 hour at room temperature (Primary and 
secondary antibodies listed in Appendix II). Membranes were then washed in 
PBS/TBST and secondary antibody applied in blocking buffer for 1.5 hours at room 
temperature (LICOR - 55 minutes with protection from light). Bound antibody was 
either detected using chemiluminescence detection or using the Odyssey infrared 
detection system were imaged directly on the LICOR Odyssey® scanner (Eaton et 
al., 2013). For chemiluminescence detection Amersham ECL western blotting 
detection reagents A and B (GE Healthcare) were used. The nitrocellulose was 
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covered with the reagents in a ratio of 1:1 for 1min and chemiluminescence was 
detected with Amersham ECL Hyperfilm (GE Healthcare), which was developed 
using a Medical Film Processor (SRX-101A; Konica Minolta, Banbury, UK).  
 
2.7.4 Stripping nitrocellulose 
Antibodies were stripped from the nitrocellulose membranes using restore plus 
stripping buffer (Thermo Scientific) at 37°C for 30 minutes. To ensure complete 
antibody removal, membranes were probed with the appropriate secondary 
antibody and chemiluminescence was repeated.  
 
2.7.5 Protein expression quantification 
For ECL detected proteins, Image J was used to compare the density of bands on the 
scanned x-ray films. Imported images were converted to grayscale (8-bit). Using the 
rectangular selections tool, a rectangle was drawn around the first lane, and using 
the gel tool, the remaining lanes were step wise selected. Following selection, the 
lanes were plotted, which produces a profile plot representing the relative density 
of the contents of the rectangle over each lane. The peaks were closed and the area 
measured. These measurements were then exported into an excel sheet where the 
relevant statistics were performed. LICOR scanned blots were quantified on single 
channels using Image Studio Lite. 
  
2.8 Histology 
2.8.1 Paraffin embedded tissue  
For wax sections all tissue was fixed in 4% PFA for 24-48 hours and then transferred 
to 70% ethanol. However calcified tissue was decalcified in 10% EDTA (pH 7.4) with 
gentle agitation at 4°C for approximately 3 weeks, with regular EDTA changes prior 
to transfer to 70% ethanol. Fixed tissue (PFA) were placed in cassettes, and subjected 
to the following automated protocol: two changes of each of the following: 70% 
ethanol for 1 hour; 80% ethanol for 1 hour; 95% ethanol for 1 hour; 100% ethanol for 
1 hour; xylene (VWR, Leicester, UK) for 1 hour; and overnight in paraffin wax 
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(VWR) at 60°C, followed by fresh paraffin wax for 1 hour.  Processed tissues was 
embedded in paraffin wax using plastic moulds and allowed to set at 4°C. All Wax 
blocks were trimmed to size and stored at 4°C until required. Prior to sectioning, 
paraffin blocks were cooled on an ice block overlaid with a wet paper towel for 30 
minutes.  Using a microtome (Ernst Leitz AG, Germany; blades used were MX35 
Premier+ Microtome Blades, Thermo Scientific, Cheshire, UK), Blocks were then 
sectioned at a 5µm thickness and sections were floated for 1 minute in a 40°C water 
bath and transferred to a poly-l-lysine coated microscope slide (VWR International 
Ltd, Lutterworth, UK). Slides were dried at 37°C overnight to ensure attachment of 
the sections to the slide and stored at room temperature until required. 
 
2.8.2 Frozen tissue 
For frozen sections proximal tibiae were coated in 5% polyvinyl acetate (PVA) and 
livers from WT and Phospho1-/- mice were snap frozen in a cooled hexane bath, and 
stored at -80°C.  Frozen tissue was embedded in optimal cutting temperature (OCT) 
embedding medium (Brights, Huntingdon, UK) and attached to a metal chuck. A 
cryostat (OTF500/HS-001, Brights) was used to section tissue. Excess OCT was 
removed and the tungsten carbon knife (Brights) blade angle was set to 25°C, 
chamber temperature to 25°C and specimen temperature to 23°C. 10µm sections 
were taken and transferred to Superfrost slides (Fisher, Loughborough) and stored 
at -80°C. For bone sample’s, the Cryojane tape-transfer system was used 
(Instrumedics Inc, Richmond, IL, US) to allow preservation of the calcified bone. 
Briefly, after the block was trimmed, a piece of transfer tape was adhered to the 
block face, the adhesive tape is placed section-side-down on the adhesive-coated 
slide, and is laminated to the adhesive layer using a cold roller, a flash of ultraviolet 
light passes through the slide to polymerise the adhesive layer on the slide into a 
hard, solvent-resistant plastic, tightly anchoring the section to the slide, the tape is 
peeled away leaving the still frozen section tightly bonded to the plastic layer. The 
slides were finally air-dried and fixed in 100% ice cold acetone and stored at -80°C 
until use.   
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2.8.3 Haematoxylin and eosin 
Paraffin embedded sections (section 2.8.1) of adipose tissue were stained with 
haematoxylin and eosin (H&E) such that morphology of adipocytes could be 
measured. Slides were first de-waxed in xylene and rehydrated through a series of 
alcohols to dH2O and stained with H&E using Leica Autostainer and mounted in 
DePeX (VWR, Lutterworth, UK). Slides were mounted with DPX and visualised 
using a Nikon E600microscope with a digital camera attached, using Image Tool 
(Image Tool Version 3.00).  The adipocyte diameters of 100 adipocytes per section 
(sections were take every 120µm throughout the tissue) were measured using 
ImageJ software (Lee et al., 2007). 
 
2.8.4 Oil-Red O 
Frozen liver sections (section 2.8.2) were washed with running tap water for 10 
minutes, rinsed with 60% isopropanol and stained with freshly prepared Oil-Red-O 
working solution for 5 minutes (Appendix I). Slides were then washed with 60% 
isopropanol and nuclei was lightly stained with haematoxylin (5 dips), rinsed with 
distilled water and mounted in aqueous mountant (Life Technologies). 
 
2.8.5 Quantification of pancreatic β-cell islet size number and size  
Paraffin embedded pancreata (as detailed in section 2.8.1) from 120 day male CD 
WT and Phospho1-/- mice were sent to  Dr. Sophie Turban (University of Edinburgh), 
who kindly immunostained sections with guinea pig anti-insulin (1:300) (AbCam, 
Cambridge, UK) prior to image quantification of islet areas using KS300 software 
(3.0 CarlZeiss Vision, GmBH).  
 
2.9 Fat phenotypic analysis  
2.9.1 Computed tomography  
The bodies of freshly sacrificed male mice (35, 120 180 and 200 day old C57BL/6 
mice and 120 day old male WT and Phospho1-/- control and HFD mice) were 
immediately CT-scanned using a Siemens Somatom Esprit Computer Tomography 
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(CT) Scanner. Multi-object (6 mice/scan), cross-sectional CT images were taken 
along the length of the body (3 mm apart, field of view 450 mm, approximately 70 
images per mouse) (Luu et al., 2009). Sheep Tomogram Analysis Routines (STAR) 
software (BioSS - V.4.8; STAR: Sheep Tomogram Analysis Routines, University of 
Edinburgh, http://www.ed.ac.uk) was used to calculate the total area and average 
densities of fat, muscle and bone in each carcass image without segmenting out guts 
and organs, based on density thresholds (low fat: -174 Hounsfield units (HU), high 
fat: -12 HU, low muscle:-10 HU, high muscle: 92 HU, bone: < 94 HU)). These values 
were established from sheep calibration trials in which lambs underwent CT 
scanning followed by slaughter and full dissection (Glasbey and Robinson, 2002). 
Sheep thresholds were used as mouse specific thresholds have not been reported in 
the literature to the best of my knowledge. 
 
2.9.2 Freeze drying  
Whole mouse carcasses and corresponding isolated adipose tissue were freeze dried 
to determine the dry matter weight (DM) of the carcass. The predication of 
individual fat percentage values was calculated by regression on DM content 
(DM/BW) using an equation (FatP _DM/BW (%) x 113 - 30.2) derived by Hastings & 
Hill (Hastings and Hill, 1989). The CT based measures of tissue weights were then 
compared to the DM-based estimates for the fat content (fat %) and the fat free mass 
(FFM) in (%) using simple linear regression: 
yi= b0 + b1xi,      
with b1= regression coefficient and b0 = intercept 
 
2.9.3 Micro magnetic resonance imaging and liver spectroscopy 
Dr. Jansen (University of Edinburgh, Preclinical Imaging) conducted micro- 
magnetic resonance imaging (µMRI) and liver spectroscopy on male 120 day-old 
WT and Phospho1-/- CD and HFD mice. Mice were sacrificed at the Roslin Institute 
and placed in a plastic bag, weighed and transported to the preclinical imaging 
facility at the Little France campus to avoid quarantine restrictions. The Varian 7 
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Tesla magnet using VnmrJ Pre-Clinical MRI Software was used to acquire T2 
weighted images in both the axial (1mm thickness, 192x192 pixels, TR – 3000ms, TE 
24ms, 1 average, FOV – 38.4 x38.4) and coronal planes (0.5mm Thickness, 512x256 
pixels, TR – 3000ms, TE 24ms, 4 averages, FOV – 102.4 x51.2) (Fig. 2.4). Liver 
spectroscopy was conducted on user defined areas (TR - 1800ms, TE – 11.5 ms, 16 
averages, Vauxhall 3x3x3). Acquired DICOM images were analysed using 
sliceOmatic (TomoVision). This software was used to tag user defined areas 
allowing the quantification of total SB and MF. Tagging was done blind and the 
same images from one mouse were analysed twice to ensure reproducibility.    Liver 
spectra were analysed by fitting Lorentzian and Gaussian lineshapes to fit peaks to 
MR data using jMRUI (Graphical User Interface that allows time-domain analysis of 
in vivo MR data http://www.mrui.uab.es/mrui/mrui). 
 
Figure 2.4 Micro magnetic resonance imaging (µMRI) in mice  
Representative image of (A) Varian 7 Tesla µMRI instrumentation (B-C) insert for micro- 
imaging (D) image reconstruction and post-processing facility.  
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2.10 Biochemical Methods 
2.10.1 Choline assay 
Serum from 35 day old and 120 day old CD and HFD mice was collected as 
described in section 2.5.3. The choline/Acetylcholine Assay Kit (Abcam) was used to 
determine serum choline. The assay was carried out in accordance with the 
manufacturer's instruction. The serum samples used in the assay were plated in 
duplicate and absorbance (750nm) was measured using a Multiskan Ascent 
microplate reader. 
  
2.10.2 Pancreas insulin content 
Pancreases from 120 day old WT and Phospho1-/- mice were dissected, weighed and 
submerged in 2ml of pancreata lysis buffer (Appendix I). Pancreata were 
homogenised using a small hand-held homogeniser. The homogenate (100µl) was 
diluted in 2ml of acidified ethanol (1.5% HCl in 70% ethanol) overnight at -20°C. 
The next day samples were centrifuged at 2000g for 15 minutes at 4°C. The aqueous 
solution neutralised by the addition of 100μl 1M Tris (pH 7.5). Insulin content was 
measured by ELISA (as described in section 2.10.6) and normalised to protein 
content as measure by the Bradford assay (section 2.7.2.2). 
 
2.10.3 Malachite green phosphatase assay 
The BIOMOL Green reagent (Enzo Life sciences, Exeter, UK) was used to measure 
free-phosphate released during enzymatic phosphatase assays. This assay is a 
modification of the classic Malachite green assay (Martin et al., 1985; Harder et al., 
1994). Briefly the reactions were measured in 96-well plates with a total volume of 
50µl. Serial dilutions of the phosphate standards were made using the assay buffer 
(20mM Tris, 2mM MgCl2, 25µg/ml BSA (Fraction V)). Substrates and the enzyme 
(rec human PHOSPHO1 – already available in the lab) were also diluted in assay 
buffer. Reactions were allowed to proceed at 37°C for 30 minutes. The reaction was 
then terminated by the addition of 100µl BIOMOL green reagent and left at room 
temperature for 20-30 minutes to allow for development of the green colour. The 
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absorbance of each well at 620 nm was measured and the specific activity was 
calculated in units of activity per mg of enzyme, where 1 unit of activity represents 
the hydrolysis of 1 nmol of phosphate per minute (Roberts et al., 2004).  
 
2.10.4 Triglyceride colorimetric assay 
The triglyceride colorimetric assay kit (Cayman Chemicals, Michigan, and USA) 
was used to measure triglyceride levels present in blood serum from 120 day old 
WT and Phospho1-/- mice. This assay is based on the enzymatic hydrolysis of the 
triglycerides by lipase to produce glycerol and free fatty acids. Briefly, 10µl of the 
prepared standards and serum was added to the provided plate in duplicate and 
the assay was initiated by the addition of 150 µl of diluted triglyceride enzyme 
mixture. The plate was then shaken, covered and incubated at room temperature for 
15 minutes. The glycerol released was measured by a coupled enzymatic reaction 
system with a colorimetric readout at 540 nm (Multiskan Ascent) and total 
triglyceride content was calculated.  
 
2.10.5 Osteocalcin carboxylation status 
Serum from 56 day old and 120 day old male WT and Phospho1-/- CD mice were 
collected as described in section 2.5.3 and sent to Prof. Karsenty and Dr. Ferron 
(Columbia University, USA) who conducted an ELISA-based method to quantify 
osteocalcin carboxylation in mice (Ferron et al., 2010b). Briefly, ELISA plates (R&D 
systems, Minneapolis, MN, USA) were coated with 100μl of a 12 μg/ml solution of 
affinity purified anti-GLU-OCN, anti-GLA13-OCN or anti-MID-OCN, washed and 
blocked. 5μl of blank, standards (purified GLU-OCN or synthetic GLA-OCN) or 
serum samples were added to the plate and incubated overnight at 4°C. HRP-
conjugated anti-CT-OCN was added to each well and the plate incubated for 1 hour 
at room temperature, further washes were conducted prior to the addition of a 
3,3′,5,5′-tetramethylbenzidine substrate and the final stop solution. Absorbance 
(450nm) was measured using a plate reader (Biorad). Concentrations of GLU-OCN, 
GLA13-OCN and total OCN in the samples were calculated from polynomial 
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second order or exponential standard curve obtained from the standard included in 
each assay. 
 
2.10.6 Enzyme-linked Immunosorbent Assay (ELISA) 
To measure serum leptin, insulin and adiponectin serum was collect (described in  
section 2.5.3) and sample was analysed in duplicate using commercially available 
ELISA’s following manufacturer’s instructions (ChrystalChem, Chicago, IL, USA). 
 
2.11 Mass Spectroscopy 
2.11.1 Protein sequencing 
To determine if PHOSPHO1 was present in various tissues recombinant 
PHOSPHO1 protein was first sent to the Mr Dougie Lamont at the FingerPrints 
Proteomics Facility (College of Life Sciences, University of Dundee) to generate a 
purpose built inclusion list that was used to detect PHOSPHO1 in protein tissue 
samples (pancreas, quadriceps femoris and calvaria). Following completion protein 
samples from the tissues of interest were sent to Mr Dougie Lamont and a mass 
spectroscopy search was performed using proteome discovery software (Thermo 
Scientific) against both IPI mouse database and purpose built inclusion list.  
 
2.11.2 Quantification of ceramide species in serum samples  
To quantify serum ceramide in 120 day old male WT and Phospho1-/- CD mice serum 
lipids were extracted according to the method of Folch et al. (Folch et al., 1957) fully 
supervised by Professor Phillip Whitfield (University of the Highlands and Islands, 
Inverness).  Briefly, 50µl of serum was extracted with 4 ml chloroform/methanol 
(2/1, v/v) containing 10µl 1nmol D2, 10pmol D3 and 10pmols D2 as internal 
standards (C17 ceramide was used as a control as this species is not present in 
humans). The mixture was stood at room temperature for 1 hour and subsequently 
partitioned by the addition of 1.3ml of 0.1M KCL. The mixture was centrifuged to 
facilitate phase separation removing the lower chloroform layer which was then 
evaporated under nitrogen gas. The lipid extract was then reconstituted in 2 ml 
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prior to solid-phase extraction. A silica solid-phase extraction cartridge (100mg/3 
ml) was attached to the chamber and primed with  5ml chloroform, the serum 
chloroform extract was then applied to the column, and the column was then 
washed with 5ml of chloroform and 10ml of chloroform/ethyl acetate (1/1, v/v) 
before elution of the glycolipid fraction with 5 ml of acetone/methanol (9/1, v/v) and 
the fraction was dried down and reconstituted in 200µl methanol containing 5mM 
ammonium formate glycolipid analysis and quantification was performed by 
Professor Phillip Whitfield via electrospray ionisation-tandem mass spectrometry 
(ESI-MS/MS) using a TSQ Quantum Ultra triple quadrupole mass spectrometer 
equipped with a heated electrospray source (HESI) and coupled to a Accela 1250 
UHPLC system (Thermo Scientific, Hemel Hempstead, UK)(Whitfield et al., 2002) 
(Fig. 2.5). Data were analysed using software driven algorithm (thermo Xcalibur 





Figure 2.5 Mass spectrometer  
Representative image of (A) TSQ Quantum Ultra triple quadrupole mass spectrometer (B) 
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2.11.3 Identification of differential expressed serum proteins 
Proteins from 120 day old male WT and Phospho1-/- CD and HFD male mice serum 
were be extracted and prepared. Protein samples were precipitated using cold 
acetone, and gently dried. Samples were dissolved in ICAT denaturing buffer 
containing the reducing agent trichloroethyl phosphine, alkylated (iodoacetamide), 
and digested with sequencing grade trypsin (Sigma). Extracted peptides were 
analysed by Dr. Cal Vary, MMCRI according to published methods (Romero et al., 
2011). Quantitation was accomplished by analysis of peak area. The search 
parameters allowed for cysteine modification by the ICAT reagent and biological 
modifications programmed in the algorithm (i.e., phosphorylation, amidation, 
tryptic fragments). The detected protein threshold was set to 2.0 to achieve 99% 
confidence. Identified proteins were grouped by the Paragon algorithm (Life 
Technologies) to minimise redundancy, and following bias correction (method 
kindly provided by Dr. Cal Vary) Functional pathway and causal network analysis 
was performed using QIAGEN’s Ingenuity (IPA), GeneMANIA and 
EXPANDER (EXpression Analyzer and DisplayER) following training from Dr. 
Jacqueline Smith, University of Edinburgh. 
 
2.11.4 Identification of differential expressed serum lipids.  
Total lipids were extracted from serum using the Bligh-Dyer method for total lipid 
extraction (Bligh and Dyer, 1959) and silica based solid phase extraction was 
employed for sample clean up and fractionation prior to analysis. This was done by 
myself with assistance from Dr. Cal Vary, MMCRI.   Lipids were subsequently 
analysed by direct infusion on a hybrid quadrupole time-of-flight (TOF) mass 
spectrometer (TripleTOF 5600, ABSciex, MA, USA) using the MS/MSALL technique 
in positive mode essentially as described (Simons et al., 2012) Lipid species were 
identified using LipidView software (ABSciex), and principle component analysis 
(ABSciex) was used to identify and group lipid species according to contribution to 
sample differences. Lipid identification was corroborated by precursor ion scanning 
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using a 4000QTRAP triple quadrupole mass spectrometer (ABSciex) (Stohn et al., 
2015). 
 
2.12 Bone analysis 
2.12.1 X-ray and 3 Point bending  
Male 35 day CD, 120 day CD and 120 day HFD WT and Phospho1-/- bones were x-
rayed using a Faxitron (Biooptics, Arizona, USA). The exposure was set to 15 
seconds at 22kV. 3-point bending was conducted on male tibias from the defined 
groups using a LXR materials testing machine (Lloyd Instruments, West Sussex, 
UK) fitted with a 500N load cell (Huesa et al. 2011). The span of the anvil was set to 
7.5mm with the lowering of the cross-head at a speed of 1 mm/min. Tibiae were 
placed on the anvil in a pre-determined orientation. Data was recorded after every 
0.2 N change in load and every 0.1 mm change in deflection. Tibiae were tested until 
fracture (if possible). From the load extension curve, failure (point of maximum 
load), fracture (load rapidly decreases to 0), maximum stiffness (maximum gradient 
of the rising portion of the curve) and yield (95% of the maximum stiffness) were 
defined (Aspden, 2003) (Fig. 2.6). Tibia lengths were measured using callipers.  
 
2.12.2 Micro-computed tomography imaging  
To assess the trabecular architecture, cortical geometry and relative density of bone 
mineral, micro-computed tomography (µCT) imaging was carried out with 
guidance from Professor Rob Van’t Hof and Dr. Camen Huesa. Bone specimens 
were dissected, placed into H20 and stored at -20°C pending analysis. High-
resolution scans with an isotropic voxel size of 5 μm  (trabecular) or 10μm cortical 
scanning  were acquired with a micro-computed tomography system (μCT, 60 kV, 
0.5 mm aluminum filter, 0.6° rotation, Skyscan 1172, Brukker microCT, Kontich, 
Belgium). Two images were averaged at each rotation angle to reduce noise. Scans 
were reconstructed using NRecon software (Brukker microCT).  The base of the 
growth plate was used as a standard reference point, and a 1000μm section of the 
metaphysis was taken for analysis of trabecular bone.  For analysis of cortical 
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structure a 400 μm section of the mid-diaphysis was scanned 1500μm below the 
base of the metaphysis section.  CTAn software (Bruker) was used to analyse 
appropriate parameters (bone volume fraction (BV/TV), trabecular thickness (Tr. 
Th.), trabecular separation (Tr. Sp.), trabecular number (Tr. No.), trabecular pattern 
formation (Tr. Pf.), structural model index (SMI), degree of anisotropy (DA), cortical 
porosity (Cor. Por. %), cortical thickness (Cor.Th.) and cortical bone mineral density 
(Cor. BMD) and reduce noise in the reconstructed images by applying a median 
filter with a radius of 1 pixel. Appropriate thresholds were set to ensure only bone 
was analysed. Calcium hydroxyapatite phantoms of a known density were scanned 





Figure 2.6 Three point bending load extension curve  
Diagram of a typical load extension curve obtained with 3-point bending. The measured 
parameters are highlighted. 
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2.13 Statistical analysis   
Data was analysed in this thesis using various statistical models. All data were 
checked for normality and equal variance. Linear regression and correlation analysis 
based on Excel (Microsoft Office 10) built-in functions with interval of confidence 
and testing of the correlation coefficients were performed according to standard 
procedures described in the statistical literature (Rasch et al., 1978a; 1978b). The SAS 
software was used to fit the generalised linear model, and the Gompertz growth 
model was performed using Excel (Microsoft Office 10) built-in functions. The 
Student's t-test, ANOVA and a Two Way Repeated Measures ANOVA (two factor 
repetition with Holm-Sidak pairwise multiple comparison procedures) for normally 
distributed data and non-parametric data was analysed using a Mann–Whitney 
Rank Sum test using Sigma Plot software v11.0 (Systat Software Inc., London, UK) 
Data are presented as means ± standard error (SEM) were appropriate. Regression 
and correlation coefficient’s are given with the intervals of confidence (P = 0.05) and 
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3.1 Introduction   
Matrix mineralisation is a tightly regulated physicochemical/biochemical biphasic 
process localised within terminally differentiating growth plate chondrocytes, 
osteoblasts and odontoblast, facilitating cartilage, bone and tooth formation (Cecil 
and Anderson, 1978; Anderson et al., 1990). Mineralisation is dependent upon the 
accumulation of calcium and Pi which are permissive for the initiation of HA 
crystals. This process requires both non-collagenous and collagenous matrix 
proteins as well as a balance of mineralisation promoters and inhibitors such as 
include TNAP, NPP1, SIBLING proteins, ANK and PHOSPHO1 (section 1.5.2). 
 
Phosphatase, Orphan 1 is a member of the HAD superfamily of Mg2+ dependent 
hydrolases, localised in sites of mineralisation whereby Phospho1 is expressed 100-
fold higher in differentiating chondrocytes compared to non‐chondrogenic tissue 
(Houston et al., 1999; Roberts et al., 2008). PHOSPHO1 shows high 
phosphohydrolase activity towards MV membrane phospholipids (e.g. P-Cho), 
whereby it scavenges Pi. This first phase of mineralisation occurs simultaneously 
with the accumulation of calcium ions in the MV, regulated by calcium binding 
molecules such as annexin I and phosphatidylserine (Stewart et al., 2003; Roberts et 
al., 2004; Stewart et al., 2006; Roberts et al., 2007) (Wu et al., 1995; Anderson, 2003) 
resulting in the formation of HA crystal’s. Upon MV membrane breakdown, 
preformed HA is exposed to the extracellular fluid allowing propagation into the 
collagenous ECM.  
 
To further understand the roles of PHOSPHO1, Phospho1−/− mutant mice were 
generated by N-ethyl-N-nitrosourea mutagenesis (ENU) (Yadav et al., 2011). These 
mice presented with significant skeletal pathology, growth plate abnormalities, 
spontaneous fractures, bowed long bones, osteomalacia, and scoliosis in early life 
(Huesa et al., 2011; Yadav et al., 2011).  To uncover gene changes engendered in the 
Phospho1−/− mutant mice, a microarray study was conducted using WT and 
Phospho1−/− primary calvarial osteoblasts (unpublished data). The key finding was 
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that Esp, the gene encoding the protein osteotesticular protein tyrosine phosphatase, 
was up regulated 20-fold in Phospho1-/- osteoblasts compared to WT osteoblasts. In 
vitro, Esp coordinates the differentiation of the pre-osteoblast to a mature, 
mineralising cell, and in vivo may be a critical regulator of the commitment of 
mesenchymal cells to the ossification of new bones during skeletogenesis (Mauro et 
al., 1994; Chengalvala et al., 2001; Yunker et al., 2004). Interestingly, PTPs are key 
regulators of InsR signalling, dephosphorylating and inactivating the InsR within 
minutes of stimulation to maintain glucose homeostasis (Mauro et al., 1994; Hunter, 
1995; Schlessinger, 2000; Dacquin et al., 2004; Tonks, 2006; Lee et al., 2007). Thus two 
models have been generated by others to explore the function of Esp: 
 
I. Global knock out of Esp (Lee et al., 1996).  
II. Osteoblast specific knock out of Esp (Dacquin et al., 2004). 
Both mutants exhibited severe hypoglycemia and hyperinsulinemia resulting in 
postnatal lethality in the first two weeks of life. Further mechanistic characterisation 
identified that OST-PTP dephosphorylates the InsR, negatively regulating the 
osteoblast insulin signalling cascade. These data were therefore suggestive that 
OST-PTP and PHOSPHO1 may crosstalk in regulating energy metabolism. 
 
Upon the commencement of my PhD two key preliminary pieces of evidence 
emerged strengthening the hypothesis that indeed PHOSPHO1 may regulate global 
energy metabolism. Firstly, utilising a commercial phosphatase profiling assay (JPT 
Peptide Technologies, Berlin, Germany), PHOSPHO1 displayed the highest 
hydrolysing activity towards the InsR S (P) 1322, suggesting PHOSPHO1 can 
potentially dephosphorylate the InsR at serine 1322. Secondly, yeast 2 hybrid 
studies revealed a potential interaction between PHOSPHO1 and GRB10 interacting 
GIGYF1 which, as the name suggests forms a complex with GRB10 to regulate both 
insulin and IGF-1 receptor signalling. In the absence of Phospho1 it could therefore 
be hypothesised that there would be increased IGF-1 receptor phosphorylation 
under insulin stimulation, as well as increased phosphorylation of IRS1 and Src 
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homology 2 domain-containing transforming protein 1 (UniProt, 2011).  Therefore 
the overarching aim of this chapter was to confirm / oppose preliminary data 
obtained by Dr. Carmen Huesa. 
    
3.2 Hypothesis   
PHOSPHO1 directly mediates the dephosphorylation and deactivation of InsR 
situated on the osteoblast.  
      
3.3 Aims 
I. Re-analysis of microarray data. 
II. Establish if Phospho1 overexpression in osteoblasts down regulates Esp 
expression.  
III. Determine if PHOSPHO1 dephosphorylates the InsR. 
IV. Investigate the effects of insulin stimulation in calvarial osteoblast 
cultures. 
V. Comparison of PHOSPHO1 expression levels in murine tissues.   
3.4 Materials and Methods 
3.4.1 Microarray analysis of WT and Phospho1-/- osteoblasts 
Analysed microarray data from WT and Phospho1-/- osteoblasts was kindly provided 
from Dr. Manisha Yadav (Sanford Children's Health Research Center, Sanford-
Burnham Medical Research Institute, La Jolla, CA, USA) in the form of a 
spreadsheet depicting fold changes. Quantitative PCR was used to confirm gene 
expression changes in Esp as described in section 2.6. Functional pathway and 
causal network analysis was performed using QIAGEN’s IPA and GeneMANIA 
using the query genes: Adamts4, Bmp4, Cd68, Cfp, Fmod, Lum, Mpeg1, Phospho1, 
Runx2, Slc1a3, Spic and Vdr.   
 
3.4.2 Primary osteoblasts 
Under sterile conditions calvariae were dissected from 3-4 day old new-born WT 
and Phospho1-/- mice as described in section 2.2.2. Extracted cells were resuspended 
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in osteoblast medium (Appendix I) and pooled to obtain a single cell suspension. 
The cells were expanded in flasks in a humidified atmosphere of 95% air/5% CO2 
and maintained at 37 °C until 80–90% confluence and were then plated at 
10 000 cells/cm2 in multi-well plates. 
 
3.4.3 Viral transduction of primary osteoblasts 
Lentivirus’ were a kind gift from Dr. Carmen Huesa who conducted virus 
packaging. Primary osteoblasts were maintained in osteoblast medium in T25 flasks 
as described in section 2.2.4. At 75% confluency 50% of the osteoblast media was 
removed and either empty vector (EV), PHOSPHO1 overexpressing virus (P1) or 
flag tagged PHOSPHO1 overexpressing virus (FP1) was added. Following 
transfection successfully transfected primary osteoblasts were selected and 
expanded (section 2.2.6).  
 
3.4.4 Malachite green phosphatase assay  
The BIOMOL Green reagent was used to measure free-phosphate released during 
enzymatic phosphatase assays (section 2.10.3).  The absorbance of each well at 
620nm was measured and the specific activity was calculated in units of activity per 
mg of enzyme, where 1 unit of activity represents the hydrolysis of 1 nmol of 
phosphate per minute. 
 
3.4.5 mRNA analysis of primary osteoblasts cells 
Ribonucleic acid  was isolated from viral transduced calvarial primary cell cultures 
using a Qiagen RNeasy Lipid Tissue Mini Kit, mRNA concentration of each sample 
was determined (section 2.6.1) and samples were reverse transcribed to produce 
cDNA which was diluted to 5ng/µl for RT-qPCR analysis described in section 2.6.2 
and 2.6.4. Results were normalised to the Atp5b housekeeping gene and the 
dissociation curve was checked for the presence of one product. Relative gene 
expression was calculated using the ΔΔCt method (Livak & Schmittgen 2001). All 
primers used are detailed in Appendix V. 
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3.4.6 Protein analysis of primary osteoblast cells 
Protein was extracted from viral transduced calvarial primary cell cultures (section 
2.7.1) and total protein content was assessed using the Bio-Rad DC protein assay 
according to the manufacturer’s instructions (section 2.7.2.1).   PHOSPHO1 protein 
expression was determined using an anti-human anti-PHOSPHO1 HuCAL Fab 
bivalent antibody at a dilution of 1:1000 and a HRP-labelled goat anti-human 
secondary antibody (1:5000). The ECL detection kit was used to detect antibody 
labelling. To allow for protein expression quantification and conformation of 
accurate protein loading, nitrocellulose membranes were stripped and probed with 
mouse monoclonal HRP-labelled anti-β actin antibody (1:50000). 
 
3.4.7 Insulin treatment of primary osteoblasts  
Primary calvarial osteoblasts were extracted as described in (2.2.2). Osteoblasts were 
plated at 10 000 cells/cm2 in 6 well plates in osteoblast medium (Appendix I). Upon 
confluency, cells were serum starved for 4 hours in serum free medium (αMEM) 
and stimulated with insulin (10nM; Sigma) for 10 minutes before lysis (non-
stimulated cells acted as controls).  Protein was extracted for analysis as described in 
section 2.7.1. Membranes were probed with  specific antibodies against phospho-
Aktser473, total Akt, phospho-GSK3βser9, total GSK3β phospho-Erk 
1/2thr202/tyr204 and total Erk1/2 and protein expression was visualised using the 
ECL western blotting detection system.  
 
3.4.8 Immunocytochemistry 
Osteoblasts were plated in collagen coated 6 well plates. At confluency, cells were 
fixed in in 4% paraformaldehyde for 15 minutes, permeabilised and blocked as 
described in (section 2.3.2).  Following removal of blocking buffer, cells were 
incubated with the primary antibody (1xPBS, 1% BSA (Faction V), 0.3% Triton X-
100)) overnight at 4°C. Cells were washed in PBS 3 x 5 minutes and the 
fluorochrome-conjugated secondary antibody diluted in antibody dilution buffer 
was added to the cells for 90 minutes at room temperature in the dark. Following a 
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final 3 x 5 minutes wash in PBS, coverslips were mounted using ProLong Gold 
Antifade Mountant with DAPI (Invitrogen). Slides were analysed using a Nikon EC-
1 confocal microscope.                 
 
3.5 Results 
3.5.1 Microarray analysis  
To determine possible functional roles of PHOSPHO1 in energy metabolism, the 
osteoblast microarray data obtained by Dr. Manisha Yadav was subjected to re-
analysis. Raw data was arranged into the correct format and inputted into the IPA 
software. Intriguingly, 21 of the 309 inputted genes significantly were significantly 
associated with T2DM (P = 1.04x10-6) (Table 3.1). This therefore warranted a deeper 
gene regulatory pathway analysis using IPA inbuilt knowledge database. Ingenuity 
knowledge database is a vast repository of biological interactions and functional 
annotations originating from original peer reviewed articles which allow the 
integration of predicted upstream and downstream regulators of the inputted 
microarray data associated with insulin dependent diabetes mellitus. Using this 
tool, an array of 45 indirect interactions were identified between insulin dependent 
diabetes mellitus, inputted genes and various cytokines, growth factors, enzymes, 
kinases, peptidases, phosphatases, transcriptional regulators, transmembrane 
receptors and transporters (Fig. 3.1A).  To establish whether the predicted molecules 
were indeed associated with diabetes and/or bone an in silico search was performed 
using PubMed (Gene + Key words: adiposity, bone, diabetes, glucose, osteoblasts, 
osteocalcin, and obesity). Of the 45 molecules identified only 10 genes were found to 
be associated with both diabetes and bone and one gene, solute carrier family 1 
(glial high affinity glutamate transporter), member 3 (Slc1a3), was only associated 
with diabetes. However, glutamate transporters are known to play important roles 
in osteoblast and osteoclast differentiation and activity, bone mass regulation and 
response to osteogenic mechanical load; therefore Slc1a3 was retained in the cohort 
(reviewed in (Brakspear and Mason, 2012) (Table 3.2). Upon completion of the in 
silico search, gene expression of the selected molecules were examined by RT-qPCR. 
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Validation using RT-qPCR ascertained that all genes (Vdr, Slc1a3, Adamts4, Bmp4, 
Cd68, Cfp, Cxcl4. Fmod and Lum) except Mpeg1 were up/down regulated as predicted 






















Table 3.1 Osteoblast microarray candidates involved associated with insulin dependent 
diabetes mellitus 
21 genes from the WT and Phospho1-/- osteoblast microarray were identified by Ingenuity 
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To further establish genetic interactions and associations between the genes 
identified from the in silico output search; the identified 10 genes were inputted into 
the online network creator,   GeneMANIA. Similarly to Ingenuity’s knowledge 
database, GeneMANIA searches publicly available biological datasets to identify 
related genes via protein-protein, protein-DNA and genetic interactions, protein 
expression data, protein domains and phenotypic screening profiles, producing a 
gene network (Fig. 3.2). 
 
Intriguingly, the GeneMANIA generated gene network highlighted that Phospho1 
may indeed interact with Grb10 and Insr to regulate the glucose metabolic process.  
Excitingly, Atf4 and FoxO1 were also highlighted in the gene network. FoxO1 has 
been shown to co-localise with Atf4 in the osteoblast nucleus, promoting the 
transcriptional activity of Atf4, thus up-regulating Esp expression in osteoblasts and 
osteocalcin (OCN) inactivation (Kode et al., 2012).  These gene network data are 
suggestive of a PHOSPHO1, OST-PTP and OCN mutual regulation.  
 
Taken together the IPA and GeneMANIA network analysis highlight a potential 
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Figure 3.1 Ingenuity Pathways Analysis network summary predictions  
To identify further genes which may be involved in the regulation of energy metabolism via 
the osteoblast, IPA was used to predict further genes associated with type two diabetes 
mellitus based upon the 21 genes found to be differentially expressed in the microarray (A). 
(B) Predicated genes were confirmed by RT-qPCR in WT and Phospho1-/- primary calvarial 
osteoblast’s. Results were normalised to the Atp5b housekeeping gene. Data are represented 
as mean ±S.E.M n = 3, t-test. * P < 0.05, ** P < 0.01, ***P < 0.01. Red = Up regulated. Green = 
Down regulated (the darker the shade of green and red colour indicates a more extreme 
up/down regulation, conversely the paler the shade indicates a more subtle up/down 
regulation. Dashed line = indirect interaction (blue = inhibition, yellow = findings underlying 
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Figure 3.2 GeneMANIA network summary predictions 
GeneMANIA network generated using Ingenuity Pathways Analysis gene predictions. The 
network highlights potential interactions between Phospho1 and related osteoblast genes in 
the glucose metabolic process, encompassing; glucose transport, InsR signalling, response to 
insulin and cellular response to insulin stimulus. Query genes (black) with the exception of 
Spic and Runx2 which were inputted manually, other genes (grey) were generated by the 
programme using a large set of inbuilt functional association data.   Node size are based on 
GO terms. Network line colour corresponds to interaction: purple = co-expression, pink = 
physical interactions, blue = co-localisation, green = shared protein domains orange = 
predicted, grey = other. 
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3.5.2 Confirmation of Esp expression 
To validate if indeed, Esp was truly up regulated 20-fold in Phospho1-/- osteoblasts 
compared to WT osteoblasts as suggested by the microarray study, gene expression 
of Esp was examined in WT and Phospho1-/- osteoblasts by RT-qPCR. There was 
approximately a 60-fold increase in Esp mRNA expression in Phospho1-/- osteoblasts 
in comparison to WT osteoblasts (Fig. 3.3A). Conversely, Phospho1-/- osteoblasts 
overexpressing PHOSPHO1 were generated and Esp mRNA was decreased by 2.5-
fold compared to the EV control (Fig. 3.3B). Furthermore, assessment of PHOSPHO1 
gene and protein expression by western blotting showed a significant increase in 
PHOSPHO1 between EV and PHOSPHO1 overexpressing osteoblasts (Fig. 3.3C-D). 
These data confirm the success of the Phospho1 over expression strategy. It is 
important to note that a flag tag PHOSPHO1 lentivirus was also used in this study 
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Figure 3.3 Conformation of Esp overexpression in Phospho1-/- osteoblasts   
To assess the relative change in Esp mRNA expression in primary calvarial osteoblasts, RT-
qPCR was conducted. (A) Non transfected primary WT and Phospho1-/- osteoblasts (B) 
Phospho1-/- osteoblasts empty vector control and Phospho1-/- osteoblasts overexpressing 
PHOSPHO1 empty vector. To confirm PHOSPHO1 gene and protein overexpression RT-
qPCR (C) and western blotting (D) was conducted in Phospho1-/- osteoblasts empty vector 
control and Phospho1-/- osteoblasts overexpressing Phospho1 (with and without the flag tag). 
mRNA values generated were normalised to the Atp5b housekeeping gene. Data are 
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3.5.3 PHOSPHO1 peptide specificities 
To examine whether PHOSPHO1 has specific activity towards the InsR S (P) 1322 
and GIGYF1 as suggested by the preliminary phosphatase screen and yeast 2 hybrid 
analysis, a commercially available phosphatase assay adapted from the classic 
malachite green assay was used (Fig. 3.4A). The phosphatase assay has been 
previously employed to successfully identify two phosphomonoesters which 
PHOSPHO1 exhibits high specific activities toward PEA and P-Cho (Roberts et al., 
2004). To determine the optimal concentration of recombinant PHOSPHO1 to use in 
these assays, varying concentrations of PHOSPHO1 (0ng, 50ng, 125ng, 250ng, 
625ng) were used in addition to varying concentrations of PEA (1mM, 100µM, 10 
µM). It was concluded that 200ng of recombinant PHOSPHO1 was sufficient to 
hydrolyse PEA releasing free phosphate (Fig. 3.4B). To select the optimum 
incubation time, 200ng of recombinant PHOSPHO1 was incubated with varying 
concentrations of PEA (1mM, 100µM, 10 µM) at 37°C for 5, 15, 30, 40 and 60 minutes 
(Fig. 3.3C), at  30 minutes sufficiently high levels of free phosphate was produced, 
therefore 30 minutes was the selected incubation time and used in future 
experiments.  
 
Following the successful optimisation of the phosphatase assay, peptides from the 
desired substrates (20mM GIGYF1 and serine containing InsR), positive control 
(PEA 1mM, 100µM, 10 µM) and negative control (tyrosine containing InsR – 
GFKRSY* EEHIP) were incubated with both 200ng and 625ng of recombinant 
PHOSPHO1. Little phosphate was released from the GIGYF1 and serine containing 
InsRin both experiments suggestive that PHOSPHO1 is unable to hydrolyse 
phosphate from these substrates (Fig. 3.4D-E).  The specific activities (unit/mg) for 
the positive, negative and GIGYF1 and serine containing InsR were calculated, 
confirming that PHOSPHO1 does not hydrolyse free phosphate from GIGYF1 and 
serine containing InsR (Fig. 3.4F).  
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Figure 3.4 PHOSPHO1 substrates 
Phosphatase assay to determine if PHOSPHO1 hydrolyses phosphate from GIGYF1 and 
serine containing InsR. (A) Representative malachite green assay plate containing blank 
reactions and standards in duplicate (From top of plate: 2nmol, 1nmol, 0.5 nmol, 0.25 nmol, 
0.125 nmol, 0.063 nmol, 0.031nmol, 0nmol) (B) Concentration curve using PHOSPHO1 (0ng, 
50ng, 125ng, 250ng, 625ng) and PEA (1mM, 100µM, 10 µM) as substrate. (C) Time course of 
BIOMOL green assay (200ng of rec enzyme) to determine optimal incubation time for future 
reactions. (D) Standard curve showing linear absorbencies utilising known concentrations of 
phosphate (BML-KI102) (E) Phosphate released from substrates of interest following 
incubation with varying concentrations of PHOSPHO1. (F) Specific units of activity 
(units/mg) of substrates of interest and reference substrate (PEA). Units of activity = 
hydrolysis of 1nmol phosphate per minute. Specific activity = units / mg enzyme.  
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3.5.4 Effects of insulin on primary osteoblasts  
To determine if in vitro osteoblast insulin signalling was altered in Phospho1 
deficiency, primary WT and Phospho1-/- osteoblasts were stimulated with 100nM, 
10nM and 1nM of insulin. As expected insulin stimulated AKT and ERK1/2 
phosphorylation in a concentration dependent manner in both genotypes, however 
Phospho1-/- osteoblasts exhibited a lesser response to 100nM insulin-stimulation AKT 
phosphorylation than WT cells.  Similarly all concentrations of insulin stimulated 
ERK1/2 phosphorylation in Phospho1-/- cells was also decreased compared to WT 
cells (Fig. 3.5A). Surprisingly, the distribution of the InsR in primary WT and 
Phospho1-/- osteoblasts was not altered in both basal and stimulated conditions (Fig. 
3.5B). 
 
3.5.5 Determination of PHOSPHO1 protein/mRNA expression in murine tissues 
It has been reported that gene expression of Phospho1 by RT-qPCR was 120-fold 
higher in bone than the lowest expression tissue (liver) and low transcript levels 
were also detected in all other tissues examined: heart (5.67), bone marrow (3.57), 
adipose tissue (3.38), brain (1.96), and gut (1.20) (fold difference compared with 
PHOSPHO1 expression in liver, which was arbitrarily set as 1 for comparison) 
(Roberts et al., 2007). However, using the online BioGPS, Gene Atlas portal 
(http://biogps.org), it appears that Phospho1 is expressed highly in skeletal muscle, 
bone marrow and testis (Fig. 3.5) but poorly in bone. Some of tissues were not 
initially screened in the study by Roberts and colleagues (2007) and therefore the 
tissue expression of Phospho1 was examined in an expanded tissue list (Fig. 3.6A).  
Phospho1 was found to be expressed at high levels in the gonad, interscapular brown 
fat (iBF) and quadriceps femoris. However, protein expression did not match this 
distribution and PHOSPHO1, as determined by western blotting was most highly 
expressed in mouse calvariae and bone with significantly lower levels observed in 
the brain, lung, heart and quadriceps femoris, suggestive that Phospho1 transcript 
levels are not indicative of translated PHOSPHO1 protein. As expected, expression 
bands in calvariae, bone, brain, lung, heart and quadriceps femoris were not present 
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in Phospho1-/- tissue.   However, a double band, approximately 1kDa lower than the 
expected PHOSPHO1 band was observed in both WT and Phospho1-/- pancreata (Fig. 
3.6A). Sequencing confirmed this was not PHOSPHO1. Unfortunately I was unable 
to perform successful immunohistochemistry (IHC) to confirm this tissue 
distribution of PHOSPHO1 protein. In brief, expected PHOSPHO1 labelling was 
observed in the tibial shaft, however the same, yet faint staining was observed in 
Phospho1-/- tibiae despite protocol optimisation and antibody repurchase. 
Furthermore, attempts by others out with the group reported that PHOSPHO1 
expression was present in odontoblasts, however later, unpublished analysis of 
Phospho1-/- teeth showed they had similar staining (McKee et al., 2013). It is likely 
that the commercially available antibody whilst (usually) good for western blotting 
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Figure 3.5 Phospho1−/− primary calvarial osteoblasts display reduced AKT phosphorylation 
in response to insulin signalling. 
(A) Representative immunoblots demonstrating the effects of insulin (100nM, 10nM and 
1nM) on the phosphorylation of AKT and ERK1/2 in calvarial osteoblast cultures (n ≥ 3). (B) 
Immunofluorescent staining of the InsR (red) on the surface of WT and Phospho1−/− neonatal 
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Figure 3.7 The expression of Phospho1 mRNA and PHOSPHO1 protein in murine tissue 
(A) RT-qPCR of Phospho1 in murine tissues. Phospho1 was found to be expressed at high 
levels in the gonad, iBF and quadriceps femoris. (B) Protein expression of PHOSPHO1 was 
shown to be only present in WT bone, illustrating complete ablation in bone. (C) 
PHOSPHO1 was highly expressed in mouse calvaria and bone, with significantly lower 
levels observed in the brain, lung, heart and quadriceps femoris. Mesenteric fat (MF), intra-
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3.6 Discussion 
The bone specific phosphatase, PHOSPHO1 has previously been shown to be 
essential for the initiation of HA crystal formation inside MVs during endochondral 
ossification (reviewed in (Millan, 2013). Through the study of in vivo models, 
PHOSPHO1 was revealed to be crucial in the production of mechanically competent 
mineralisation enabling the skeleton to withstand habitual load thus avoiding 
spontaneous fractures (Huesa et al., 2011).  However the underlying biochemical 
details whereby PHOSPHO1 generates Pi remains largely unknown. In an attempt 
to provide a deeper understanding to how PHOSPHO1 contributes to HA crystal 
formation, a microarray study was conducted in WT and Phospho1−/− primary 
calvarial osteoblasts. The data from this comparison have subsequently been pivotal 
to the focus of this thesis. The embryonic stem cell protein-tyrosine phosphatase 
was found to be up regulated 60-fold in Phospho1-/- osteoblasts, confirmed by 
elevated mRNA levels in Phospho1-/- osteoblasts and conversely decreased in 
Phospho1-/- osteoblasts overexpressing PHOSPHO1, suggestive that PHOSPHO1 is 
involved in global energy metabolism (Fig. 3.3). Thus, a more compressive in silico 
analysis was performed to determine if indeed PHOSPHO1 had alternate roles out-
with bone mineralisation. Unquestionably, IPA revealed that Phospho1 ablation is 
significantly associated with insulin dependent diabetes mellitus. Further analysis 
by GeneMANIA a complimentary in silico data mining software highlighted 10 
genes which were associated with both diabetes and bone. The identification of this 
subset of genes therefore warrants future investigation by genetic manipulation (e.g. 
the generation of gene specific osteoblast conditional knockout mice) which was 
outside the possibilities of this PhD. However, in the midst of the era of integrative 
physiology, these data add to the rapid and expanding body of evidence linking 
bone with global energy regulation.  
 
Preliminary data suggested that PHOSPHO1 may directly dephosphorylate the InsR 
S (P) 1322 and interact with GIGYF1. However, upon further investigation a 
phosphatase assay showed recPHOSPHO1 released little phosphate from both InsR 
Chapter 3                       Initial observations on the importance of PHOSPHO1 in the regulation of energy metabolism 
~ 96 ~ 
 
S (P) 1322 and GIGYF1 peptides, demonstrating the inability of PHOPSHO1 to 
dephosphorylate the outlined candidates. Furthermore, InsR S (P) 1322 and InsR Y 
(P) 1322 appear to have synonymous names in the literature. Insulin has been 
shown to stimulate autophosphorylation of the InsR on multiple tyrosines, 
including Tyr 1322 on the COOH-terminus (Fig. 3.8) (King and Sale, 1990; White 
and Kahn, 1994). However, deletion of tyrosine (Tyr1322, Tyr1316) and threonine 
(Thr1336) phosphorylation sites of the COOH terminal has no effect on insulin 
stimulated receptor kinase activity or biological activity, suggesting the COOH 
terminus does not modulate the kinase function of the insulin receptor. Whilst not 
essential for signalling these tyrosine residues including Tyr 1322 may play a 
regulatory role as they autophosphorylated in native receptors (Myers et al., 1991; 
Takata et al., 1991).   
 
In contrast to the in vitro experiments, in silico analysis suggested that Phospho1 may 
interact with Grb10 and the InsR to regulate the glucose metabolic process. It is 
important however to recognise the limitations associated with in silico network 
analysis. Networks are created based upon large sets of functional association data. 
These association data encompass protein and genetic interactions, pathways, co-
expression, co-localisation and protein domain similarity. These pathways are based 
upon predictions and similar to microarray studies, require further in vitro and/or in 
vivo experimentation to confirm predictions. A united effort of experimental biology 
and theory therefore must be applied. It remains unclear if PHOSPHO1 has a direct 
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Figure 3.8  Model of the InsR 
Tyr01322 is situated on the COOH terminus of the β subunit linked to the α subunit by 
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To try to unravel these complex data, primary calvarial osteoblasts were stimulated 
with insulin. Intriguingly, Phospho1-/- osteoblasts exhibited decreased AKT 
phosphorylation in response to 100nM insulin. This observation however this was 
not a result of an altered distribution of the InsR mRNA expression levels between 
the two genotypes. These conflicting data may be as a consequence of the 60-fold 
increase of Esp in Phospho1-/- osteoblasts leading to greater dephosphorylation of the 
InsR.  This is discussed fully in Chapter 6.   
 
All data available indicated that PHOSPHO1 is preferentially expressed by bone.  
Indeed in the avian model, IHC localised PHOSPHO1 protein to the osteoid layer of 
the periosteum, forming surfaces of growing osteons, newly formed osteocytes, 
cartilage remnants and trabecular bone. All soft tissues analysed were negative. 
Moreover whole-mount in situ hybridisation showed that Phospho1 expression 
occurred prior to E6.5, restricted to the bone collar within the mid-shaft of the 
diaphysis of long bones but by E11.5 expression was observed over the entire length 
of the diaphysis (Houston et al., 2004; Stewart et al., 2006; Roberts et al., 2007). 
Further evidence from the online transcriptome atlas database for mouse embryo 
(Eurexpress -http://www.eurexpress.org/ee/databases/assay.jsp?assayID=euxassay_ 
007708&image=01) revealed that in the E15.5 mouse the strongest hybridisation for 
Phospho1 was in the skeletal elements (Fig. 3.8). However, contradictory to these 
data, the BioGPS, Gene Atlas portal highlighted Phospho1 is expressed at high levels 
in skeletal muscle, BAT, and testis. If this wider expression pattern is indeed true, 
any metabolic phenotype of the Phosho1-/- mice may not be due to bone derived 
PHOSPHO1 but potentially a consequence of non-osseous tissue derived 
PHOSPHO1. Quantification of mRNA expression in a large panel of tissues not 
previously analysed, demonstrated Phospho1 was found to be expressed at high 
levels in the gonad, iBF and quadriceps femoris however this did not translate to 
PHOSPHO1 protein expression. These data were not in accordance with previously 
reported expression of Phospho1 (Roberts et al., 2007), this is likely due to the primer 
sequence used. Roberts et al. selected primers that were specific to Phospho1, 
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however the amplicon obtained was 2070 base pairs, dramatically above the desired 
50-150 base pairs for optimal PCR efficiency. Similarly, expression of Esp in murine 
tissue is widespread (data not shown), however protein levels of OST-PTP are 
restricted to osseous and testicular tissue as suggested by the name osteotesticular 
protein tyrosine phosphatase (Lee et al., 2007).   
 
It is not uncommon for genes to be transcribed into mRNA but not translated into 
protein due to various regulatory mechanisms, encompassing post-transcriptional 
or post-translational regulation.  These processes usually occur due to errors during 
protein synthesis and sensitivity to environmental changes, allowing only a small 
percentage of proteins to reach their intended functional state (Medicherla and 
Goldberg, 2008). However, some mRNA is translated and rapidly degraded which 
may contribute to the lack of PHOSPHO1 being observed in the gonad, iBF and 
quadriceps femoris. As protein synthesis and maturation requires up to 75% of the 
total cellular energy budget this degradation is a somewhat wasteful process (Kim et 
al., 2013b). Specifically, 15-30% of newly synthesised proteins are rapidly degraded 
in a ubiquitin-proteasome dependent manner in which substrates are tagged with 
ubiquitin prior to transportation to the 26S proteasome for degradation (Schubert et 
al., 2000; Vabulas and Hartl, 2005; Welchman et al., 2005). Alternatively, autophagy 
is a further mechanism for both non-specific and specific protein degradation. This 
protein degradation pathway occurs within the lumen of the lysosomes, following 
transportation via macroautophagy, microautophagy or chaperone-mediated 
autophagy (reviewed in (Wang et al., 2015).  
 
In addition to the post-translational regulation described above, post-transcriptional 
regulation may also explain the disparity observed between mRNA and protein 
levels.  Short endogenous RNAs, microRNAs (miRNAs), pair to sites in the 3′ 
untranslated region to regulate protein expression (Welchman et al., 2005). Studies 
have suggested that miRNAs chiefly affect protein expression and may not have 
measurable effects on mRNA abundance (Welchman et al., 2005). The investigation 
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of the process underlying the disparity between PHOSPHO1 mRNA and protein 
expression was not investigated in this thesis but such information would be 
informative in future studies. 
 
In conclusion, the conflicting data obtained from both in vitro and in silico work 
make it difficult to confirm if PHOSPHO1 affects osteoblast InsR signalling or if the 
upregulation of Esp expression in the Phospho1-/- osteoblasts offers protection from 
excessive insulin signalling. The subsequent chapters aim to determine if Phospho1-/- 
mice have a metabolic phenotype in vivo as suggested by the altered Esp expression 




Figure 3.9 Skeletal specific expression of Phospho1 in the E14.5 mouse  
High-throughput transcriptome-wide acquisition of expression patterns by in situ 
hybridisation of sagittal sections from E14.5 wild type murine embryos. The strongest 
hybridisation for Phospho1 was in the skeletal elements (e.g. radius, ulna, humorous, fibular, 
tibiae, femur, mandible, maxilla, rib, axial skeleton, clavicle, scapular, pelvic girdle) 
indicated by dark purple staining. Adapted from: 
http://www.eurexpress.org/ee/databases/assay.jsp?assayID=euxassay_007708. 
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4.1 Introduction   
The bone specific phosphatase PHOSPHO1 is present in MV’s of osteoblasts and 
chondrocytes (Houston et al., 2004; Stewart et al., 2006). Analysis of mice lacking 
PHOSPHO1 showed that these animals had significant skeletal pathology, 
spontaneous fractures, bowed long bones, osteomalacia, and scoliosis in early life 
(Huesa et al., 2011; Yadav et al., 2011). Further investigation revealed that the double 
ablation of both PHOSPHO1 and tissue-nonspecific alkaline phosphatase (TNAP) is 
perinatally lethal and that these mice display a complete absence of skeletal 
mineralisation at embryonic day 18 (E18), suggestive that PHOSPHO1 and TNAP 
have complementary, non-redundant functional roles during endochondral 
ossification (Yadav et al. 2011). Using these models a comprehensive paradigm of 
skeletal mineralisation was suggested, whereby PHOSPHO1 is responsible for 
intravesicular production of Pi and TNAP mediates extravesicular Pi transport into 
the MV, via phosphate transporter 1 (PiT) (Yadav et al., 2011; Millan, 2013). Despite 
the advances that have made been made in generating this inclusive model for the 
initiation of skeletal mineralisation, the intimate biochemical details of how 
PHOSPHO1 is implicated in intravesicular Pi generation have yet to be elucidated. 
As outlined in Chapter 3 a microarray was used to provide clues to the molecular 
pathways underlying the functional role of PHOSPHO1. The key finding was that 
Esp, the gene encoding the OST-PTP, was up regulated 20-fold in Phospho1-/- 
osteoblasts compared to WT osteoblasts, which was later confirmed by RT-qPCR 
(60-fold) and lentivirus overexpression studies (Chapter 3). Embryonic stem 
cell protein-tyrosine phosphatase is expressed by only two cell types, the osteoblast 
and the sertoli cells of the testis. In vitro, Esp coordinates the progression of the pre-
osteoblast to a mature, mineralising cell, and in vivo may be a critical regulator of the 
commitment of mesenchymal cells to the ossification of new bones during 
skeletogenesis (Mauro et al., 1994; Chengalvala et al., 2001; Yunker et al., 2004). 
Protein tyrosine phosphatases are master regulators of InsR signalling. 
Osteotesticular protein tyrosine phosphatase has been recently shown to be 
involved in the decarboxylation of OCN, whereby Esp dephosphorylates the InsR 
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situated on the osteoblast, negatively regulating the osteoblast-insulin-signalling 
cascade and subsequent release of GLU13-OCN into the systemic circulation (Mauro 
et al., 1994; Hunter, 1995; Schlessinger, 2000; Dacquin et al., 2004; Tonks, 2006; Lee et 
al., 2007; Ferron et al., 2010b). The fully carboxylated OCN regulates mineral 
formation and matrix mineralisation (Chenu et al., 1994), however upon 
decarboxylation of OCN on its three glutamic acid residues (GLU13, GLU17 and 
GLU20) OCN is realised into the general circulation and regulates global energy 
metabolism  via the stimulation of insulin secretion and β cell proliferation in the 
pancreas, energy expenditure by muscle, and insulin sensitivity in adipose tissue, 
muscle and liver (Rosen and Motyl, 2010; Karsenty and Ferron, 2012).  Indeed, the 
60-fold increase in Esp in Phospho1-/- mice is therefore suggestive that Phospho1-/-  mice 
may resemble OST-PTP overexpression mice and OCN-deficient mice; Both OST-
PTP overexpression and OCN-deficient mice are phenocopies; the mice are 
hyperglycemic, hypoinsulinemic and have reduced insulin secretion and sensitivity 
compared to the litter mate WT mice (Lee et al., 2007). These data indicate that there 
may be a reciprocal regulation between OST-PTP and PHOSPHO1, whereby global 
energy metabolism is affected via circulating GLU13-OCN. Certainly to add 
credence to this hypothesis, pathway analysis of the existing microarray data 
obtained from WT and Phospho1-/- primary calvaria osteoblasts highlighted that 
PHOSPHO1 is associated with T2DM (P = 1.04x10-6). Furthermore, 10 genes (Vdr, 
Slc1a3, Mpeg1, Adamts4, Bmp4, Cd68, Cfp, Cxcl4. Fmod and Lum) were found to be 
associated with both diabetes and bone following an in silico search (validated by 
RT-qPCR) and GeneMANIA network analysis predicted Phospho1 interacts with 
Grb10, Insr, Atf4 and FoxO1 (involved in the GLU13-OCN regulation) (Chapter 3). 
Therefore the overarching aim of this chapter was to characterise the metabolic 





Chapter 4                                                               Characterising the Phospho1 knock-out mouse metabolic phenotype 
~ 104 ~ 
 
4.2 Hypothesis 




I. Analyse the metabolic phenotype of juvenile and aged Phospho1-/- mice.  
 
II. Examine the effect of a HFD on the metabolic phenotype of WT and 
Phospho1-/- mice  
 
III. Study Phospho1 heterozygote mice to explore the possibility that PHOSPHO1 
may represent a druggable target. 
 
IV. Determine if a HFD affects the skeletal phenotype of WT and Phospho1-/- 
mice. 
 
4.4 Materials and Methods 
4.4.1 Glucose tolerance and insulin tolerance test 
Male juvenile, adult and aged mice were weighed and fasted for 4 hours between 
9am and 1pm. 2 mg of D-glucose per g of BW was administered by gavage or 0.5mU 
of insulin per g of BW was administered IP and blood glucose and circulating 
insulin was measured (detailed in section 2.5.3.3).  Animals were allowed to recover 
for two weeks prior to euthanasia. Tissues were collected for protein, gene and 
histological analysis.  
 
4.4.2 Growth curves 
WT and Phospho1-/- mice on both CD and HFD were weighed every week from 
weaning until 120 days of age.  
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4.4.3 Food consumption, activity and energy expenditure   
Ad libitum food consumption was monitored for 6 days and basal nocturnal activity 
was quantified using an AM524 Single Layer X, Y IR activity monitor and associated 
Amonlite software (Linton Instrumentations, Norfolk, UK). Metabolic activity was 
measured using indirect calorimetry (Oxymax Lab Animal Monitoring System: 
CLAMS (Columbus Instruments, OH USA). This was done in collaboration with Dr. 
Monzur Murshed and Dr. Zohreh Khavandgar, University of Montreal, Canada.  
All experiments were conducted blind to the operator.   
 
4.4.4 mRNA analysis of primary osteoblasts cells and cell lines 
RNA samples were extracted from primary calvarial osteoblasts, using a Qiagen 
RNeasy lipid kit according to the manufacturer’s instructions. cDNA was prepared 
(section 2.6.1) and was used at 5ng/µl for RT-qPCR analysis, as detailed in section 
2.6.4. Results were normalised to the Atp5b housekeeping gene and the relative gene 
expression level was calculated using the ΔΔCt method (Livak & Schmittgen 2001).  
 
4.4.5 Protein analysis of primary osteoblasts cells and cell lines 
Protein was extracted from primary calvarial osteoblasts in RIPA buffer as detailed 
in section 2.7.1. Protein concentration was quantified (section 2.7.2) and appropriate 
quantities were used for western blot analysis (section 2.7.3). UCP1 protein 
expression was determined using an anti-rabbit anti-UCP1 antibody at a dilution of 
1:1000 and a HRP-labelled goat anti-rabbit secondary antibody (1:5000).  Antibody 
labelling was visualized using the ECL detection kit. Equality of protein loading 
was confirmed by also probing the membrane with mouse monoclonal HRP-
labelled anti-β actin antibody (1:50000). 
 
4.4.6 Tissue histology  
Male juvenile, adult and aged mice (35, 120 and 220 day-old, respectively) CD and 
HFD were sacrificed by cervical dislocation.  Tissue was fixed in 4% PFA and 
embedded in paraffin wax.  5-μm sections were stained with haematoxylin and 
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eosin (H&E) using the Leica Autostainer and mounted in DePeX (VWR, 
Lutterworth, UK). Adipocyte diameter and pancreatic β-cell islet number and size 
was quantified using ImageJ software as previously described (section 2.8.5) (Lee et 
al., 2007; Huesa et al., 2014). 
 
4.4.7 Serum isolation from whole blood samples  
Blood was extracted from mice via cardiac puncture and blood was transferred to 
an EDTA coated tube, serum was collected and stored at -80°C until use.  
 
4.4.8 Pancreas insulin content 
Dissected pancreata from 120 day old WT and Phospho1-/- mice were homogenised 
and diluted in 2ml of acidified ethanol overnight at -20°C. Samples were neutralised 
by the addition of 100μl 1M Tris (pH 7.5) and insulin content was measured by 
ELISA (section 2.10.6) and normalised to protein content as measure by the 
Bradford assay (section 2.7.2.2). 
 
4.4.9 µCT x-ray and 3 point bending  
µCT imaging was carried on 35 day CD, 120 day CD and 120 day HFD tibiae. High-
resolution scans with an isotropic voxel size of 5 μm  (trabecular) or 10μm cortical 
scanning  were acquired with a micro-computed tomography system (μCT, 60 kV, 
0.5 mm aluminum filter, 0.6° rotation, Skyscan 1172, Brukker microCT, Kontich, 
Belgium). Scans were reconstructed and using CTAn software (Bruker) was used to 
analyse appropriate parameters (section 2.12.2). Calcium hydroxyapatite phantoms 
of a known density were scanned using the same settings to calculate BMD. Bones 
were then x-rayed (section 2.12.1) and subsequently loaded until fracture (where 
indicated) using a LXR materials testing machine fitted with a 500N load cell. Data 
was recorded after every 0.2 N change in load and every 0.1 mm change in 
deflection. From the load extension curve, failure, fracture, maximum stiffness   
and yield were defined (Aspden, 2003).  
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4.5 Results 
4.5.1 Phospho1 inactivation improves glucose tolerance and insulin sensitivity in 
juvenile mice 
I reasoned that if the ablation of Phospho1 was associated with T2DM and caused a 
60-fold up-regulation of Esp expression in osteoblasts (Chapter 3) Phospho1-/- mice 
would have a similar phenotype to transgenic mice overexpressing full-
length Esp cDNA selectively in osteoblasts (α1(I)-Esp mice). α1(I)-Esp mice are 
hyperglycemic, glucose intolerant and insulin resistant as a result of impaired 
insulin secretion in response to glucose (Lee et al., 2007).  Unexpectedly, metabolic 
analysis revealed that juvenile (35 day old) Phospho1-/- mice had a significant 
reduction in blood glucose levels (WT: 9.31±0.31 mmol/L, Phospho1-/-: 7.76±0.32 
mmol/L; P < 0.01) (Fig. 4.1A). Phospho1-/- mice also showed an improvement in 
glucose tolerance (Fig. 4.1B) and were more insulin sensitive compared to WT 
counterparts (Fig. 4.1C). These observations were consistent with a significantly 
decreased body mass (g) of Phospho1-/- mice (WT: 22.58±0.96, Phospho1-/-: 19.03±0.10; 
P < 0.05)(Fig. 4.2A)and the finding of smaller (mg/g BW) SB (WT: 4.31±0.27, 
Phospho1-/-: 2.58±0.20; P  < 0.01), MF (WT: 5.30±0.30, Phospho1-/-: 3.39±0.40; P < 0.01), 
GF (WT: 4.31±0.27, Phospho1-/-: 2.58±0.20; P  < 0.01) and interscapular brown (iBF) 
(WT: 5.11±0.57, Phospho1-/-: 3.05±0.40; P < 0.01) fat depots noted in Phospho1-/- mice at 
necropsy (Fig. 4.2B).  Consistent with these observations, histological analysis 
revealed smaller gonadal adipocytes in Phospho1-/- mice (P < 0.05) (Fig. 4.2C).  These 
changes were not a consequence of altered food intake (g/gBW/day) (WT: 0.13±0.01; 
Phospho1-/-: 0.12± 0.01) (Fig. 4.3A), but may be partly explained by a significant 
increase in total activity of Phospho1-/- mice (beam breaks) (WT: 4048.33±238.58; 
Phospho1-/-:9176.33±901.03; P < 0.01) (Fig. 4.3B). However, no change in energy 
expenditure was observed between WT and Phospho1-/- mice (Fig. 4.3C-F).  
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Figure 4.1 Juvenile Phospho1-/- male mice are protected from glucose intolerance 
Metabolic analysis of 35 day old WT and Phospho1-/- male mice. (A) Phospho1-/- mice had a 
reduction in blood glucose levels compared to WT counterparts. (B) GTT tests revealed that 
Phospho1-/- mice also showed an improvement in glucose tolerance and (C) were significantly 
more insulin sensitive compared to WT counterparts as determined by an insulin tolerance 
test. n ≥ 10, t-test (A), two way repeated measures ANOVA (B&C). Data are represented as 
mean ±S.E.M. * P < 0.05, ** P < 0.01, ***P < 0.001.   
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Figure 4.2 Juvenile Phospho1-/- male mice are smaller than WT counterparts having 
decreased adipose tissue stores 
Simple weighing of 35 day old WT and Phospho1-/- male mice revealed (A) Phospho1-/- mice are 
smaller than WT counterparts. (B) These mice were then dissected and the outlined tissues 
were removed and weighed: Subcutaneous fat (SB), gonadal fat (GF), mesenteric fat (MF), 
pancreas, spleen, liver, intra-scapular brown fat (iBF), quadriceps femoris, heart, kidney, 
lungs and gonad. Dissection analysis revealed that all fat depots weighed (mg/g BW) in 
Phospho1-/- were smaller than WT counterpart mice. The GF were then fixed, processed and 
sectioned and used to examine the adipocyte size in these mice. (C) Histological analysis 
revealed smaller gonadal adipocytes in Phospho1-/- mice. n ≥ 5, t-test. Data are represented as 
mean ±S.E.M. * P < 0.05, ** P < 0.01, ***P < 0.001.   
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Figure 4.3 Energy expenditure and activity analysis of Juvenile Phospho1-/- male mice  
Food intake was measured in 35 day old WT and Phospho1-/- male mice, no difference was 
observed when normalised to BW (A). (B) An increase in slow activity was observed in 
Phospho1-/- mice which results in an increased in total activity, measure by beam breaking. 
(C-F) No change in energy expenditure, measured by indirect calorimetry was observed 
between WT and Phospho1-/- mice. n ≥ 3, t-test. Data are represented as mean ±S.E.M. * P < 
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4.5.2 Phospho1 inactivation improves glucose tolerance and insulin sensitivity in 
aged mice  
It is likely, that as the genetic ablation of Phospho1 results in a hypomineralised, 
fracture-prone skeleton in juvenile mice (Huesa et al. 2011) aged Phospho1-/- mice may 
not display any metabolic abnormalities.  Therefore to discern if aged Phospho1-/- 
mice are also protected from obesity and insulin resistance aged (220 day old) 
Phospho1-/- mice were subject to metabolic analysis. Indeed, aged Phospho1-/- mice had 
improved glucose tolerance compared to WT counterparts, however the fasting 
glucose levels were unchanged between the genotypes (WT: 8.33±1.20, Phospho1-/-: 
8.60±0.15; P = 0.61) (Fig. 4.4A). In accordance with juvenile mice, aged Phospho1-/- 
mice had smaller (mg/g BW) subcutaneous (WT:6.13±0.51, Phospho1-/-: 4.12±0.12; P < 
0.05), gonadal (WT: 10.54±0.52, Phospho1-/-: 5.98±0.43; P < 0.05) and iBF (WT: 
5.49±0.10, Phospho1-/-: 3.75±0.18; P < 0.05) fat depots compared to WT controls (Fig. 
4.4B).  Furthermore, improved metabolic activity seen in aged Phospho1-/-: mice was 
not a consequence of altered food intake (g/gBW/day) (WT: 0.12±0.004; Phospho1-/-: 
0.103± 0.005 p = 0.15) (data not shown) or altered activity (Table 4.1). Unfortunately 
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Figure 4.4 Aged Phospho1-/- male mice are insulin sensitive and have decreased adipose 
tissue stores 
Metabolic analysis of 220 day old WT and Phospho1-/- male mice. (A) Phospho1-/- mice had no 
change in fasting blood glucose levels compared to WT counterparts however they showed 
an improvement in glucose tolerance as determined by glucose tolerance testing. (B)  These 
experimental mice were then dissected and the outlined tissues were removed and weighed: 
Subcutaneous fat (SB), gonadal fat (GF), mesenteric fat (MF), pancreas, spleen, liver, intra-
scapular brown fat (iBF), quadriceps femoris, heart, kidney, lungs and gonad. Dissection 
analysis revealed that (B) SB, GF and iBF fat depots (mg/g BW) were smaller in Phospho1-/- 
mice than WT counterpart mice. n ≥ 3, two way repeated measures ANOVA (A), t-test (B). 
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4.5.3 Phospho1 deficiency protects from diet induced hyperglycemia and insulin 
resistance 
As Phospho1-/- mice disclosed an improvement in glucose tolerance it is likely that 
these mutant mice may be protected from hyperglycemia and insulin resistance.  
Wild type and Phospho1-/- mice were therefore fed mice a HFD from weaning until 
120 days of age (data summarised in Table 4.2).  In agreement with data from 
juvenile and aged mice, Phospho1-/- mice fed a CD remained leaner then WT 
counterparts until adulthood (Fig. 4.5A). Furthermore Phospho1-/- mice had 
decreased fasting glucose levels compared to WT mice which were not increased 
with HFD feeding (CD: WT:9.50 ±0.37, Phospho1-/-:8.59±0.27;HFD: WT 10.3±0.53 
mmol/L, Phospho1-/- 9.27±0.77 mmol/L; P < 0.05) and  Phospho1-/- mice resisted the 
pronounced HFD induced weight gain (CD: WT:34.20 ±1.12, Phospho1-/-:28.30±0.59; 
HFD: WT: 38.0±1.54 g, Phospho1-/-: 32.4±1.26 g; P < 0.05) (Fig. 4.5 B-C). Indeed, 
Phospho1-/- mice displayed an improvement in glucose tolerance on the CD which 
persisted when Phospho1-/- mice were fed the chronic HFD (Fig. 4.6A). It is important 
to highlight the fasting glucose levels observed in the WT mice are very similar with 
previously reported fasted (5 hours) glucose levels of C57BL/6 mice (9.1±0.2  
mmol/L) which had the highest fasting blood glucose compared to 3 commonly 
used imbred mouse stains (129X1/Sv, FVB/N and DBA/2 mice) (Berglund et al., 
2008).  
 
To assess if the improved glucose tolerance was due to increased insulin secretion in 
response to glucose, GSIS were performed. In comparison to WT mice the GSIS 
revealed decreased insulin secretion in response to an IP injection of glucose in 
Phospho1-/- mice fed either a CD or HFD, suggestive of a highly insulin sensitive 
phenotype (Fig. 4.6B). Insulin tolerance tests revealed Phospho1-/- mice remained 
insulin sensitive on the HFD, which was unlike WT mice that became insulin 
resistance when fed a HFD (Fig. 4.6 C-D).  These observations were consistent with 
the significant decrease in the HOMA-IR reading (a clinical method to 
quantify insulin resistance and beta-cell function) in Phospho1-/- HFD mice compared 
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to WT HFD controls, indicative that Phospho1-/- resist diet induced insulin resistance  
(HFD: WT 0.90±0.26, Phospho1-/- 0.33±0.04; P < 0.05)(Fig. 4.6 E). These observations 
were not explained by altered food intake (no data available for HFD due to 
crumbly nature of food deeming it impossible to measure without specialist 
equipment) (Fig. 4.6F). The detailed evaluation of fat deposition and localisation 
adult WT and Phospho1-/- is presented in Chapter 5).   
 
Interestingly, histological analysis of pancreata from adult WT and Phospho1-/- male 
mice revealed CD adult Phospho1-/- mice had a significant decrease in islet number 
(CD: WT 1.40 ±0.10, Phospho1-/- 1.10±0.001; P < 0.05) however this did not translate to 
a decrease in islet area, indicative that  Phospho1-/- mice have  larger islets than WT 
controls (Fig. 4.7 & 4.8A-B). Moreover, no change in pancreas insulin content 
between the genotypes was observed in the CD cohort, but WT HFD mice had a 
significant decrease in insulin content (µg/mg protein) compared to Phospho1-/- HFD 
mice (HFD: WT 280.00 ±11.32, Phospho1-/- 258.01±6.12; P < 0.05) (Fig. 4.8C). 
 
Intriguingly, histological analysis of BAT from all ages indicate that Phospho1-/- mice 
had a markedly decreased lipid content and increased cellular nuclei number(Fig. 
4.9 and 4.10A). Importantly no differences were observed in the expression of Ucp1 
and other BAT enriched genes e.g. Pparα, dio2, Pgc1α, prdm16, Cidae and Adipoq (Fig. 
4.10B). UCP1 was also found to be normally expressed at the protein level (Fig. 
4.10C). Since UCP1 is responsible for the majority of non-shivering thermogenesis, 
this suggests that canonical thermogenesis through UCP1 does not underlie the 
metabolic protection seen in Phospho1-/- mice 
 
To deduce if increased energy expenditure/activity or decreased food intake could 
offer a simple explanation for the metabolic protection observed in Phospho1-/- mice 
these parameters were measured. No change in slow or total activity was seen 
between the genotypes as observed in juvenile mice (Fig. 4.11 A-B). Intriguingly 
Phospho1-/- HFD mice had significantly increased oxygen consumption (ml/kg/hr) 
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(HFD Dark: WT 3835.77 ±168.54, Phospho1-/- 4263.99±;72.05 P < 0.05), produced 
significantly less heat (kcal/hr)than WT counterparts (Dark HFD: WT 0.68 ± 0.014, 
Phospho1-/- 0.65±; 0.01P < 0.01) despite the dramatic change in BAT histology (Fig. 
4.9)  and had a decreased respiratory exchange ratio (RER) (VCO2/VO2), suggestive 
of switch to fatty acid oxidation (Dark HFD: WT 0.83± 0.006, Phospho1-/- 0.81±; 0.005P 
< 0.05) (Fig. 4.11 C-F).  
 
4.5.4 PHOSPH01 may represent a druggable target for the treatment of insulin 
resistance and diabetes 
Finally if the observed metabolic phenotype in Phospho1-/- mice was primarily bone 
driven and not due to food intake or activity, it was of interest to ascertain if 
Phospho1 heterozygote (Phospho1-/+) mice displayed an intermediate insulin sensitive 
phenotype. Glucose and ITT revealed that juvenile Phospho1-/+ male mice displayed 
an intermediate insulin sensitive phenotype, showing improvement in glucose 
tolerance and insulin sensitivity compared to WT mice (Fig. 4.12A-B), however no 
significant difference between WT and Phospho1-/+ mice fat depots (mg/g BW) were 
seen at necropsy, subcutaneous (WT:4.31 ±0.28, Phospho1-/+:4.26 ±0.35;), MF (WT:5.30 
±0.30, Phospho1-/+:6.45±1.63 ), GF (WT:4.31 ±0.28, Phospho1-/+: 4.26±0.35) and iBF 
(WT:5.11 ±0.56, Phospho1-/+:4.69 ±0.44)  These data suggest that PHOSPHO1 may 
represent a druggable target which may be of importance in the global epidemic of 
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Figure 4.5 Adult Phospho1-/- male mice are protected from hyperglycemia and weight gain 
following the administration of a HFD 
WT and Phospho1-/- mice on the CD were weighed once a week on the same day and time.  
Phospho1-/- mice remained leaner then WT counterparts until adulthood (120 days) (A).  
Following administration of a HFD from weaning until 120 days of age the fasting glucose 
levels and mass of WT and Phospho1-/- mice on the CD and HFD were measured. Phospho1-/- 
mice had decreased fasting glucose levels compared to WT mice which were not increased 
with HFD feeding (B), likewise there was no significant increase in BW following HFD 
feeding which was observed in WT mice (C). n ≥ 3, one way ANOVA. Data are represented 
as mean ±S.E.M. Values assigned the same letter show no significant difference from one 
another (P < 0.05). 
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Figure 4.6 Adult Phospho1-/- male mice are protected from diet induced glucose 
intolerance and insulin resistance 
WT and Phospho1-/- were fed a HFD from weaning until 120 days of age. Glucose tolerance 
tests (A) and insulin tolerance tests (B) revealed WT mice fed a HFD became insulin resistant 
whereas Phospho1-/- mice showed an improvement in glucose tolerance on the CD compared 
to WT mice which then persisted when Phospho1-/- mice were fed the chronic HFD.  
Furthermore GSIS revealed the improved glucose tolerance in Phospho1-/- mice fed either a 
CD or HFD was accompanied by a decreased insulin response in response to glucose. 
Phospho1-/- mice resist insulin resistance observed in WT HFD mice (C). There was a 
significant decrease in the area under the curve (GTT) on the HFD between WT and 
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Phospho1-/- mice (D) which translated into a significant decrease in the HOMA-IR reading in 
Phospho1-/- HFD mice compared to WT HFD controls (E). These changes were independent 
on altered food intake (F).  n ≥ 3, two way repeated measures ANOVA (A-C), one way 
ANOVA (D&E) t-test (F).Data are represented as mean ±S.E.M. Values assigned the same 





Figure 4.7 Immunolocalisation of insulin in the pancreas of adult WT and Phospho1-/- 
male mice  
Immunohistochemistry showed insulin present in WT and Phospho1-/- islets (positive insulin 
protein is indicated by brown stain). Arrows indicate insulin negative islets (n = 4).   
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Figure 4.8 Quantification of Immunolocalisation of Insulin in the adult WT and 
Phospho1-/- male mice 
Insulin immunohistochemistry analysis revealed that 120 day old Phospho1-/- mice have a 
significant decrease in islet number (A) however no change in islet area. (B) No change in 
insulin content between the genotypes was observed in the CD cohort; however WT HFD 
mice had a significant decrease in insulin content compared to Phospho1-/- HFD mice (C). n = 
4, t-test (A&B), one way ANOVA (C). Data are represented as mean ±S.E.M. Values assigned 
the same letter show no significant difference from one another (P < 0.05).* P < 0.05, ** P < 
0.01, ***P < 0.001.   
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Figure 4.9 Phospho1-/- male mice have smaller brown fat adipocytes compared to WT 
controls 
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Figure 4.10 Brown fat characterisation of adult mice 
(A) 120 day old Phospho1-/- mice had a significant increase in brown fat nuclei number 
indicative of an increase number of small brown adipocytes. However this was not 
accompanies by mRNA expression of brown fat specific genes (B) or (C) UCP1 protein 
expression.  n ≥ 3, t-test (A&B). Data are represented as mean ±S.E.M. *P < 0.05, ** P < 0.01, 
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Figure 4.11 Energy expenditure and activity analysis of adult Phospho1-/- male mice  
(A) No major changes in slow activity or (B) total activity was observed between the 
genotypes however HFD significantly decreased activity in both genotypes. Phospho1-/-  HFD 
mice had a significantly increased VO2 in the dark (C), however no change in VCO2 was 
observed (D).  Phospho1-/-  HFD mice produced significantly less heat than WT counterparts 
both in the light and dark (E). Furthermore Phospho1-/-  respiratory exchange ratio (RER) was 
significantly decreased compared to WT counterparts both in the light and dark suggestive 
of a switch to fatty acid oxidation (F). ). n ≥ 3, one way ANOVA (A&B), t-test (C-F).Data are 
represented as mean ±S.E.M. * P < 0.05, ** P < 0.01, ***P < 0.001.   
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Figure 4.12 Juvenile Phospho1-/+ male mice display an intermediate insulin sensitive 
phenotype  
Metabolic analysis of 35 day old WT, Phospho1+/- and Phospho1-/- male mice. (A) Glucose 
tolerance tests revealed that Phospho1-/+ mice also showed an improvement in glucose 
tolerance compared to WT mice and were (B) more insulin sensitive compared to WT 
counterparts as determined by an ITT. These data are suggestive that PHOSPHO1 may 
represent a druggable target. n = 5, two way repeated measures ANOVA. Data are 
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4.5.5 Analysis of HFD feeding on the phenotype of WT and Phospho1-/- adult bone 
There is a clear disparity in the literature regarding the relationship between HFD 
feeding and bone mineral density (BMD) in murine models. Whilst some murine 
models lose bone with a HFD others do not (Doucette et al., 2015). It is also 
important to highlight that in genetically homogenous mice, HFD feeding leads to 
different metabolic adaptations which may affect bone parameters (Burcelin et al., 
2002). Therefore, to investigate the interrelationship of diet, age and bone in male 
WT and Phospho1-/-, we first x-rayed tibiae of juvenile (35-days-old) and adult (120-
days-old) WT and Phospho1-/- tibiae (CD and HFD). All Phospho1-/- tibiae irrespective 
of age/diet show clear deformation (Fig. 4.13).  Densitometry analysis confirmed 
that Phospho1-/- tibia are shorter in length and have increased width, this was not 
changed by the administration of a HFD (Fig. 4.14 A-B). However HFD feeding 
normalised the increased OD seen in 120 day old CD Phospho1-/- tibiae to the WT 
basal state (Fig. 4.14 C), indicative that HFD lowers mineral content in Phospho1-/- 
tibiae but does not affect WT tibiae.  
 
Next juvenile (35 day old) WT and Phospho1−/− male mice tibiae were subject to 3-
pont-bending and µCT to assess the biomechanical, trabecular and cortical 
parameters. Previous analysis revealed that long bones of 30 day old 
Phospho1−/− mice undergo plastic deformation and do not fracture upon bending. 
Furthermore these bones had reduced accumulation of osteoid in the long bones, 
reduced ash mineral content and reduced BMD of cortical bone (Huesa et al., 2011; 
Yadav et al., 2011). In this present study however, only subtle changes in bone 
architecture and biomechanistic properties were seen between juvenile tibiae from 
Phospho1−/− and WT mice.  The Phospho1−/− mice had a significant reduction in cortical 
thickness and increase in maximum stiffness (Table 4.3). 
 
To determine if HFD had an effect on biomechanical, trabecular and cortical 
parameters of tibiae from WT and Phospho1−/− mice, tibiae were again subjected to 3-
point-bending and µCT analysis. The general linear model was used to ascertain if 
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the differences in biomechanical, trabecular and cortical parameters were due to a 
genotype effect only, diet effect only or the combination of genotype and diet (Table 
4.4).  The expected the genetic ablation of Phospho1 in mice significantly decreased 
cortical porosity and increased the load and slope to maximum stiffness, yield, 
failure and fracture. Interestingly diet had the greatest effect on trabecular bone, 
increasing trabecular separation, trabecular pattern formation and structural model 
index, but reduced trabecular number and the degree of anisotropy.  Indeed HFD 
also significantly reduced bone volume fraction. Surprisingly the combination of 
genotype and diet only had a significant effect the trabecular degree of anisotropy 
and cortical porosity (P values outlined in Table 4.4).   
 
Combining the data from juvenile and CD adult mice it was then possible to 
ascertain if the differences in biomechanical, trabecular and cortical parameters 
were due to a genotype effect only, age effect only or the combination of genotype 
and age (Table 4.5).  Most surprisingly, genotype only had a significant effect on 
structural model index, load and slope to maximum stiffness. As anticipated age 
had an effect on most of the parameters measured, whereas the combination of 
genotype and age have no significant effect on any of the parameters measured 
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Figure 4.13 X-rays of WT and Phospho1-/- tibiae 
X-rays of juvenile (35-days-old) and adult (120-days-old) WT and Phospho1-/- tibiae. All  
Phospho1-/- tibiae show clear deformation irrespective of diet (n = 6).  
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Figure 4.14 X-ray densitometry analysis  
X-ray of densitometry of juvenile (35-days-old) and adult (120-days-old) WT and Phospho1-/- 
tibia. All Phospho1-/- tibiae have are significantly decreased length (A) and increased in width 
(B) irrespective of diet compared to WT tibiae. Optical density measurements of juvenile and 
HFD mice were unchanged between the genotypes however Phospho1-/- CD adult tibiae were 
significantly more dense than WT controls (C). n = 6, one way ANOVA. Data are represented 
as mean ±S.E.M. Values assigned the same letter show no significant difference from one 
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4.6 Discussion    
Recent developments in endocrinology made possible by the combination of mouse 
genetics, integrative physiology and clinical observations have resulted in rapid and 
unanticipated advances in the field of skeletal biology. Indeed, the skeleton, 
classically viewed as a structural scaffold necessary for mobility and regulator of 
calcium–phosphorus homoeostasis and maintenance of the haematopoietic niche 
has now been identified as a more complex organ involved in the regulation of male 
fertility and whole-body glucose metabolism which is in addition to the classical 
insulin target tissues (Ducy et al., 2000a; Lee et al., 2007; Ferron et al., 2008; 
Confavreux et al., 2009; Ferron et al., 2010a; Clemens and Karsenty, 2011; Karsenty, 
2012). These seminal data have established the skeleton as a bona fide endocrine 
organ. 
 
Data presented in Chapter 3 revealed that Esp, the gene encoding the protein OST-
PTP, was up regulated 60 fold in Phospho1-/- osteoblasts. OST-PTP dephosphorylates 
the InsR, negatively regulating osteoblast-insulin-signalling and thereby controlling 
GLU13-OCN release (Mauro et al., 1994; Hunter, 1995; Schlessinger, 2000; Dacquin et 
al., 2004; Tonks, 2006; Lee et al., 2007). Furthermore mice lacking Esp in osteoblasts 
have severe hypoglycemia and hyperinsulinemia (Lee et al., 2007).  Conversely, mice 
overexpressing Esp only in osteoblasts were glucose intolerant and insulin resistant 
(Lee et al., 2007). Therefore the identification of increased Esp expression in Phospho1-
/- mice has important implications for osteoblast differentiation and glucose 
homeostasis, possibly identifying a novel link between bone and energy 
metabolism.   
 
Indeed, the results presented in this Chapter reveal that the ablation of Phospho1 
results in decreased blood glucose levels, improved insulin sensitivity and glucose 
tolerance in juvenile, adult and aged mice. Furthermore following HFD feeding, 
Phospho1 ablation confers a remarkable degree of protection against insulin 
resistance in mice despite the 60-fold increase in Esp expression.  These data support 
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the notion that the osteoblast is an important target used by insulin to control 
whole-body glucose homeostasis and suggest that Esp may act as a fine controller of 
insulin sensitivity, offering protection from severe hypoglycemia and 
dyslipidaemia.   
 
Following the comprehensive phenotypic analysis of WT and Phospho1-/- mice it is 
apparent that changes in food intake are not responsible for the improved metabolic 
phenotype as no change in food intake was seen in all three age groups. However 
juvenile Phospho1-/- mice displayed increased activity which was not seen at 
adulthood or during ageing. This initial increase in activity may result in improved 
life-long insulin sensitivity; however this seems unlikely as no change in energy 
expenditure was observed. It is also possible that the ablation of Phospho1 
expression in the developing embryo can have long lasting effects, effectively 
“priming” the mice for an insulin sensitive phenotype throughout life. To discern if 
aged Phospho1-/- mice are protected from obesity and insulin resistance, a tamoxifen 
inducible Phospho1 knockout model would be required (Chapter 7). It is also likely 
that bone architecture composition including fracture incidence does not influence 
the metabolic phenotype in this model. It has been reported that the genetic ablation 
of Phospho1 produces significant skeletal deficits, which are transiently suppressed 
during skeletal maturity, therefore if bone architecture was the sole determinant of 
this phenotype it would have been expected to note a normalisation at 120 day old 
mice (Javaheri et al., 2015). 
 
An alternative explanation for the improved metabolic phenotype in Phospho1-/- mice 
may be due to the increased nuclei number and decreased lipid content of BAT from 
Phospho1-/- mice, possibly indicating increased mitochondria number. An increase in 
mitochondria number would lead to elevated canonical thermogenesis. BAT 
regulates metabolism and energy expenditure. Specifically, BAT dissipates large 
amounts of energy as heat, thus maintaining the energy balance of the whole body, 
but crucially only when the ambient temperature is below the thermoneutral range 
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for mice (30°C) (Richard and Picard, 2011). Since no differences were observed in 
the expression of BAT enriched genes e.g. Ucp1 this suggests that canonical 
thermogenesis through Ucp1 does not underlie the metabolic protection we see in 
Phospho1-/- mice.  However, as these experiments were conducted in temperatures 
(23°C) which are below the rodent thermoneutral temperature (30°C), mice housed 
at this sub-thermoneutrality were potentially mildly cold-stressed, hyper-metabolic, 
hypertensive and obesity-resistant and therefore gene expression may have been 
altered. It would be therefore beneficial to study mice at thermoneutrality, which 
would be of more direct relevance to energy balance in humans (unfortunately this 
was not possible but discussed fully in Chapter 7) (Maloney et al., 2014). However, if 
the observation that Ucp1 expression is unchanged at thermoneutrality, these data 
would suggest the existence of a new non-canonical BAT protective pathway.  
 
Finally in an effort to investigate the controversial effect of HFD on mice, WT and 
Phospho1-/- mice were fed a HFD from weaning until 120-days of age and subject to 
3-point-bending and µCT analysis. Bone microarchitecture of trabecular bone was 
significantly influenced by HFD feeding, specifically the HFD resulted in bone loss 
in Phospho1-/- mice. These skeletal changes are in agreement with previous studies 
that demonstrate that bone loss occurs in C57BL/6J following HFD feeding (Cao et 
al., 2010; Patsch et al., 2011; Huesa et al., 2014) but, are in contrast to a recent study 
that suggested that bone mass is not altered in C57BL/6J  mice fed a HFD (Doucette 
et al., 2015). The loss of bone in our model is consistent with the dogma that that 
HFD feeding increases adipocyte size and proliferation leading to the secretion of 
adipokines and cytokines such as TNFα, IL-6, Pref-1, resistin, leptin, that influence 
bone remodelling (Skurk et al., 2007; Doucette et al., 2015).  
 
In conclusion, the results presented in this chapter highlight that the ablation of 
Phospho1 in mice offers protection against diet induced hyperglycemia and insulin 
resistance. Importantly, the improved metabolic phenotype observed in Phospho1-/- 
mice is present in both juvenile and aged mice on a CD, highlighting that Phospho1-/- 
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mice display lifelong protection from metabolic disease.  Importantly, Phospho1-/+ 
mice display an intermediate insulin sensitive phenotype suggesting PHOSPHO1 
may represent a druggable target. Following the quantification of fat mass in 
Phospho1-/+ mice (Chapter 5), Chapter 6 will aim to elucidate the mechanisms 
regulating PHOSPHO1 mediated energy metabolism. 
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5.1 Introduction 
Body weight coupled with dissection is the simplest and most common predictor of 
fat mass, however it has been previously reported that body weight (BW) alone is a 
poor predictor of fat percentage especially in leaner mice (Rogers and Webb, 1980). 
The dissection of single fat pads, exemplified by GF, has been shown to be highly 
correlated with total body fat percentage, but the experimental animals need to be 
sacrificed (Sharp et al., 1984).  The gold standard methods for evaluating fat mass 
include freeze drying and chemical analyses. Briefly, freeze dried mass / wet weight 
allows for the prediction of fat percentage from dry matter content (FatP_FD) 
(Hastings and Hill, 1989; Bunger and Hill, 1997) and subsequent chemical analysis 
of the dried and ground animal allows for the prediction of protein content (from 
nitrogen)(Reynolds et al., 2001). These methods are time consuming and destructive 
implying they can only be used post mortem (with the exception of BW) and 
therefore cannot be used in longitudinal studies.   
 
In the last decade many sophisticated modalities have emerged to quantify 
adiposity in both rodent and larger animal models in a non-invasive way, including 
both standard and small animal dual-energy X-ray absorptiometry (DXA),  PIXImus 
DXA, in-vivo CT and µCT and standard and µMRI. Whilst these modalities have a 
high resolution, are quantifiable and allow for longitudinal studies, they have a low 
throughput and are relatively expensive (Table 5.1). They also require initial 
calibration against accepted gold standard methods such as dissection, freeze 
drying and chemical analysis (Hastings and Hill, 1989; Bunger and Hill, 1997).  
 
The genetic ablation of Phospho1 dramatically improves glucose and insulin 
tolerance (Chapter 4), suggesting that lack of Phospho1 may protect against diet 
induced obesity in mice. Therefore the overarching aim of this chapter was to 
quantify total fat mass and adipose localisation in WT and Phospho1-/-mice. 
However, due to the small cohort of mice available it was first necessary to evaluate 
the robustness of simple dissection, freeze drying and multi-object in vivo CT in 
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mice. These data would not only extend Prof. Lutz Bunger’s (SRUC) preliminary 
data indicating that multi-object in vivo CT in the ovine model was capable of 
providing precise and robust quantification of adipose tissue in C57BL/6 mice, the 
most widely used of all inbred strains (Clelland et al., 2013), but also determine if the 
simplistic weighing of SB, GF, MF and iBF fat pads is indeed an accurate method to 
predict whole body adiposity.  Following validation, it would be then possible to 
exploit these findings and precisely quantify fat in the WT and Phospho1-/- control 
and HFD cohort. As imaging is of great importance within The University of 
Edinburgh, I was awarded a small project grant from the Roslin Institute to expand 
upon these initial aims and establish if the use of µCT and µMRI in murine models 
was a good predictor of total fat mass and indeed if these modalities provided 
additional advantages to CT, dissection and freeze drying methods.  
 
5.2 Hypothesis   
Phospho1-/- mice are leaner than their WT counterparts in both subcutaneous and 
visceral fat deposits.   
             
5.3 Aims                      
I. To assess the repeatability, reproducibility and accuracy of multi-object in 
vivo CT in mice. 
II. To evaluate the robustness of simple dissection and freeze drying in mice. 
III. To quantify total fat mass and adipose localisation in WT and Phospho1-/- 
mice using the selected method from aim I and II.  
IV. To assess if µCT and µMRI provide additional advantages to CT, dissection 
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5.4 Materials and Methods   
5.4.1 CT 
35, 120 180 and 200 day old (n = 5) C57BL/6 mice and 120 day old male WT and 
Phospho1-/- control and HFD (n = 6) mice were sacrificed by cervical dislocation 
immediately prior to CT-scanning. Cross-sectional CT images were taken along the 
length of the body and Sheep Tomogram Analysis Routines (STAR) software was 
used to calculate the total area and average densities of fat, muscle and bone in each 
carcass image without gutting as outlined in section 2.9.1. 
 
5.4.2 Freeze Drying  
Individual fat pads (SB, GF, MF & iBF) were extracted and weighed (Fig. 5.1B and 
C). Whole mouse carcasses and corresponding isolated adipose tissue were freeze 
dried to determine the dry matter weight (DM) of the carcass and the predication of 
individual fat percentage values was calculated by regression on dry matter content 
as outlined in section 2.9.2. The CT based measures of tissue weights were 
compared to the DM-based estimates for the fat content (fat %) and the fat free mass 
(FFM) in (%) using simple linear regression: yi= b0 + b1xi, with b1= regression 
coefficient and b0 = intercept.  
 
5.4.3 µMRI 
Following sacrifice, 120 day old WT and Phospho1-/- male mice (n = 4) on both the 
control and HFD were subject to MRI. T2 weighted images were acquired both in 




Spectra were obtained from livers from 120 day old WT and Phospho1-/- male mice on 
both the control and HFD (n = 4).  Two peaks were fitted using jMRUI with either a 
Lorentzian and Gaussian lineshapes. 
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5.4.5 In vivo µCT 
Frozen 120 day old WT and Phospho1-/- mice (n =  3) were scanned using the Skyscan 
1076 in vivo scanner. Scans were performed at a resolution of 35 μm with the X-ray 
source set to 40kV, 250 μA and using a 0.5mm Al filter, step size of 0.4° combined 
with frame averaging set to 3.  
 
5.4.6 Histological staining of fat depots 
Following sacrifice by cervical dislocation, fat pads were dissected from 35, 120 and 
220 day old WT and Phospho1-/- male mice on both the control (n = 5) and HFD (120 
day old mice) (n = 4) and fixed in 5% PFA for 24 hours and stored in 70% ethanol.  
The fat depots were processed into wax as described in section 2.8.1 and stained 
with haematoxylin and eosin (section 2.8.3).  
 
5.4.7 Oil-Red-O staining of the liver in vivo 
Adult (120 day old) WT and Phospho1-/- mice on both the control and HFD (n = 4) 
were sacrificed by cervical dislocation and livers were snap frozen in a cooled 
hexane bath. Oil-Red-O staining of 10µm-thick liver cryo-sections was performed as 
outlined in section 2.8.4. Nuclei were lightly stained with haematoxylin and sections 
were mounted in aqueous mountant prior to visualisation.  
 
5.4.8 Statistical analysis  
The data analysis has used linear regression and correlation analysis based on Excel 
(Microsoft Office 10) built-in functions with interval of confidence and testing of the 
correlation coefficients according to standard procedures described in the statistical 
literature (Rasch et al., 1978a; 1978b). Data are presented as means ± SEM where 
appropriate. Regression and correlation coefficient’s are given with the intervals of 
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Figure 5.1 – Multi-object CT scanning 
(A) Multi-object CT scanning. (B) Photograph depicting locations of fat depots. (C) 
Representative images of the dissected fat depots. From top to bottom: subcutaneous fat 
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5.5 Results 
5.5.1 Live weight, fat and non-fat traits measured by freeze drying, CT and 
dissection 
The description of the dataset regarding these traits in terms of simple means and 
their standard errors is given in Table 5.2.  The live tissue weight (LTW) of the mice 
was on average 31.5g, but splitting into the age groups shows a high variation 
between the age group means (20.9g to 41.1g). This produced the required variation 
in the fat traits, with fatness increasing with age. Taking the FatP_FD as an example, 
the fat content increases from about zero % (-1.1%) at 35 days to 18% at 200 days 
(with an average of 9%). Given the different methods to measure the size of the fat 
and non-fat compartment of the body it is not unexpected to find that the 
magnitude of the measured quantities of fat and non-fat differed between the 
methods used. The total estimated fat by FD across all ages amounts to 3.4g (9.0%). 
The value obtained from CT is 6.5g (23.6%) and thus much higher, probably 
indicating that the thresholds derived from sheep dissection trials need to be refined 
for mice. Another opportunity is to use the obtained CT values in suitable 
regression equations to predict accurately the fat values obtained by freeze drying; 
the gold standard. Similarly, it is not unexpected to find the lowest total fat amount 
from dissecting out the 4 above mentioned fat depots (SB, GF, MF and iBF). This 
method finds on average 1.5g of the total fat (sum of the 4 depots), which is less 
than half of the existing body fat. Again, the total body fat can be easily predicted 
from appropriate regression equations which either use the information from one or 
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5.5.2 Live weight as a predictor for fat and non-fat 
The simplest predictor of fatness is often LTW (Table 5.3). This assumes however 
that there is a wide variation in fatness.  This was the case in the present cohort 
where mice aged between 35 and 200 days of age were studied. Both, FatW_FD and 
FatP_FD are highly correlated with LTW, r = 0.95 and 0.95, respectively, indicating 
that LTW alone allows good prediction of the fat weight and content in this sample 
of mice. LTW also correlates highly with the non-fat weight and content estimated 
by FD: r= 0.98 and 0.95. It is of note that these seemingly good prediction abilities of 
LTW will be diminished when looking at mice at one age or animals with a small 
age span only, although the low sample sizes per age group in this study did not 
allow me to prove this. As the FD measures of fatness are highly correlated with 
those obtained from CT it is not surprising to find that LTW is also a good predictor 
for the CT based traits, with the correlations slightly lower (r = 0.85 to 0.94; Table 
5.3). 
  
5.5.3 Benchmarking CT predictions against freeze drying 
Water content is a robust indicator of fat proportion as described previously and can 
be easily measured by freeze drying (Sharp et al., 1984). This method is cheaper and 
quicker than the equivalent chemical analysis. As the latter was not available in this 
study, freeze drying was the chosen benchmarking method. The initial use of both 
methods on the same sample allows the derivation of prediction equations, which 
can be utilised to allow the use of subsequent CT measures alone to predict fat and 
non-fat traits given the results of both methods correlate highly. Here, high positive 
correlations between CT measured fat (FatW_CT and FatP_CT) and the 
corresponding traits quantified by FD (r = 0.91 to 0.98) was shown. Moreover, high 
positive and just slightly lower correlations between the non-fat traits measured by 
FD and CT were observed. Interestingly, the correlations between the measures 
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5.5.4 Benchmarking isolated dissected fat pad mass against freeze drying and CT  
The dissection of a single isolated fat pad from mice is a very common, invasive but 
highly simplistic and rapid exercise to evaluate total fat mass in mice. However the 
accuracy of this in C57BL/6 mice has not yet been reported. High positive 
correlations (r = 0.92, 0.93, 0.98 and 0.89, respectively) were found between all 
isolated fad pads and the FatW_FD(g) with the highest correlation between GF_DS 
and FatW_FD indicating that the GF pad seems the best single trait predictor for the 
total body fat in a mouse (r = 0.98; Table 5.3). Again, as the FD and CT measured fat 
traits are highly correlated it is expected that the mass of the individual fat depots 
also correlates highly with the CT based fat mass measures, with the highest value (r 
= 0.98) between the GF_DS and FatW_CT emphasising the good prediction 
opportunities if only one depot is being used, and highlighting the accuracy of 
multi-object CT.  
 
The last 4 rows of Table 5.3 highlight that the prediction accuracy can be increased if 
the fat weight found in all 4 depots is summed up and all correlated to FD and CT 
measured fat mass. The correlations are both 0.98 and therefore comparable to the 
GF_DS vs. FatW ones.  
 
These data highlight that there is a strong correlation between BW alone and fat 
mass / percentage. Moreover, simplistic dissection is sufficient to quantify whole 
body adiposity in mice and CT can accurately predict the degree of adiposity in the 
murine model. Thus these techniques were applied to the experimental WT and 
Phospho1-/- cohort. 
  
5.5.5 WT and Phospho1-/- control and HFD dissection analysis 
Phospho1 deficient mice had significantly decreased fat accumulation in SB, GF, MF 
depots than the WT mice on the CD. Upon HFD feeding WT mice became obese and 
had a significant increase in fat accumulation in all depots measured; however 
Phospho1-/- mice only accumulated fat in the SB and GF depots with no change in fat 
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accumulation noted in the MF depot between the control and HFD fed Phospho1-/- 
mice. No change in fat mass accrual was seen in the iBF deport between genotypes 
on the two diets (Fig. 5.2). There was no significant change in the size of adipocytes 
from GF of Phospho1-/- mice on the control and HFD with both groups having 
significantly more smaller adipocytes (< 20μm diameter) than the WT groups on 
both diets. Wild type HFD mice had significantly more larger adipocytes ( > 60μm 
diameter) (P < 0.05) that WT CD mice suggestive that the HFD does not affect the 
size of Phospho1-/- adipocytes, however HFD increased the number of larger and 
decreased the number of smaller adipocytes in WT mice, consistent with obesity 
(Fig.5.2).  
 
5.5.6 WT and Phospho1-/- control and HFD CT analysis  
Multi-object CT values from the WT and Phospho1-/- were calculated from non-
segmented mouse carcass (Fig. 5.3A) (preliminary data suggested that time 
consuming segmentation did not improve fat prediction accuracy). Computed 
tomography based fat predictions indicated that WT mice regardless of diet had 
increased total fat mass compared to Phospho1-/- mice and diet did not increase fat 
mass of the two genotypes. Interestingly, CD Phospho1-/- mice had increased muscle 
and bone mass compered to CD WT mice (P < 0.05) (Fig. 5.3B).  Micro computed 
tomography confirmed the decrease of SB fat mass of CD Phospho1-/- mice to WT 
mice (Fig. 5.4).   
 
5.5.7 µMRI adiposity and hepatic analysis          
The mass of iBF predicted by µMRI did not significantly change between the 
genotypes however iBF did show a tendency to increase with HFD feeding similar 
to dissection analysis (Fig. 5.5B, Fig. 5.2C).  The mass of SB and MF was not 
increased in Phospho1-/- mice between the two diets, whereas a HFD increased WT 
SB by 27.1% and MF by 64.5% (P < 0.05) indicating that Phospho1-/- mice are protected 
from diet induced obesity. Following conventional µMRI, MR spectroscopy was 
then conducted using time-domain analysis of in vivo MR data. Fitting both 
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Lorentzian and Gaussian lineshapes revealed that fat content was unchanged in the 
liver of Phospho1-/- mice between the two diets, consistent with µMRI fat depot 
analysis. Concomitant to this, fat content was significantly increased (84.8%) in WT 
HFD mice compared to Phospho1-/- HFD mice resulting in non-alcoholic fatty liver 
(NAFLD) disease which was visualised by both gross dissection and increased Oil-
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Figure 5.2 Dissection based fat quantification from WT and Phospho1-/- mice on both a 
control and HFD 
(A) Photograph depicting fat accumulation in WT and Phospho1-/- mice on both a control and 
HFD. (B) Representative Images of the dissected GF fat depots. (C)  Fat depots were 
dissected from WT and Phospho1-/- control and HFD mice. Results were normalised to BW 
(mg/g). (D) Percent of total GF adipocytes per 10µm diameter size class. n = 3 replicates, one 
way ANOVA. Data are represented as mean ±S.E.M. Values assigned the same letter show 
no significant difference from one another (P < 0.05). 
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Figure 5.3 CT based fat quantification from WT and Phospho1-/- mice on both a control 
and HFD 
(A) Multi-object CT scanning. Left non-segmented, right segmented mouse carcass. (B) Fat, 
muscle and bone mass determined by non-segmented multi-object CT scanning. Results 
were normalised to BW (mg/g). n = 6, one way ANOVA. Data are represented as mean 
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Figure 5.4 Cross section µCT scans of WT and Phospho1-/- mice 
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Figure 5.5 µMRI fat quantification from WT and Phospho1-/- mice on both a control and 
HFD 
(A) Representative reconstructed µMRI scan. Green = SB fat, red = MF fat, blue = iBF. (B) SB, 
MF and iBF mass determined by µMRI. Results were normalised to BW (mg/g). n = 6, one 
way ANOVA. Data are represented as mean ±S.E.M. Values assigned the same letter show 
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Figure 5.6 WT and Phospho1-/- mice liver analysis from both a control and HFD 
(A)  Typical photographs of liver histology (Oil-Red-O stained) from each group.  (B) 
Representative photographs of dissected liver. (C) Quantitative assessment of liver fat 
utilising spectroscopy. Water and fat peak areas were defined with the assumption of either 
Gaussian or Lorentzian line shapes. n = 2 WT, n = 3 for remaining groups, one way ANOVA.  
Data are represented as mean ±S.E.M (n = 3 replicates). Values assigned the same letter show 
no significant difference from one another (P < 0.05). 
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5.6 Discussion 
PHOSPHO1, the bone specific phosphatase has been previously been shown to be 
essential for the initiation of bone mineralisation (Houston et al., 2004; MacRae et al., 
2010; Huesa et al., 2011; Yadav et al., 2011). Moreover, I have shown that in addition 
to the roles in bone mineralisation Phospho1 ablation confers a remarkable insulin 
resistance and diabetes in mice (Chapter 4). Here, the fat deposition and localisation 
in WT and Phospho1-/- control and HFD mice was determined (Fig. 5.2-5.6). Prior to 
these studies it was first necessary to compare both invasive and non-invasive 
methods for measuring adiposity in young to old C57BL/6 male mice. These 
parameters were necessary as the WT and Phospho1-/- experimental mice were 
predominantly C57BL/6 male mice with a large variation of fat traits.  Previous 
publications have evaluated the use of BW alone as predictor of fat mass or fat 
percentage, reporting a good correlation in obese mice, yet a poor correlation in 
very lean mice (Rogers and Webb, 1980).   Contrary to this, a strong correlation 
between BW alone and fat mass and percentage in mice of 20g (35 days of age) to 
40g (200days of age) measured by freeze drying and by multi-object CT was 
observed in the cohort of this present study. There was a tendency for the r values to 
be slightly lower for the relative measures (%) compared to the absolute values (g), 
and the correlation to FD measures seem slightly higher compared to the CT based 
measures. These high correlations are likely due to the large age span present in the 
cohort, selected to produce a large variation in fat traits. However, in mice with 
similar BW’s, this may not be the case and the use of LTW as solely predictor of fat 
mass is not recommended. 
 
Compared to the LTW as a fat predictor, the multi-object CT yielded slightly higher 
accuracies, e.g. the FatW_CT  is a very good predictor for the total fat mass in the 
body (r = 0.98). The chosen approach in this study to CT scan freshly killed mice 
allows conclusions for CT scanning mice in vivo. This study shows the fat amount in 
live animals can be predicted very well with multi-object spiral CT.   There was only 
limited research exploring the use of multi-object CT in fat mass prediction in mice. 
Chapter 5                                                 Evaluating fat deposition and localisation in WT and Phospho1 knock-out mice 
~ 157 ~ 
 
This study now provides prediction equations based on one predictor (Table 5.3), 
indicating that CT can accurately predict the degree of adiposity in the murine 
model. Moreover, with the use of multiple regression analysis, a further small 
increase in accuracy could be expected.  
 
This study highlighted that simplistic dissection is also sufficient to quantify whole 
body adiposity, and the measurement of one depot (GF pad) achieves the same 
predicted accuracy than the dissection of all 4 depots. These results are in agreement 
with previous work (Hull, 1960) and are based on the strong positive correlation 
between isolated fat depots and predicted fat mass. Therefore it was concluded that 
LTW, dissection and multi-object in vivo CT fat quantification are highly valuable 
techniques to evaluate fat mass.  Multi-object in vivo CT offers the clear advantages 
of being a minimally invasive technique allowing longitudinal studies to be 
completed in a high throughput manner.   
 
With these insights, simplistic dissection was first employed to quantify whole body 
adiposity. These data were suggestive that Phospho1-/- mice had smaller (mg/g BW) 
GF, SB and MF fat deposits compared to the WT counterparts. Indeed Phospho1-/- 
mice resisted MF accumulation when fed the chronic HFD. In concordance with 
these data, multi-object CT based fat predictions indicated that WT mice had 
increased total fat mass compared to Phospho1-/- mice however diet did not increase 
fat mass of the two genotypes. The lack of a detectable effect of HFD feeding on 
mice may be due to the fact that the thresholds derived from sheep dissection trials 
need to be refined for mice to more accurately detect small changes in fat mass or 
the mice used in this study may have developed adaptive mechanisms that 
participated in in the protection against diet induced obesity (Burcelin et al., 2002). 
However, these data are consistent with the insulin sensitivity and hypoglycemia 
observed in Phospho1-/- mice (Chapter 3),but this phenotype was not expected due to 
the 60-fold increase in Esp mRNA expression in Phospho1-/- osteoblasts that has been 
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reported to be associated with InsR inactivation, thus insulin resistance and obesity 
(Lee et al., 2007).  
 
Coincidently, additional funding became available to evaluate µCT and µMRI 
imaging modalities in mice. Both µCT and µMRI were in concordance with 
dissection and CT fat predictions, indicating that Phospho1-/- mice were leaner than 
WT mice. However these modalities, specifically µMRI provided the ability to 
delineate between different fat depots, with the additional benefit of 
MR spectroscopy, not possible with conventional CT, freeze drying and dissection. 
µMRI revealed that Phospho1-/- mice resisted diet induced obesity and NAFLD.  
 
The discrepancy between hypothesised fat mass and actual fat mass evaluated by 
dissection, CT,  µCT and µMRI highlighted that PHOSPHO1 regulates global 
energy metabolism despite the 60-fold increase in Esp, strengthening the notion that 
a novel pathway may exist between osteoblasts and glucose homeostasis, and like 
other studies points towards further osteoblast-derived hormones that regulate 
glucose metabolism (Yoshikawa et al., 2011). This study also revealed that both µCT 
(qualitative) and µMRI (quantitative) were good predictors of total fat mass in mice 
and indeed provided additional advantages to conventional CT, dissection and 
freeze drying methods, such as the ability to accurately dissect fat tissue in silico 
(allowing total fat quantification), the ability to delineate between different tissues 
thus providing high resolution, longitudinal tools to study fat distribution in mice, 
muscle shape and hepatic fat / water ratios.  
 
In conclusion this study highlights that simple dissection and BW is an accurate 
predictor of whole body fat mass; however for longitudinal studies multi-object CT 
has the capability to accurately predict total fat mass and with appropriate bench 
marking muscle and bone mass (as shown in other species), thus replacing time 
consuming dissection in experimental design. Furthermore, this study has 
highlighted that µMRI and µCT provide high spatial resolution and contrast, 
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allowing not only quantification of adiposity in longitudinal studies, but also the 
ability to distinguish between normal and pathological tissues. Specifically µMRI is 
quantifiable, and provides the additional benefit of MR spectroscopy,  however 
further work is required to benchmark both µMRI and µCT to DM based prediction 
or chemical analyses in allow for the dissection of the genetic basis of diet induced 
obesity and study of diet effects over age. Utilising these various imaging modalities 
I have shown that PHOSPHO1 ablation is protective against obesity and NAFLD 
likely via OCN independent mechanism that will be explored in Chapter 6.
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6.1 Introduction                   
Energy metabolism is a precisely regulated process, involving intricate paracrine, 
autocrine and endocrine signalling pathways that work in synergy to coordinate 
energy expenditure and storage in metabolically active tissues. In the last decade, 
bone has been identified as a true endocrine organ, possessing the capabilities to 
regulate energy metabolism, expanding our understanding and identifying a new 
and unconventional role of bone beyond its classical functions (section 1.6). Whilst 
this thesis has identified and characterised the role of PHOSPHO1 in this 
phenomenon, the underlying mechanisms have not yet been examined.   Of 
particular interest was OCN, the most abundant osteoblast-specific non-collagenous 
protein accounting for 10-20% of the non-collagenous protein content of bone 
(Hauschka et al., 1989b). Initially synthesised in the osteoblast as a pre–pro 
molecule, OCN is largely unstructured when calcium is not present. In the presence 
of calcium the OCN protein becomes folded regulating the maturation of bone 
mineral (detailed in section 1.5.2.8) (Hauschka et al., 1989b; Chenu et al., 1994). 
However, OCN also exists in partially carboxylated and completely uncarboxylated 
forms in the circulation which has recently been shown to regulate energy 
metabolism by stimulating insulin sensitivity, insulin secretion and energy 
expenditure (Plantalech et al., 1991; Cairns and Price, 1994; Vergnaud et al., 1997; 
Schilling et al., 2005; Ferron et al., 2008). Indeed, the bioactivity of OCN is tightly 
regulated by OST-PTP, the product of the Esp gene, mutations of which result in 
insulin sensitivity and protection from induced obesity and diabetes due to 
increased circulating GLU13-OCN (Lee et al., 2007; Ferron et al., 2008). More 
recently, FoxO1 has been implicated as a regulator of Esp. In the osteoblast nucleus 
FoxO1 co-localises with ATF4, promoting the transcriptional activity of ATF4 
resulting in the up-regulation of Esp in osteoblasts, leading to OCN inactivation 
(Kode et al., 2012). Indeed, a 60-fold increase in Esp mRNA expression was observed 
in Phospho1-/- osteoblasts and in silico gene network analysis was suggestive that Atf4 
and Fox01 were differentially expressed between WT and Phospho1-/- osteoblasts 
indicative of PHOSPHO1, OST-PTP and OCN mutual regulation. However, 
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contrary to the established dogma, Phospho1-/- mice have lower blood glucose, 
improved glucose and insulin tolerance and resist obesity on a HFD despite the 60-
fold increase in Esp expression which is indicative of a hyperglycemic, insulin 
resistant and obese phenotype (section 1.6.1) (Lee et al., 2007). These observations 
point towards an OCN-independent influence of osteoblasts on energy metabolism 
with Esp possibly offering protection against excessive insulin signalling. It is 
therefore plausible to suggest that in addition to OCN, other bone-derived 
hormones may contribute to the function of the skeleton as a regulator of energy 
metabolism (Yoshikawa et al., 2011). Mindful of this, SMPD3 catalyses the 
hydrolysis of sphingomyelin to from ceramide and phosphocholine (section 1.5.2.7) 
(Stoffel et al., 2005). Phosphocholine is subsequently hydrolysed to choline and 
phosphate by PHOSPHO1. Elevated levels of both ceramide and choline result in 
insulin resistance in mice (Yang et al., 2009; Wu et al., 2013). Ceramide may have 
direct effects on genes (e.g. Ucp3) involved in energy metabolism and expenditure 
and induce the suppressor of cytokine signalling-3 which plays a central 
mechanistic role in the development of both leptin and insulin signalling pathways.  
It does this by attenuating phosphorylated  signal transducer and activator of 
transcription (STAT) proteins binding to the InsR (Ueki et al., 2004; Kanatani et al., 
2007),  inhibiting IRS-1 phosphorylation and downstream insulin signalling (Lebrun 
and Van Obberghen, 2008) and targeting both IRS-1 and IRS-2 for proteosomal 
degradation (Lebrun and Van Obberghen, 2008). Furthermore, choline has been 
shown to induce hyperglycemia and insulin intolerance in mice via the modulation 
of plasma glucagon. Glucagon subsequently enhances hepatic gluconeogenesis, 
concomitant with increasing mitochondrial fatty acid uptake and oxidative stress 
that increases phosphorylation of IRS1-s-307, thereby inhibiting insulin-mediated 
signal transduction (Nakatani et al., 2004; Wu et al., 2013). Theoretically, the genetic 
ablation of Phospho1 would result in decreased choline and preliminary mass 
spectroscopy analysis indicated that plasma ceramide was reduced in Phospho1-/- 
mice.  Choline and / or ceramide deficiency may therefore provide an alternative 
hypothesis for the improved metabolic profile of Phospho1-/- mice in vivo.  
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Therefore the overarching aim of this chapter was to elucidate the mechanisms 
regulating PHOSPHO1 mediated energy metabolism. This will provide new 
insights into the molecular mechanisms surrounding the dynamic interplay 
between bone and glucose regulation.    
 
6.2 Hypothesis 




I. Quantify serum OCN levels in WT and Phospho1-/- mice. 
 
II. Analyse the effects of Phospho1-/- and WT osteoblast conditioned medium on 
hepatic, pancreatic, myoblast, osteoblastic and adipogenic cell lines. 
 
III. Examine whether ceramide species are decreased in Phospho1-/- serum 
 
IV. Determine if choline supplementation normalises glucose metabolism in 
Phospho1-/- mice. 
 
V. Identify the candidates underlying the protection from obesity and insulin 
resistance in Phospho1 deficiency. 
 
 
6.4 Materials and Methods 
6.4.1 Primary osteoblasts 
Under sterile conditions calvariae were dissected from 3-4 day old new-born WT 
and Phospho1-/- mice as described in section (2.2.2). Extracted cells were resuspended 
in osteoblast medium (Appendix I) and pooled to obtain a single cell suspension. 
The cells were expanded in flasks in a humidified atmosphere of 95% air/5% CO2 
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and maintained at 37 °C until 80–90% confluence before being plated at 10, 000 
 cells/cm2 in multi-well plates. 
 
6.4.2 Cell lines (FAZA, Ins1e, C2C12, 3T3-L1) 
Under sterile conditions cells lines (FAZA - rat liver cell line, Ins1e -
rat insulinoma cell line, C2C12 - mouse myoblast cell line and 3T3-L1 maintained at 
-160°C were thawed quickly at 37C and 5ml of pre-warmed appropriate 
maintenance media (Appendix I) was added slowly and centrifuged. The cell pellet 
was resuspended in maintenance media and transferred to a T175 tissue culture 
flask (T75 for C2C12 cells) and expanded in flasks in a humidified atmosphere of 
95% air/5% CO2 and maintained at 37 °C.   When the cells were 80–90% confluent 
they were plated at 10, 000 cells/cm2 in multi-well plates until differentiated. 
 
6.4.3 Conditioned medium with insulin treatment 
Following differentiation, C2C12, FAZA, Ins1e, 3T3-L1 and primary WT osteoblast 
cells were cultured for 24 hours in αMEM containing 0.5% FBS. Medium was 
changed to serum free αMEM containing 0.1% BSA (Fraction V) and HEPES 10mM 
pH 7.4. 1 hour prior to insulin stimulation, cells were incubated with 1ml WT or 
Phospho1-/- osteoblast conditioned medium. Cells were finally stimulated with 10nM 
insulin or vehicle control (PBS) for 15 minutes and washed in ice-cold PBS prior to 
protein and mRNA extraction (section 2.6, 1.7). 
 
6.4.4 mRNA analysis of primary osteoblasts cells and cell lines 
RNA samples were extracted from primary calvarial osteoblasts, using a Qiagen 
RNeasy lipid kit according to the manufacturer’s instructions. cDNA was prepared  
and was used at 5ng/µl for RT-qPCR analysis, as detailed in section 2.6  Results 
were normalised to the appropriate housekeeping gene and the relative gene 
expression level was calculated using the ΔΔCt method (Livak & Schmittgen 2001).  
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6.4.5 Protein analysis of primary osteoblasts cells and cell lines 
Protein was extracted from primary calvarial osteoblasts and cell lines in RIPA 
buffer as detailed in section 2.7.1. Protein concentration was quantified (section 
2.7.2) and appropriate quantities were used for western blot analysis (section 2.7.3). 
pAKT, AKT, GLUT 4, pGSK3 and GSK3 expression was determined using a goat 
anti-rabbit (goat anti-mouse GLUT4)  antibody at a dilution of 1:1000 and the 
appropriately HRP-labelled donkey anti-rabbit/mouse secondary antibody (1:5000) 
(Appendix II).  Antibody labelling was visualised using the ECL detection kit. 
Equality of protein loading was confirmed by also probing the membrane with 
mouse monoclonal HRP-labelled anti-β actin antibody (1:50000). 
 
6.4.6 ELISA analysis of serum OCN, adiponectin and leptin  
Serum from 8 week and 120 day old male WT and Phospho1-/- CD mice was collected 
via cardiac puncture and transferred to an EDTA coated tube and stored at -80°C 
until use. An ELISA-based method to quantify osteocalcin carboxylation was used 
(section 2.10.5) (Ferron et al., 2010b). Commercially available ELISA kits were used 
to measure leptin, adiponectin and insulin in serum from 120 day old male WT and 
Phospho1-/- CD and HFD (section 2.10.6). 
 
6.4.7 Analysis of serum triglyceride 
A triglyceride colorimetric assay kit was used to measure triglyceride levels present 
in blood serum from 120 day old male WT and Phospho1-/- CD and HFD mice. This 
assay was based on the enzymatic hydrolysis of the triglycerides by lipase to 
produce glycerol and free fatty acids. The glycerol released was measured by a 
coupled enzymatic reaction system with a colorimetric readout at 540 nm (detailed 
in section 2.10.4).  
 
6.4.8 Ceramide mass spectrometry   
Serum was collected as described in section 2.5.3 from 120 WT and Phospho1-/- mice. 
50µl of serum was used to extract lipids according to the method of Folch et al. 
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(Folch et al., 1957). Glycolipid analysis and quantification was performed by 
Professor Phillip Whitfield (University if Highland and Islands) via electrospray 
ionization-tandem mass spectrometry (ESI-MS/MS) (detailed in section 2.11.2). Data 
were analysed using software driven algorithm (thermo Xcalibur Quad Browser) 
imputing known ceramide species (Appendix VI). 
 
6.4.9 In vitro 2-deoxyglucose [3H]  
WT and Phospho1-/- primary osteoblasts were extracted and expanded as described 
in section 2.2.2 and 2.2.4. Cells were then incubated in serum free medium for 4 
hours and washed in PBS.  Either basal (2ml PBS), 100nM insulin (in 2ml PBS), 
1000nM insulin (in 2 ml PBS) or 10µM Cytochalasin B (in 2 ml PBS) was added for 
15 minutes at 37oC. Following insulin treatment 0.1 mM (9250 Bq/ml (0.25µCi/ml)) 2-
DG (3H-labelled) was then added to each well for 15min at 37°C. Glucose uptake 
was terminated by washing the cells 3 times with ice cold 0.9% saline with the plates 
on ice. Cells were scraped in PBS+0.1% SDS and homogenised. Radioactivity was 
measured and normalised to protein content (section 2.3.3).   
 
6.4.10 BRL-37344 
Male juvenile, adult and aged mice (35, 120 and 220 day-old) were weighed and 
fasted for 4 hours between 9am and 1pm. 1mg/kg BW of BRL-37344 was 
administered IP for 3 hours. Mice were later euthanised and tissues were collected 
for protein and gene analysis (2.6 and 2.7). 
 
6.4.11 Mitochondria stress test 
Osteoblasts were plated at a density of 25,000 and 50,000 cell’s per well (24 well 
plate) and transferred to a 37C CO2  incubator until 100% confluency was reached. 
Cells were washed in 500µl XF assay media supplemented with 25 mM glucose and 
10 mM pyruvate and placed in a non-CO2  incubator at 37C for 1 hour prior to start 
of assay. Oligomycin (1.2µM), FCCP (0.56µM), antimycin A / rotenone (0.96µM) 
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were prepared and following equilibration the Seahorse plate was placed in the 
Seahorse XF24 Analyser for analysis (section 2.3.4).  
 
6.4.12 2% choline diet 
Male mice were fed a 2% supplemented choline diet (Harlan Laboratories) or CD 
(Harlan Laboratories) for 5 weeks prior to cull at 120 days. Metabolic tests were 
conducted as detailed in section 2.5.3.3.  
 
6.4.13 Proteomics 
Proteins from serum were extracted and prepared (section 2.5.3) and the extracted 
proteins were analysed using a RSLC 3000 nanoscale capillary LC followed by qTOF 
mass spectrometry (QSTAR, ABSciex).  This was done by Dr. Cal Vary (Center for 
Molecular Medicine, Maine Medical Center Research Institute (MMCRI), ME, 
USA)).    ProteinPilot™ was used for protein identification and quantitation, as well as 
visualising peptide-protein associations and relationships. Functional pathway and 
causal network analysis was performed using QIAGEN’s Ingenuity (IPA), 
GeneMANIA and EXPANDER (EXpression Analyzer and DisplayER) following 
training from Dr. Jacqueline Smith.  
 
6.4.14 Lipidomics 
Total lipids were extracted from serum and osteoblast conditioned medium and 
silica based solid phase extraction was employed for sample clean up and 
fractionation prior to analysis. Resulting mass spectra was analysed by LC-MS in 
both positive and negative ion scanning modes. This was done by myself with 
assistance from Dr. Cal Vary, MMCRI.  LipidView™ was used for the molecular 
characterisation and quantification of lipid species and principle component 
multivariate data analysis established preliminary lipid classes and their 
contribution to sample differences. 
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6.5 Results 
6.5.1 Quantification of serum adipokines 
To uncover the mechanism leading to the increase in insulin sensitivity in 
Phospho1−/− mice, various serum adipokines were first studied. Adiponectin, an 
adipokine that plays an important role in the modulation of glucose and lipid 
metabolism in insulin-sensitive tissues (Chandran et al., 2003) was decreased 2.62 
and 1.92 fold respectively in Phospho1−/− mice on both the CD and HFD (Fig. 6.1A), 
suggestive that insulin sensitivity and protection from obesity is independent of 
elevated adiponectin. Serum leptin levels were unaffected between WT and 
Phospho1−/− mice on a CD, however in the diet challenged study leptin was decreased 
by 1.31-fold in HFD Phospho1−/− mice compared to HFD WT controls (Fig. 6.1B). 
Circulating triglycerides were increased 1.30-fold in CD Phospho1−/− mice compared 
to CD WT mice (Fig. 6.1C).  
 
6.5.2 Expression of genes metabolic target genes 
The expression of target genes involved in metabolism was next evaluated. 
Surprisingly, selected metabolic target genes were largely unaltered in SB adipose, 
quadriceps femoris and liver tissue of Phospho1 deficient mice. Specifically, 
lipoprotein lipase (lpl) which is involved in the regulation of fatty acid turnover was 
up regulated 2.16-fold in Phospho1−/− adipose tissue compared to controls (Fig. 6.2A). 
Irisin, an exercise-induced myokine suggested to induce browning of white 
adipocytes (Huh et al., 2014), was up regulated 1.62-fold in Phospho1−/− 
quadriceps femoris compared to controls (Fig. 6.2B) and AMP-activated protein 
kinase (Prkaa1), phosphoenolpyruvate carboxykinase 1 (Pck1) and peroxisome 
proliferator-activated receptor alpha (Ppara) were up regulated 1.25, 1.57 and 1.62 
respectively in Phospho1−/− hepatic tissue compared to controls (Fig. 6.2C). 
Furthermore, both adipose and quadriceps femoris tissue had a significant increase 
in Slc2a1 in the Phospho1−/− mice (Fig. 6.2D-E) however no such change was observed 
in hepatic tissue (Fig. 6.2F). These subtle changes were seen on both the CD and 
HFD fed mice (data not shown). Results of this phenotypic analysis established that 
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Phospho1 function is required for the development of obesity and glucose 
intolerance in mice. 
 
 
Figure 6.1 Phospho1-/- mice are insulin sensitive despite decreased adiponectin  
Serum levels of adipokines and triglycerides were measured in serum from 120 day old CD 
and HFD male mice by  ELISA (A) adiponectin and (B) leptin (C) triglyceride.  n ≥ 8, two 
way repeated measures ANOVA. Data are represented as mean ±S.E.M. * P < 0.5, ** P < 0.01, 
***P < 0.001. 
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Figure 6.2 Selected metabolic target genes were largely unaltered in subcutaneous adipose 
quadriceps femoris and liver tissue of Phospho1-/- mice 
RT-qPCR analysis of tissue extracted from 120 day old WT and Phospho1-/- mice (A) adipose 
tissue (B) quadriceps femoris and (C) liver. RT-qPCR analysis of GLUT receptors from (D) 
Adipose tissue (E) quadriceps femoris and (F) liver. mRNA values generated were 
normalised to Gapdh housekeeping gene. n = 3, t-test and Mann–Whitney rank sum test. Data 
are represented as mean ±S.E.M. * P < 0.5, ** P < 0.01, ***P < 0.001. 
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6.5.3 Examination of in vitro and in vivo glucose metabolism in WT and 
Phospho1−/− mice 
 
Glucose metabolism and insulin responses were initially assessed in vitro. In brief, 
primary osteoblasts extracted from WT and Phospho1−/− mice were stimulated with 
[3H]2-deoxyglucose and the  incorporation of radioactive tritium (as a surrogate of 
glucose uptake) was measured. Surprisingly Phospho1−/− osteoblasts incorporated 
less glucose than WT osteoblasts, suggestive that they are less metabolically active 
(Fig. 6.3).  
 
Furthermore, Phospho1-/- mice subjected to a sub-maximal in vivo administration of 
insulin (1mU/g) displayed a significant increase in the key markers of insulin 
sensitivity in bone (Akt phosphorylation) (P < 0.05) and decreases in 
phosphorylated-p44/42, total p44/42 and GLUT4 (P < 0.05). These changes were 
absent in WT bone and no such changes were noted in liver, muscle and fat (data 
not shown) suggestive of a Phospho1−/− bone driven regulation of whole body 
metabolism (Fig. 6.4A-B).   
 
The differences in metabolism observed between WT and Phospho1-/- mice prompted 
me to compare the metabolic profile of WT and Phospho1-/- calvarial osteoblasts. The  
XF-24 extracellular flux analyser was used to measure oxygen consumption rate 
(OCR) and then a Mito Stress test was performed by using inhibitors of the 
mitochondrial electron transport chain in a sequence (Guntur et al., 2014). 
Oligomycin was first injected to inhibit oxygen consumption; FCCP was injected 
which uncouples the electron transport chain thus increasing OCR and finally 
respiration was completely inhibited using a combination of complex I and complex 
III inhibitors, rotenone and antimycin A.  It was observed that Phospho1-/- calvarial 
osteoblasts had higher OCRs than WT osteoblasts. Suggestive that Phospho1-/- 
calvarial osteoblasts may be cells less glycolytic than WT osteoblasts, however this 
may be due to the inability of Phospho1-/- calvarial osteoblasts to mineralise in vitro 
(6.4C).   
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Figure 6.3 Phospho1-/- osteoblasts show decreased 2-deoxyglucose [3H] uptake upon 
insulin stimulation 
2-deoxyglucose [3H] incorporation into insulin stimulated primary osteoblasts extracted 
from WT and Phospho1-/- mice. . n = 3, t-test. Data are represented as mean ±S.E.M. * P < 0.5, ** 
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Figure 6.4  Phospho1-/- mice show increased insulin sensitivity in bone 
(A) Immunoblot of WT and Phospho1-/- mice subjected to in vivo insulin administration 20 
minutes prior to cull. (B) Densitometric analysis of proteins shows a significant increase in 
pAKT and decrease in p-p44/42 and GLUT4 was observed in insulin stimulated Phospho1-/- 
bone. (C)  Seahorse X-24 analysis of OCR (an indication of oxidative phosphorylation) in WT 
and Phospho1-/- primary calvarial osteoblasts under basal conditions or following the addition 
of oligomycin, the uncoupler FCCP or the electron transport inhibitor antimycin A.  
Phospho1-/- primary calvarial osteoblasts had decreased OCR. . n ≥ 3, one way ANOVA (B) 
and t-test (C). Data are represented as mean ±S.E.M. Values assigned the same letter show no 
significant difference from one another (P < 0.05). * P <  0.05.  
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6.5.4 The effect of β3-adrenergic receptor agonist on WT and Phospho1−/− mice 
The increased mitochondrial mass of Phospho1-/- BAT noted in Chapter 4 implied 
that the ablation of Phospho1 may improve the metabolic phenotype by impacting 
non-shivering thermogenesis mechanisms. Therefore to test if the improved 
metabolic phenotype of Phospho1-/- mice was a consequence of enhanced sensitivity 
of BAT thermogenesis, 35 day old WT and Phospho1-/- mice were challenged 3 hours 
prior to cull with BRL-37344, a preferential β3-adrenergic receptor agonist that 
activates SNS signalling (Doucette and Rosen, 2014). This approach is an alternative 
to acute cold exposure and was used to test the immediate effects of environmental 
stress. Few metabolically significant changes were observed between WT and 
Phospho1-/- mice challenged with BRL (Fig. 6.5). However of importance, transcript 
levels of β3-adrenergic receptor (Adrb3) were increased in Phospho1-/- BAT following 
BRL administration. No such change was seen in WT mice (Fig. 6.5A).  This 
suggested that there was an increase in intracellular lipolysis of triglycerides from 
lipid droplets, resulting in release of fatty acids into the cytoplasm. Furthermore, in 
Phospho1-/- mice, Pparγ transcript levels were increased in BAT but decreased in GF 
following BRL administration. No change in transcript Pparγ was seen in BAT or GF 
from WT mice.   This suggests that PPARγ is involved in the physiological 
recruitment process in BAT but not WAT (Fig. 6.5A&B). Interestingly the expression 
of thermogenic associated genes in GF were differentially expressed between WT 
and Phospho1-/- mice in response to BRL treatment, these changes were seen at a 
lesser extent in SB fat. These results reveal that mimicking acute cold exposure using 
β3-adrenergic receptor may indicate that GF contributes to the insulin sensitive 
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Figure 6.5 Effect of β3-adrenergic receptor agonist on WT and Phospho1−/− mice   
RT-qPCR analysis of tissue extracted from 35 day old WT and Phospho1-/- mice challenged 
with β3-adrenergic receptor agonist (A) iBF (B) GF and (C) SB adipose tissue. mRNA values 
generated were normalised to the Gapdh housekeeping gene. n = 6, one way ANOVA. Values 
assigned the same letter show no significant difference from one another (P < 0.05).  
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6.5.5 Phospho1-/- osteoblasts secrete a factor which regulates insulin signalling, 
independent of OCN 
The low blood glucose levels and enhanced insulin sensitivity observed in the 
Phospho1-/- transgenic mice is opposite to the expected similarity to the OST-PTP 
overexpression-like phenotype. This was therefore suggestive that there may be an 
increase in circulating GLU13-OCN rather than a decrease as inferred by the 60-fold 
up-regulation of Esp in Phospho1-/- osteoblasts. Indeed, I saw an increase in total OCN 
(GLA13-OCN) which was expected as Phospho1-/- mice display increased bone 
turnover (Huesa et al., 2011). However, no change in GLU13-OCN in both juvenile 
and adult Phospho1-/- mice was observed indicating that lowered GLU13-OCN may 
not underlie the improved metabolic phenotype observed in Phospho1-/- mice (Fig. 
6.6A-B).  
 
Therefore, to establish if PHOSPHO1 truly regulates glucose metabolism via its 
osteoblastic expression, conditioned medium from WT and Phospho1-/- primary 
calvarial osteoblasts was collected and tested on various cell lines. This approach 
indicated that Phospho1-/- osteoblasts secreted factors that increased basal insulin 
sensitivity in primary calvarial osteoblasts (Fig. 6.7A-B), decreased insulin 
stimulated sensitivity in INS1e cells (Fig. 6.7C-D) and increased insulin stimulated 
sensitivity in 3T3-L1 cells (Fig. 6.7E-F) compared to WT conditioned medium. No 
effect was seen in FAZA and C2C12 cells (data not shown). These results provide 
evidence that in addition to GLU13-OCN other osteoblast-derived factors contribute 
to the global regulation of energy metabolism.  
 
6.5.6 Investigation of ceramide and choline as regulators of insulin signalling  
Having established that GLU13-OCN is not responsible for the metabolic phenotype 
of the Phospho1-/- mice, it is likely that other osteoblast secreted molecules contribute 
to global energy regulation. Neutral sphingomyelinase  catalyses the hydrolysis 
of sphingomyelin to form ceramide and P-Cho (Stoffel et al., 2005). Phosphocholine 
is subsequently hydrolysed into choline and Pi by PHOSPHO1 (Fig. 6.8A). Elevated 
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levels of both ceramide and choline result in insulin resistance in mice (Yang et al., 
2009; Wu et al., 2013). This led to the hypothesis that Phospho1-/- mice may have 
reduced ceramide or choline levels resulting in increased insulin sensitivity. 
Analysis indicated however that there was no significant difference between various 
ceramide species in the two genotypes highlighting that ceramide was unlikely to 
underlie the insulin sensitive phenotype observed in the Phospho1-/- mice (Fig. 6.8B).  
Unfortunately we were unable to measure serum choline due to the lack of a mass 
spectrometry assay, therefore we next supplemented WT and Phospho1-/- mice with a 
2% choline diet.  Choline supplementation normalised the insulin sensitivity 
measured in Phospho1-/-, measured by GTT however (Fig. 6.9A), unlike WT mice 
which when fed a 2% choline diet took longer to recover from the insulin challenge, 
Phospho1-/- showed no metabolic change in response to insulin between the diets 
(Fig. 6.9B). Furthermore, choline supplementation had no effect on mass, but 
normalised the lean phenotype observed in Phospho1-/- mice to the level seen in basal 
WT mice (P < 0.05)(Fig. 6.9C-D). This result suggested that PHOSPHO1-deficiency 
improves the metabolic profile of mice in vivo and confers resistance to obesity and 
diabetes possibly via the alteration of bone choline levels.   
 
6.5.7 Identification of novel regulators of insulin signalling  
The regulation of bone is a complex, multifactorial process; therefore it is possible 
that bone derived choline may not be the only skeletal regulator in mice and further, 
undefined bone secreted factors may play an important role in global energy 
regulation.  To identify secreted proteins or lipids that may also be involved in the 
energy regulation via the skeleton, quantitative proteomics and lipidomics were 
conducted in serum from WT and Phospho1-/- CD and HFD mice. Proteomic analysis 
identified > 100 differentially expressed proteins in Phospho1-/- serum. These unique 
proteins were highly associated with glycolysis, gluconeogenesis and ‘metabolic 
pathways’ (Fig. 6.10A-B) and showed enrichment for miR-34a; a microRNAs 
(miRNAs) that affects diverse parts of insulin signalling in the pancreas, liver, 
muscle and adipose tissue (Rottiers and Naar, 2012).  Furthermore, lumican, a 
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proteoglycan secreted by differentiating and mature osteoblasts, a constituent of the 
bone matrix and is observed in the decidua of the diabetic patients was found to be 
enriched in serum of Phospho1-/- mice by both proteomic and microarray analysis 
(section 6.5.7) (Raouf et al., 2002; Favaro et al., 2013). The key finding of preliminary 
lipid analysis was that cholesteryl esters (CE), were not detected in WT HFD serum 
(Fig. 6.11). Cholesteryl esters are molecular species that are important in 
the intracellular storage and intravascular transport of cholesterol and integral to 
membrane function (Ginsburg et al., 1984; Bowden et al., 2011). Conditions that 
effect cholesterol metabolism e.g. tumour promotion, alter tissue CE levels. 
Furthermore, over-nutrition which is characteristic of the HFD mouse model results 
in elevated tissue CE levels in the form of CE-enriched lipid droplets in tissues 
(Mahlberg et al., 1990). As tissue levels of CE were not measured it can only by 
hypothesised that the lack of CE in serum may be due to the accumulation of CE in 
WT HFD tissue, which Phospho1-/- mice are protected from.  However this must be 
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Figure 6.6 No difference in GLU13-OCN serum levels between WT and Phospho1-/- 
mice 
(A)(B) Osteocalcin analysis in WT and Phospho1-/- mice serum from 60 and 120 days of age. . 
n ≥ 6, t-test. Data are represented as mean ±S.E.M. * P < 0.05, ** P < 0.01, ***P < 0.01.  
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Figure 6.7 Phospho1-/- osteoblast secreted factors increased basal insulin sensitivity in 
primary calvarial osteoblasts 
Effect of a 1 hour pre-treatment with osteoblast conditioned medium prior to 10nm insulin 
stimulation (15 minutes) on primary cells and cell lines. WT Primary osteoblast (A) 
Densitometry analysis (B) RT-qPCR analysis. Insulinoma cell line - INS-1E (C) Densitometry 
analysis(D) RT-qPCR analysis. Differentiated adipocytes (3T3-L1) (E) Protein densitometry 
analysis (F) RT-qPCR analysis. n ≥ 3, one way ANOVA. Data are represented as mean 
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Figure 6.8 No difference in Ceramide between WT and Phospho1-/- mice 
(A) Schematic diagram outlining the mechanisms by which ceramide and choline and 
linked. (B) Mouse serum ceramide analysis by LC-MS/MS. n = 5, t-test.  Data are represented 
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Figure 6.9   Bone derived choline regulates insulin sensitivity  
(A) GTT and ITT (B) of 120 CD and 2% supplemented choline WT and Phospho1-/- mice (C) 
Simple weighing of 120 CD 2% choline mice revealed choline did not alter body mass. (D) 
Dissected fat depot weights, a 2% choline diet increased both SB, GF in Phospho1-/- mice 
however did not increased fat GF in WT mice. n ≥ 9, two way repeated measures ANOVA 
(A&B), one way ANOVA (C&D). Data are represented as mean ±S.E.M. Values assigned the 
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Figure 6.10 Proteomic analysis of serum from WT and Phospho1-/- mice 
(A) Ven diagram representing number of unique proteins from proteomics (B) Phospho1-/- 
HFD unique network of carbohydrate, lipid metabolism (grey proteins in data set). (n = 3). 
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Figure 6.11 Lipidomic analysis of serum from WT and Phospho1-/- mice 
All Lipid species present in serum from 120 day old male WT and Phospho1-/- CD and high fat 
diet mice. (Glycerophospholipid - PC, PE, PG, PS; Sphingolipids - SM, Cer, HexCer, 
Glycerolipids - TAG, MADAG; Sterol Lipids – CE) (n = 3). Graph kindly provided by Dr. Cal 
Vary, MMCRI.  
 
6.6 Discussion    
In the last decade, many reports have begun to unravel the precise mechanisms and 
address the aetiology, genetic and molecular aspects and the pathophysiology 
whereby the skeleton regulates energy metabolism. Moreover, as obesity plays a 
central role in the pathophysiology of diabetes mellitus, insulin resistance, 
dyslipidaemia, hypertension and atherosclerosis (constituting the metabolic 
syndrome) (Redinger, 2007); understanding the relationship between bone and 
energy metabolism may be helpful for the development and identification of new 
preventative, therapeutic and genetic strategies to combat obesity and the metabolic 
syndrome.  
 
The results presented in this chapter uncover a novel role for PHOSPHO1 and bone 
derived choline in the regulation of energy metabolism, expanding the notion that 
the skeleton regulates global energy metabolism inclusive of insulin sensitivity, 
glucose tolerance and fat metabolism via both OCN-dependent and independent 
mechanisms.  The data presented also suggests that Esp may act as a fine controller 
of insulin sensitivity, offering protection from severe hypoglycemia and 
dyslipidaemia without affecting OCN.  Therefore these data add to the emerging 
notion of the complex skeletal regulation of energy metabolism.  
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6.6.1 Esp - a fine controller of insulin sensitivity in mice 
As Esp offers protection against excessive insulin signalling the key finding that Esp 
was up regulated 60-fold in Phospho1-/- osteoblasts suggested the existence of an 
insulin resistant phenotype (Lee et al., 2007). This was not found however and 
Phospho1-deficiency resulted in decreased blood glucose levels, improved insulin 
sensitivity and glucose tolerance and conferred protection from diet induced obesity 
and diabetes in mice.  Furthermore, the increased insulin sensitivity was not 
associated with an expected rise in serum GLU13-OCN levels suggesting that 
PHOSPHO1-regulated energy metabolism is via OCN-independent mechanisms. 
This notion has previously been observed when partial genetic ablation of 
osteoblasts profoundly affected energy expenditure, GF weight and insulin 
sensitivity which were not restored by the administration of OCN (Yoshikawa et al., 
2011). Nevertheless, it cannot be discounted that the increased insulin sensitivity 
noted in the Phospho1-/- mice may be primed by an initial rise in GLU13-OCN levels, 
which is eventually normalised in a compensatory manner by the observed increase 
in Esp and OST-PTP expression.  This being the case it would be predicted that the 
loss of Esp on a Phospho1-/- background would exacerbate the insulin sensitivity due 
to increased GLU13-OCN serum levels. Such experiments would be informative but 
were not possible due the time and budget restraints of this studentship. These data 
strengthen the concept that a novel pathway exists between osteoblasts and glucose 
homeostasis, however, it does highlight the potential cross-talk between OCN-
dependent and OCN-independent mechanisms of glucose metabolism.  
 
6.6.2 Mechanism of osteoblasts metabolic functions 
The role of PHOSPHO1 in controlling bone mineralisation has been extensively 
investigated through the use of both in vitro and in vivo mouse models. Crucial in 
the initiation of mineralisation within the MV, PHOSPHO1 hydrolyses membrane 
lipids, primarily P-Cho to produce Pi (utilised in HA formation) and choline 
(Roberts et al., 2004). P-Cho is generated from the hydrolysis of sphingomyelin to 
form P-Cho and ceramide. Mindful of this, it has been reported that elevated levels 
Chapter 6                                          Elucidating the mechanism(s) by which PHOSPHO1 regulates energy metabolism 
~ 186 ~ 
 
of both ceramide and choline result in insulin resistance in mice (Yang et al., 2009; 
Wu et al., 2013). No change in ceramide species in Phospho1-/- mice were noted, 
whereas Phospho1-/- mice fed 2% choline rich diet displayed a normalisation in 
insulin sensitivity and fat mass. Choline induces hyperglycemia and insulin 
intolerance in mice via the modulation of plasma glucagon (Nakatani et al., 2004). 
This chapter highlights for the first time the importance of bone derived choline in 
the regulation of energy metabolism, however, the precise mechanism(s) still 
remains unclear. It is possible that lack of choline in Phospho1-/- medium leads to the 
altered insulin stimulated sensitivity observed in vitro in INS1e and 3T3-L1 cells.  
However, it is also possible that alterations in bone choline influence other 
osteoblasts secreted factors that may regulate energy metabolism. 
 
I have recently reviewed the literature on other osteoblast candidates beyond OCN 
that may be involved in bones ability to regulate glucose homeostasis (Oldknow  et 
al., 2015).  These include AMP-activated protein kinase (AMPK), BMP’s, GSK, 
FGF23, ‘osteokines’, sphingolipids and NPP1. Proteomic and lipidomic analysis of 
Phospho1-/- serum identified over 100 differentially expressed proteins and lipids in 
Phospho1-/- serum associated with the regulation of glycolysis and gluconeogenesis 
and these candidates included miR-34a which is known to affect diverse parts of 
insulin signalling in the pancreas, liver, muscle and adipose tissue (Kim et al., 
2013a). Further investigate of these candidates may uncover new skeletal regulators 
of energy metabolism.  To add credence to our findings, a large independent 
prospective, nested case-control study found that DNA methylation markers that 
regulate gene expression and mediates the biological response to environmental 
exposures at the PHOSPHO1 loci were associated with BMI, waist: hip ratio, 
glucose concentrations, HOMA-IR, and future type 2 diabetes incidence among 
Indians, Asians and Europeans (Chambers et al.). 
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6.6.3 Skeletal regulation - beyond osteocalcin  
Collectively, the results of this chapter add further credibility to the concept that 
OCN is not the sole mediator of the endocrine function of the skeleton (Yoshikawa  
et al., 2011). The umbrella term ‘glucose metabolism’ encompasses insulin secretion 
and sensitivity, energy expenditure and lipid accumulation, which are precisely 
regulated by the function of the liver, pancreas, adipose tissue and muscle.  
Therefore, the notion that only one osteoblast/bone-derived factor (osteocalcin), 
contributes to the regulation of whole body glucose metabolism by regulating these 
diverse functions is highly unlikely. We therefore suggest, as have others have done, 
that further bone derived proteins/lipids work in collaboration with OCN to 
regulate the metabolic function of the skeleton. Indeed, this chapter has raised the 
possibility that bone derived choline may contribute to the regulation of the 
development of the metabolic syndrome, since Phospho1-/- mice who lack the ability 
to hydrolyse P-Cho in bone (Roberts et al., 2004),  do not develop obesity or diabetes. 
Finally the results presented in the chapter suggest that Esp may act as a fine 
controller of insulin sensitivity in mice, offering protection from severe 
hypoglycemia and dyslipidaemia. 
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7.1 General discussion  
Recent developments in endocrinology, made possible by the combination of mouse 
genetics, integrative physiology and clinical observations have resulted in rapid and 
unanticipated advances in the field of skeletal biology. Indeed, the skeleton, 
classically viewed as a structural scaffold necessary for mobility, and regulator of 
calcium–phosphorus homoeostasis and maintenance of the haematopoietic niche 
has now been identified as a more complex organ, involved in the regulation of 
male fertility and whole-body glucose metabolism, in addition to the classical 
insulin target tissues. These seminal data have established the skeleton as a bona 
fide endocrine organ, challenging and fascinating researchers, resulting in an 
increased number of laboratories working in this field.  
 
In the last decade, many laboratories have begun to unravel the precise mechanisms 
and address the aetiology, genetic and molecular aspects and the pathophysiology 
whereby the skeleton regulates energy metabolism. Obesity plays a central role in 
the pathophysiology of T2DM, insulin resistance, dyslipidaemia, hypertension and 
atherosclerosis (constituting the metabolic syndrome) (Redinger, 2007). 
Understanding the relationship between bone and energy metabolism may 
therefore be helpful for the development and identification of new preventative, 
therapeutic and genetic strategies to combat obesity and the metabolic syndrome. 
This would be both invaluable and timely as the current obesity global epidemic, 
presently the fifth leading risk of death worldwide costs approximately $147 billion 
annually (Finkelstein et al., 2009; Stevens et al., 2009; Grube et al., 2013). 
 
There are currently many efforts to reduce obesity, encompassing the promotion of 
a healthy diet and increasing physical activity in the entire population. In addition, 
the lipase inhibitor, Orlistat is a clinically approved anti-obesity medication that is 
offered to UK patients with a body mass index (BMI) of > 28 coupled with related 
obesity conditions including high blood pressure. In more severe cases, bariatric 
surgery is offered to patients whereby dietary efforts have not been successful, 
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therefore they continue to have a BMI of > 40 or > 35 coupled with obesity related 
comorbidity’s such as type 2 diabetes mellitus (T2DM), obstructive sleep apnoea or 
high blood pressure. The two most common types of bariatric surgery are the fitting 
of a gastric band, reducing the volume of the stomach, or a gastric bypass whereby 
the ‘pouch’ created in the upper stomach then bypasses the remaining stomach, 
resulting in dramatically decreased digestion thus less calorie intake (NHS, 2014). 
 
Obesity is clearly preventable; however, if steps are not taken to tackle obesity, the 
current statistic of one in four adults in the UK whom are affected could rapidly 
increase, constituting a huge burden to the NHS. Furthermore, obesity is associated 
with a multitude of chronic diseases including stroke, coronary heart disease, cancer 
of the breast, endometrium and colon.  
 
This thesis focused on the bone specific phosphatase PHOSPHO1 which is 
indispensable for bone mineralisation and the prevention of soft tissue ossification 
abnormalities. Here I show that the ablation of Phospho1 confers a remarkable 
degree of protection against NAFLD, insulin resistance and T2DM in mice (Chapter 
4 & 5). These data support the notion that further, yet undefined osteoblast derived 
factors contribute to whole body energy metabolism 
 
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease 
in Western countries, commencing with hepatic lipid accumulation and primarily 
affecting the hepatic structure and function resulting in both morbidity and 
mortality from cirrhosis, liver failure and hepatocellular carcinoma (Table 7.1). It is 
now accepted that NAFLD is a multisystem disease affecting non-hepatic organs, 
leading to increased risk of cardiovascular and cardiac diseases, chronic kidney 
disease and T2DM (Anstee et al., 2013)(reviewed (Byrne and Targher, 2015)). The 
current major  risk factors for NAFLD are well established, in addition to obesity, 
insulin resistance and T2DM, increased ferritin and the patatin-like phospholipase 
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domain-containing 3 (Pnpla3) I148M polymorphism (prevalence of this risk allele is 
in 40 to 50% of Europeans) are known to result in NAFLD. However the 
mechanisms underlying disease progression are less well understood 
(particularly Pnpla3 genotype) (Romeo et al., 2008; Wang et al., 2011). Alarmingly, 
there are currently no approved drugs for the treatment of non-alcoholic 
steatohepatits (NASH) (stage 2 of NAFLD -2-5% UK population), with current 
clinical trials focusing on insulin sensitisers (e.g. glitazones) and hepatoprotective 
agents (e.g. vitamin E). However it is predicted none of the molecules under 
investigation are likely to improve NAFLD, thus new targets must be identified 
(Soden et al., 2007; Gastaldelli et al., 2009) (reviewed in (Ratziu et al., 2015). The data 
presented in this thesis (Chapter 5) certainly indicates that the genetic ablation of 
Phospho1 offers a remarkable protection against NAFLD when mice are fed a chronic 
high fat diet. It is therefore plausible to suggest that the administration of 
PHOSPHO1 inhibitors or PHOSPHO1 neutralising antibodies may provide a 
therapeutic intervention in patients with NAFLD, potentially preventing the onset 
of fibrosis, cirrhosis and possibly reducing the risk of developing cardiovascular 
and cardiac diseases. Certainly this seems viable, as juvenile Phospho1 heterozygous 
mice display an intermediate insulin sensitive phenotype suggestive that 
PHOSPHO1 may represent a druggable target (Chapter 4). Furthermore, 
administration of the a highly selective PHOSPHO1 inhibitor MLS-0263839 (with no 
detectable cross-inhibition of TNAP or NPP1) was shown to inhibit vascular 
calcification in mineralising murine WT vascular smooth muscle cells to 
41.8% ± 2.0% of control (Kiffer-Moreira et al., 2013).  Additionally, inhibition of 
PHOSPHO1 by lansoprazole, ebselen and SCH-202676 disrupts MV mediated 
mineralisation in Akp2-/- osteoblasts and impairs the skeletal development chick long 
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Insulin resistance, often termed pre-diabetes, occurs when insulin is produced at a 
high level, over a prolonged period of time, reducing insulin tissue sensitivity, 
occurring years prior to the development of glucose intolerance, β cell failure and 
T2DM (Tabak et al., 2009). Upon the onset of T2DM, patients may present with 
insulin resistance in muscle, adipose tissue, and liver, impaired insulin secretion, 
impaired incretin (hormone secreted from enteroendocrine cells, incretin functions 
to regulate insulin following eating) secretion and action, and altered balance of 
central nervous system (CNS) pathways controlling food intake and energy 
expenditure (Kim and Egan, 2008). Both genetic and environmental factors 
contribute to the onset of T2DM, with risk factors including obesity, inactivity and 
aging. Furthermore, mitochondrial oxidative dysfunction, endoplasmic reticulum 
stress, oxidative stress, and alterations in insulin signalling have all been linked to 
insulin resistance as reviewed in (Doria et al., 2008; Sales and Patti, 2013). The 
recommended strategy for achieving glucose control in insulin resistance or T2DM 
patients is to establish a metabolic target and to adjust treatment to achieve reduced 
glucose levels, via lifestyle changes (controlled and healthy diet, weight loss and 
increase of physical activity) and medication (including but not restricted to 
metformin, sulphonylureas, glitazones, gliptins, GLP-1 agonists, acarbose, acarbose, 
nateglinide and repaglinide). Comorbidity is common in patients with T2DM taking 
glucose lowering drugs resulting in further chronic disease, such as joint disorders, 
respiratory disease, anaemia, malignancy, depression, thus further research into 
new drug targets must be undertaken to reduce comorbidities, reducing chronic 
diseases (Wami et al., 2013). Since the realisation that the skeleton is an important 
regulator of whole-body glucose metabolism via the hormonally active OCN, which 
stimulates insulin secretion and β cell proliferation in the pancreas and promotes 
insulin sensitivity in peripheral organs in mice, many clinical studies have been 
conducted to deduce whether this mechanism is present in humans. One of the 
earliest studies to show an association between OCN and glucose metabolism was 
published over a decade ago. Osteocalcin levels were significantly lower in diabetic 
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patients, although OCN levels increased with improved glycaemic control (Rosato 
et al., 1998). In many human studies only total OCN levels were quantified; 
however, the effects on glucose metabolism via bone are attributed to GLU13-OCN. 
These studies yielded mixed results with several of them indicating a positive 
correlation between serum GLU13-OCN levels and enhanced β-cell function 
(Hwang et al., 2009; Prats-Puig et al., 2010; Pollock et al., 2011). However, results 
from other studies indicate no association between lower circulating GLU13-OCN 
levels and higher HOMA-IR (Shea et al., 2009). Results from one recent study have 
indicated that there is a sex-specific action of the bone–energy homoeostasis axis 
with OCN being associated with improved metabolic state via adiponectin in 
females, and via testosterone in males (Buday et al., 2013). Direct clinical evidence 
has been reported for the role of OCN in energy metabolism, via the removal of an 
OCN-producing osteoid osteoma, which resulted in elevated serum glucose, 
potentially associated with decreased levels of GLU13-OCN (Confavreux et al., 
2012). These conflicting results may be attributable to the lack of a commercially 
available GLU13-OCN ELISA, or differing methodologies (Ducy, 2011). The 
potential therapeutic implications of these recent findings have however not yet 
been fully exploited. Whether the use of OC is efficacious in the treatment of T2DM 
remains to be determined.  
 
As highlighted in Chapter 4 & 5, the ablation of Phospho1 offers protection against 
obesity and T2DM in mice, however in Phospho1-/- mice the serum levels of GLU13-
OCN were normal, suggesting an OCN-independent mechanism of PHOSPHO1 
regulated energy metabolism (Chapter 3 & 6). Therefore as described previously, 
PHOSPHO1 inhibitors or PHOSPHO1 neutralising antibodies may provide a 
therapeutic intervention in patients with insulin resistance and T2DM. However, it 
is important to note that as in addition to the skeletal pathologies such as, 
spontaneous fractures, bowed long bones, osteomalacia, and scoliosis in early life 
observed in the Phospho1-/- mice (Chapter 1)(Huesa et al., 2011; Yadav et al., 2011), 
recent data obtained from our lab suggests that Phospho1-/- mice show subchondral 
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bone thickening, a hallmark of osteoarthritis (OA) and unquestionably contribute to 
OA pathogenesis, in addition to severe articular cartilage degeneration and 
osteophyte formation (unpublished data). As T2DM is associated with various 
skeletal comorbidities such as joint disorders, PHOSPHO1 may be a challenging 
drug target resulting in undesirable side effects and therefore any therapeutic 
approaches using inhibitors will need to be managed very carefully and further 
research will be required 
 
Nevertheless, in addition to PHOSPHO1, it seems plausible that other proteins 
expressed in bone may affect energy metabolism via OCN independent 
mechanisms, providing further novel drug candidates including AMPK (Jeyabalan 
et al., 2012), BMPs, GSK3, osteokines (osteocyte-derived factors), sphingolipids and 
NPP1 (Fig. 7.1) reviewed in (Schulz and Tseng, 2009; Jeyabalan et al., 2012; Oldknow 
et al., 2015).   
 
In conclusion, this thesis identifies for the first time that Phospho1 deficiency 
improves the metabolic profile of mice via an OCN-independent mechanism, 
supporting the notion that further, yet undefined osteoblasts derived hormones 
contribute to whole body energy regulation via the skeleton. However many 
questions still remain: does OCN regulate insulin secretion over the short/long 
term? How does the osteoblast or osteocyte sense and use glucose or other fuels? Do 
bone cells utilise glucose or amino acids? Does bone fracture increase whole-body 
energy expenditure? Do osteocytes truly have an effect on energy metabolism? 
(Fulzele et al., 2007; Fulzele and Clemens, 2012). The complex OCN- dependent and 
independent mechanisms discussed here are still somewhat in their infancy; 
therefore it is vital that the research community endeavour to fully establish the 
mechanisms undelaying these endocrine interactions resulting in the better 
diagnosis, clinical management and treatment of patients with metabolic diseases. 
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Figure 7.1 The endocrine role of bone: Osteocalcin and beyond 
(Arrow key: Solid – accepted; dashed – speculative. Black = known interactions, green = 
indirect interactions, red = direct interactions, blue = osteokines). A feed forward loop links 
insulin, bone resorption and OCN activity. Insulin signalling in osteoblasts decreases the 
expression of Opg via decreasing the ratio of Opg (a RANKL decoy receptor) to RANKL thus 
increasing bone resorption by osteoclasts. This osteoclastic bone resorption generates an 
acidic pH in the resorption lacunae necessary to decarboxylate OCN stored in the bone 
extracellular matrix. GLU13-OCN is released into the blood stream, affecting glucose 
metabolism by binding to the OCN receptor (GPRC6A) thus stimulating insulin secretion 
and β cell proliferation in the pancreas and promoting insulin sensitivity in peripheral 
organs. In addition, GLU13-OCN promotes male fertility by stimulating testosterone 
synthesis in leydig cells of the testis through GPRC6A activation. Esp acts as an inhibitor, 
dephosphorylating the insulin receptor, supressing the levels of GLU13-OCN. To complete 
this feed forward loop, peripheral / central tissues (adrenal gland, adipose tissue, pancreas) 
can further indirectly regulate the release of GLU13-OCN into the peripheral circulation. 
New emerging evidence suggests in addition, NPP1 can indirectly inhibit GLU-13 OCN 
release via OPG. Independently of OCN, osteoblast specific proteins (PHOSPHO1, AMPK 
and GSK3β) can influence insulin secretion from β cell functions and adiposity. Osteocyte 
derived factors - Osteokines, may also be implicated in the endocrine regulation of glucose 
metabolism (Figure adapted from (Rosen and Motyl, 2010; Ferron and Lacombe, 2014) 
Published: (Oldknow et al., 2015)  
Chapter 7                                                                                                      Final discussion and future research possibilities 
~ 197 ~ 
 
7.2 Direction for future research    
The results presented in this thesis have identified that the genetic ablation of 
Phospho1 results in hypoglycemia, improved glucose and insulin tolerance and 
offers protection from diet induced fatty liver and obesity in mice. However, further 
work is necessary to fully elucidate the mechanism underlying this protection in 
PHOSPHO1 deficiency (Chapter 6) and indeed if this mechanism is truly GLU13-
OCN independent. Mouse genetic technology would offer a gateway to the 
exploration of these questions.  
 
PHOSPHO1 is preferentially expressed by bone, however low protein expression is 
observed in non-bone organs (e.g. brain and muscle) (Chapter 3), which in its 
absence could possibly contribute to the insulin sensitive phenotype of Phospho1-/- 
mice.  It would therefore be beneficial to generate a Phospho1-/-Col1a1-Phospho1 
mouse model, in which Phospho1 expression is restored in bone (using the Col1a1 
promoter – Appendix VII) in a Phospho1-/- global mouse to firmly confirm that the 
Phospho1-/- insulin sensitive phenotype is osteoblast driven. If this were the case, 
metabolic normalisation would be observed in this model. Alternatively, it may be 
found that the insulin sensitivity is not normalised, suggestive that PHOSPHO1 has 
a new, non-redundant role in non-bone organs. Furthermore, it is unclear if the 
ablation of Phospho1 expression in the developing embryo can have long lasting 
effects, effectively “priming” the mice for an insulin sensitive phenotype in later life.  
To discern if aged Phospho1-/- mice are protected from obesity the study of a 
tamoxifen inducible Phospho1 knockout model could be of enormous value. 
Phosphatase, Orphan 1, conditionally ready mice (Tm1a) using ‘knockout-first’ 
(Phospho1 embryonic stem cell clones are available from the EUCOMM consortium). 
Mice (Tm1a) could be bred with a FLPE line reverting to the Tm1c allele which is 
effectively a WT mouse but with a floxed critical exon. Finally, Tm1c mice could be 
bred with tamoxifen (TM) inducible germ line-Cre-driver mice to permit temporally 
knock-out Phospho1 expression in all tissues (Hayashi and McMahon, 2002). Both 
germ line Cre-ERTm and FLPE mice are available at The Edinburgh University 
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however were unattainable during this PhD and the costs of these experiments 
would have been prohibitive.  It would be beneficial to characterise insulin 
sensitivity in 35, 120 and 220 day old mice following intraperitoneal injection of TM 
to ascertain when PHOSPHO1 deficiency is most influential in age related metabolic 
disease.  
 
Certainly, it would be of benefit to establish the functional role of Esp in Phospho1-/- 
mice. As described, Esp was more highly expressed in Phospho1-/- osteoblasts (60-
fold, P < 0.01) indicative of decreased of GLU13-OCN secretion and insulin 
resistance, however this was not the case in the Phospho1-/- mice (Chapter 3).  The 
generation of Phospho1;Esp double knockout mice would clarify if Esp offers 
protection against excessive insulin signalling due to increased GLU13-OCN serum 
levels. Once the role of Esp in mice is established, it would be essential to generate 
Phospho1;Ocn double knockout mice and conduct metabolic analysis to address if 
either the increased insulin sensitivity in Phospho1-/- mice is: 
 
I. Truly OCN independent. 
II. Due to an initial rise in GLU13-OCN levels which effectively “primes” the 
Phospho1-/- mice for an insulin sensitive phenotype throughout life. This 
insulin sensitivity is eventually normalised due to the compensatory increase 
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It has been hypothesised that PHOSPHO1, together with SMPD3, through the 
generation and processing of P-Cho (Chapter 6), respectively, network to regulate 
glucose homeostasis and insulin sensitivity (Stoffel et al., 2005; Oldknow et al., 2015). 
Indeed SMPD3 may act upstream of PHOSPHO1 within the same metabolic 
pathway to regulate glucose homeostasis and insulin sensitivity. To investigate this 
two mice could be generated: 
  
I. Smpd3/Phospho1 double knockout and Smpd3-/- mice.  
II. Phospho1-/- and Phospho1-/-Col1a1-Smpd3 mice (Smpd3 is overexpressed in the 
osteoblasts of Phospho1-/- mice). 
 
If SMPD3 acts upstream of PHOSPHO1 the degree of insulin sensitivity in 
Smpd3/Phospho1 double knockout and Smpd3-/- mice would be similar, and no 
correction of insulin sensitivity would be observed in the Phospho1-/-Col1a1-Smpd3 
mice. Moreover, ceramide and choline, products of SMPD3 and PHOSPHO1 activity 
respectively, in excess can cause insulin resistance. Consequently, lower levels of 
either ceramide or choline due to Smpd3 or Phospho1 ablation may explain the 
resultant insulin sensitivity (Chapter 6) (Yang et al., 2009; Wu et al., 2013). However, 
as outlined in this thesis, normal levels of ceramide species were observed in 
Phospho1-/- mice, however administration of a 2% choline rich normalised the insulin 
sensitive phenotype in Phospho1-/- mice suggesting that decreased choline may be 
responsible for the insulin sensitivity observed in Phospho1-/- mice. It is therefore 
important to quantify total bone and serum choline by mass spectroscopy to 
ascertain if indeed bone derived choline is indispensable for whole body 
metabolism.  
 
I have shown that osteoblast secreted candidate(s) regulate energy metabolism in 
Phospho1-/- mice, however these candidates remain undetected. I have conducted 
proteomic, lipidomic and in silico analysis with the aim to identify secreted 
candidates in serum and osteoblast conditioned medium, and for lipids principle 
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component multivariate data analysis was conducted to establish preliminary lipid 
classes and their contribution to sample differences (Chapter 6). However it was not 
possible to fully verify this data by western blotting, siRNA knockdown or 
microRNA screening. Furthermore, it would also be advantageous to obtain 
samples from alkaline phosphatase null mice (Alpl-/-; hypomineralised, 
normoglycaemic), that would act as a control to help eliminate proteins whose 
expression is altered solely as a result of impaired matrix mineralisation. 
 
Finally, in the thesis, I reported that BAT of Phospho1-/- mice had markedly reduced 
fat content and increased nuclei number (P < 0.05). Indeed if the elevated nuclei 
number translated to increased mitochondria number, the metabolic phenotype 
observed in Phospho1-/- mice may be due to alterations in non-shivering 
thermogenesis. If this is the case, Phospho1 ablation is less likely to have persisting 
anti-obesity effects at thermoneutrality. Therefore it would be essential to determine 
if the reduced fat mass and improved metabolic phenotype of Phospho1-/- mice is a 
consequence of BAT thermogenesis by comparing energy expenditure in mice 
maintained at thermoneutrality (30°C) and ambient temperatures (23°C).  As I 
observed no differences in the expression of BAT enriched genes (e.g. Ucp1), this is 
suggestive that canonical thermogenesis through Ucp1 does not underlie the 
metabolic protection seen in Phospho1-/- mice. However, as these experiments were 
conducted at ambient temperatures (23°C – mice are considered mildly cold-
stressed, hyper-metabolic, hypertensive and obesity-resistant). Studying WT and 
Phospho1-/- mice at thermoneutrality may lead to the identification of novel genes 
underlying increased mitochondrial number and improved metabolism with 
Phospho1 deficiency directly relevant to humans (who spend most of their time at 
thermoneutrality) (Hayashi and McMahon, 2002). To test if the reduced fat mass 
and improved metabolic phenotype of Phospho1-/- mice is a consequence of enhanced 
sensitivity of the BAT thermogenesis system, mice could be challenged with low 
temperatures stimulating Ucp1 and engendering an insulin sensitive phenotype.  
Mice could be exposed to chronic cold exposure from ambient (23°C) to 8°C for 98 
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hours, then to 4°C for up to 5 weeks. Additionally, acute cold exposure could be 
used to test the immediate effects of environmental stress, whereby mice could be 
subject to a 6-hour cold exposure (4°C). Body weight, fat and lean mass (using time 
domain nuclear magnetic resonance) glucose homeostasis and energy expenditure 
and BAT mitochondrial activity could also be determined. Specifically, 
mitochondrial activity in BAT could be assessed through (i) the expression of 
biomarkers of mitochondrial biogenesis (e.g. PGC-1α & β) and metabolic pathways 
linked to BAT fat oxidation (e.g. Ucp3, Cpt1b and Pdk4) by RT-qPCR, (ii) the 
expression of mitochondrial respiratory proteins (e.g. ND6, COX, CII, CIII-CORE2 
and CVα) by immunoblotting and (iii) BAT mitochondrial activity (oxidative 
phosphorylation) and glycolysis by the 24 extracellular Flux Analyzer (Seahorse 
Bioscience). Furthermore, mitochondrial respiration and glycolysis of primary BAT 
adipocytes could be assessed using Seahorse technology (Chapter 6).  
 
These proposed experiments would methodically illustrate the complex role of 
PHOSPHO1 in glycaemic control and energy metabolism. Uncovering the 
mechanisms whereby PHOSPHO1 impacts energy metabolism is vital, to provide 
impetus for the development of novel therapeutic and intervention strategies again  
obesity, T2DM and NAFLD.
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Appendix I – Buffers and solutions 
Cell culture buffers 
Primary osteoblast medium  
αMEM with 10% FBS and 0.05mg/ml gentamicin.  
 
FAZA maintenance medium 
McCoy’s 5a (1:1), supplemented with 10% FBS, 2mM L-Glutamine and 0.05mg/ml 
gentamicin.  
 
INS1e maintenance medium  
RPMI (1640) (1:1), supplemented with 5% FBS, 2mM Hepes, 50μM β-
mercaptoethanol, 1mM pyruvate and 0.05mg/ml gentamicin.  
 
C2C12 maintenance medium  
DMEM (d5796 high glucose 4500 mg/L glucose), supplemented with 10% FBS, 2mM 
L-Glutamine and 0.05mg/ml gentamicin.  
 
C2C12 Differentiation medium 
DMEM (d5796) (1:1), supplemented with 1% FBS, 2mM L-Glutamine and 0.05mg/ml 
gentamicin.  
 
3T3 maintenance medium  
DMEM (d5546 low glucose 1000 mg/L glucose), supplemented with 10% foetal 
bovine serum (FBS), 2mM L-Glutamine and 0.05mg/ml gentamicin.  
 
3T3 Differentiation medium 
DMEM (d5796 high glucose 4500 mg/L glucose), supplemented with 10% FBS, 2mM 
L-Glutamine, 100nM dexamethasone and 0.05mg/ml gentamicin (1st 2-3 days 
additional IBMX supplementation).  
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Freezing mix 1  
60% DMEM/F-12; 20% FBS; 20% DMSO (suitable for standard cell lines)  
 
Freezing mix 2  
70% αMEM; 20% FBS; 20% DMSO (suitable for primary calvarial osteoblasts) 
 
Gel Electrophoresis  
Tris-Acteric Acid-EDTA (TAE)  
40mM Tris, 1mM EDTA, 0.1 % Acetic Acid 
 
Tris-Boric Acid-EDTA (TBE) 




20mM Tris-HCl (pH8), 135mM NaCl, 10% Glycerol, 1% IGEPAL, 0.1% SDS, 0.5% Na 
Deoxycholate, 2mM EDTA 
 
LDS Sample Buffer 
10% Glycerol, 141 mM Tris Base, 106 mM Tris HCl, 2% LDS, 0.51 mM EDTA, 0.22 
mM SERVA® Blue G250, 0.175 mM Phenol Red, pH 8.5 
 
MOPS running buffer  
50 mM MOPS pH 7.7, 50 mM Tris, 0.1% SDS, 1mM EDTA 
 
1X Transfer buffer 
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10X Transfer buffer 
29.3mg/ml glycine, 58mg/ml Tris Base (trismethylamine), 18.8μl/ml 20% SDS in 
dH2O 
 
Tris-Bufferd Saline with Tween 20 (TBST) 
10mM Tris HCl pH8.0, 150mM NaCl, 0.1% Tween-20 
 
Blocking Solution ECL 
5% (w/v) dried milk protein (Marvel) / BSA Faction V in TBST 
 
Pancreas Lysis  
Lysis buffer 
50mmol/l Tris, pH 7.4, 0.27 mol/l sucrose, 1mmol/l sodium orthovanadate, pH 10, 
1mmol/l EDTA, 1mmol/l EGTA, 10mmol/l sodium β-glycerophosphate, 50mmol/l 
NaF, 5mmol/l sodium pyrophosphate, 1%[wt/vol] Triton X-100, 0.1% [vol/vol] 2-
mercaptoethanol, and protease inhibitors—EDTA free tablets (Roche) 
 
Fixatives and histological stains  
10% Neutral Buffered Formalin (NBF) 
100ml strong formalin, 900ml tap water, 4.0g sodium dihydrogen phosphate, 
monohydrate (NaH2PO4.H2O) and 6.5g Disodium hydrogen phosphate, anhydrous 
(Na2HPO4) 
 
4% Paraformaldehyde (PFA) 
800ml 1x PBS 60°C, 40g paraformaldehyde powder, 1N NaOH added dropwise 
until the solution cleared, adjust volume to 1L with 1x PBS 
 
Oil-Red-O stock stain 
0.5g Oil-Red-O (CI 26125, Merc Millipore) dissolve in 100ml isopropanol with gentle 
heat     
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Oil-Red-O working solution 
Dilute 30ml stock stain in 20 ml of dH20, stand and filter 
 
General buffer recipes 
Phosphate Buffered Saline (PBS) 
140mM NaCl, 2.5mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4 
 
Hanks Buffered Saline Solution (HBSS) 
1.26 mM CaCl2, 0.493 mM MgCl2, 0.407 mM MgSO4, 5.33 mM KCl, 0.441 mM 
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Appendix II - Antibodies 
Primary antibodies 






















































Western Blotting 1:1000 
β-actin (HRP-
linked) 
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Secondary antibodies  























Goat anti-mouse Dako Western Blotting 1:5000 
Goat anti-rabbit Dako Western Blotting 1:5000 
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Appendix III - Seahorse XF24 Analyzer protocol 
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Appendix IV - Genotyping 
DNA extraction solutions 
Solution 1 
100ml dH2O, 40ul of 0.5M EDTA, 0.1g NaOH 
Solution 2 
96ml dH2O, 4ml 1M TRIS, Adjust to pH 5.5 
 












Mutation position  
5’-GTACATGCAAC/TGAGTCTTTAA-3’ 
WT: C 
Phospho1-/-: T  
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Phospho1 genotyping mix 
1µl 10x Buffer, 0.5µl 10mM DNTPs, 0.75 µl 50mM MgCl2, 1µl forward primer, 1µl 
reverse primer, 1.25µl 1%W, 0.25µl Taq DNA Polymerase and 4.25 µl  extracted 
DNA per reaction.   
 
Phospho1 genotyping programme 
(94.0°C  30 sec, 61.0°C  30 sec, 72.0°C 90 sec) x 2 
(94.0°C  30 sec, 59.0°C  30 sec, 72.0°C  90 sec) x 2 
(94.0°C  30 sec, 57.0°C  30 sec, 72.0°C  90 sec) x 2 
(94.0°C  30 sec, 55.0°C  30 sec, 72.0°C  90 sec) x 28  
(94.0°C  30 sec, 61.0°C 30 sec, 72.0°C 10 min) End 
 
Phospho1 Restriction mix 
0.15µl BSA Faction V, 0.5µl Bsrd1 restriction enzyme, 1.5µl NEB buffer and 2.85µl 
dH20. Heat together with PCR product at 65.0°C for 1 hour. Run product on 1.5% 
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F Not disclosed 
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Appendix VI – Ceramide species 
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Appendix VII – Phospho1-/-Col1a1-Phospho1 mice 




Primer Source Sequence (5'-3') 
Col1a1/F 
Dr. Monzur 
Murshed 
CAGCTCTCCATCAAGATGGT 
Beta-g-
intron 
Dr. Monzur 
Murshed 
CCGGTTTGGACTCAGAGTAT 
 
 
 
 
 
 
